0001460702
false
Q2
--12-31
P5Y
0001460702
2023-01-01
2023-06-30
0001460702
2023-08-10
0001460702
2023-06-30
0001460702
2022-12-31
0001460702
2023-04-01
2023-06-30
0001460702
2022-04-01
2022-06-30
0001460702
2022-01-01
2022-06-30
0001460702
QLGN:NetProductSalesMember
2023-04-01
2023-06-30
0001460702
QLGN:NetProductSalesMember
2022-04-01
2022-06-30
0001460702
QLGN:NetProductSalesMember
2023-01-01
2023-06-30
0001460702
QLGN:NetProductSalesMember
2022-01-01
2022-06-30
0001460702
us-gaap:CommonStockMember
2022-12-31
0001460702
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-12-31
0001460702
us-gaap:RetainedEarningsMember
2022-12-31
0001460702
us-gaap:ParentMember
2022-12-31
0001460702
us-gaap:NoncontrollingInterestMember
2022-12-31
0001460702
us-gaap:CommonStockMember
2023-03-31
0001460702
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-03-31
0001460702
us-gaap:RetainedEarningsMember
2023-03-31
0001460702
us-gaap:ParentMember
2023-03-31
0001460702
us-gaap:NoncontrollingInterestMember
2023-03-31
0001460702
2023-03-31
0001460702
us-gaap:CommonStockMember
2021-12-31
0001460702
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2021-12-31
0001460702
us-gaap:RetainedEarningsMember
2021-12-31
0001460702
us-gaap:ParentMember
2021-12-31
0001460702
us-gaap:NoncontrollingInterestMember
2021-12-31
0001460702
2021-12-31
0001460702
us-gaap:CommonStockMember
2022-03-31
0001460702
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-03-31
0001460702
us-gaap:RetainedEarningsMember
2022-03-31
0001460702
us-gaap:ParentMember
2022-03-31
0001460702
us-gaap:NoncontrollingInterestMember
2022-03-31
0001460702
2022-03-31
0001460702
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001460702
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-01-01
2023-03-31
0001460702
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001460702
us-gaap:ParentMember
2023-01-01
2023-03-31
0001460702
us-gaap:NoncontrollingInterestMember
2023-01-01
2023-03-31
0001460702
2023-01-01
2023-03-31
0001460702
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001460702
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-04-01
2023-06-30
0001460702
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001460702
us-gaap:ParentMember
2023-04-01
2023-06-30
0001460702
us-gaap:NoncontrollingInterestMember
2023-04-01
2023-06-30
0001460702
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001460702
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-01-01
2022-03-31
0001460702
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001460702
us-gaap:ParentMember
2022-01-01
2022-03-31
0001460702
us-gaap:NoncontrollingInterestMember
2022-01-01
2022-03-31
0001460702
2022-01-01
2022-03-31
0001460702
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001460702
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-04-01
2022-06-30
0001460702
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001460702
us-gaap:ParentMember
2022-04-01
2022-06-30
0001460702
us-gaap:NoncontrollingInterestMember
2022-04-01
2022-06-30
0001460702
us-gaap:CommonStockMember
2023-06-30
0001460702
us-gaap:AdditionalPaidInCapitalMember
2023-06-30
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2023-06-30
0001460702
us-gaap:RetainedEarningsMember
2023-06-30
0001460702
us-gaap:ParentMember
2023-06-30
0001460702
us-gaap:NoncontrollingInterestMember
2023-06-30
0001460702
us-gaap:CommonStockMember
2022-06-30
0001460702
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001460702
us-gaap:AccumulatedOtherComprehensiveIncomeMember
2022-06-30
0001460702
us-gaap:RetainedEarningsMember
2022-06-30
0001460702
us-gaap:ParentMember
2022-06-30
0001460702
us-gaap:NoncontrollingInterestMember
2022-06-30
0001460702
2022-06-30
0001460702
QLGN:NanoSynexLtdMember
QLGN:SeriesAOnePreferredStockMember
2022-05-24
2022-05-26
0001460702
QLGN:NanoSynexLtdMember
2022-05-24
2022-05-26
0001460702
QLGN:PrefundedWarrantMember
2022-05-26
0001460702
2022-05-24
2022-05-26
0001460702
us-gaap:SeriesBPreferredStockMember
2022-05-24
2022-05-26
0001460702
QLGN:NanoSynexLtdMember
us-gaap:SeriesBPreferredStockMember
2022-05-24
2022-05-26
0001460702
QLGN:NanoSynexLtdMember
2022-05-26
0001460702
us-gaap:ShippingAndHandlingMember
2023-04-01
2023-06-30
0001460702
us-gaap:ShippingAndHandlingMember
2022-04-01
2022-06-30
0001460702
us-gaap:ShippingAndHandlingMember
2023-01-01
2023-06-30
0001460702
us-gaap:ShippingAndHandlingMember
2022-01-01
2022-06-30
0001460702
us-gaap:SellingAndMarketingExpenseMember
2023-04-01
2023-06-30
0001460702
us-gaap:SellingAndMarketingExpenseMember
2022-04-01
2022-06-30
0001460702
us-gaap:SellingAndMarketingExpenseMember
2023-01-01
2023-06-30
0001460702
us-gaap:SellingAndMarketingExpenseMember
2022-01-01
2022-06-30
0001460702
2022-01-01
2022-12-31
0001460702
srt:MinimumMember
QLGN:PatentsAndLicensesMember
2023-06-30
0001460702
srt:MaximumMember
QLGN:PatentsAndLicensesMember
2023-06-30
0001460702
us-gaap:WarrantMember
2023-06-30
0001460702
us-gaap:WarrantMember
2022-12-31
0001460702
QLGN:NanoSynexLtdMember
2022-01-01
2022-12-31
0001460702
2023-12-31
0001460702
us-gaap:MachineryAndEquipmentMember
2023-06-30
0001460702
us-gaap:ComputerEquipmentMember
2023-06-30
0001460702
QLGN:MoldsAndToolingMember
2023-06-30
0001460702
us-gaap:FurnitureAndFixturesMember
2023-06-30
0001460702
2023-07-20
0001460702
2023-07-20
2023-07-20
0001460702
2022-12-01
2022-12-31
0001460702
2022-12-01
2023-12-31
0001460702
QLGN:NanoSynexLtdMember
us-gaap:SubsequentEventMember
2023-07-20
2023-07-20
0001460702
QLGN:AmendmentAndSettlementAgreementMember
QLGN:NanoSynexLtdMember
us-gaap:SubsequentEventMember
2023-07-20
0001460702
QLGN:AmendmentAndSettlementAgreementMember
us-gaap:SubsequentEventMember
2023-07-20
0001460702
QLGN:AmendmentAndSettlementAgreementMember
QLGN:NanoSynexLtdMember
us-gaap:SubsequentEventMember
2023-11-30
0001460702
QLGN:AmendmentAndSettlementAgreementMember
QLGN:NanoSynexLtdMember
us-gaap:SubsequentEventMember
2024-03-31
0001460702
us-gaap:SubsequentEventMember
2023-07-20
0001460702
us-gaap:MachineryAndEquipmentMember
2022-12-31
0001460702
us-gaap:ComputerEquipmentMember
2022-12-31
0001460702
us-gaap:LeaseholdImprovementsMember
2023-06-30
0001460702
us-gaap:LeaseholdImprovementsMember
2022-12-31
0001460702
QLGN:MoldsAndToolingMember
2022-12-31
0001460702
us-gaap:FurnitureAndFixturesMember
2022-12-31
0001460702
us-gaap:EquipmentMember
2023-06-30
0001460702
us-gaap:EquipmentMember
2022-12-31
0001460702
QLGN:SekisuiDistributionAgreementMember
2022-03-30
2022-03-31
0001460702
QLGN:DevelopedProductTechnologyRightsMember
2023-06-30
0001460702
QLGN:DevelopedProductTechnologyRightsMember
2022-12-31
0001460702
QLGN:DevelopedProductTechnologyRightsMember
srt:MinimumMember
2023-06-30
0001460702
QLGN:DevelopedProductTechnologyRightsMember
srt:MaximumMember
2023-06-30
0001460702
QLGN:LicensingRightsMember
2023-06-30
0001460702
QLGN:LicensingRightsMember
2022-12-31
0001460702
us-gaap:InProcessResearchAndDevelopmentMember
2023-06-30
0001460702
us-gaap:InProcessResearchAndDevelopmentMember
2022-12-31
0001460702
us-gaap:PatentsMember
2023-06-30
0001460702
us-gaap:PatentsMember
2022-12-31
0001460702
us-gaap:PatentsMember
2023-04-01
2023-06-30
0001460702
us-gaap:PatentsMember
2022-04-01
2022-06-30
0001460702
us-gaap:PatentsMember
2023-01-01
2023-06-30
0001460702
us-gaap:PatentsMember
2022-01-01
2022-06-30
0001460702
us-gaap:LicenseMember
2023-06-30
0001460702
us-gaap:LicenseMember
2022-12-31
0001460702
us-gaap:LicenseMember
2023-04-01
2023-06-30
0001460702
us-gaap:LicenseMember
2022-04-01
2022-06-30
0001460702
us-gaap:LicenseMember
2023-01-01
2023-06-30
0001460702
us-gaap:LicenseMember
2022-01-01
2022-06-30
0001460702
QLGN:NotesPayableMember
QLGN:NanoSynexMember
2021-09-02
0001460702
QLGN:NotesPayableMember
QLGN:NanoSynexMember
2023-06-30
0001460702
QLGN:NotesPayableMember
QLGN:NanoSynexMember
2020-03-26
2021-09-02
0001460702
QLGN:SeriesCWarrantsMember
2023-06-30
0001460702
srt:MinimumMember
QLGN:SeriesCWarrantsMember
2023-06-30
0001460702
srt:MaximumMember
QLGN:SeriesCWarrantsMember
2023-06-30
0001460702
srt:MaximumMember
QLGN:SeriesCWarrantsMember
2022-04-25
0001460702
srt:MinimumMember
QLGN:SeriesCWarrantsMember
2022-04-25
0001460702
QLGN:SeriesCWarrantsMember
2022-04-23
2022-04-25
0001460702
srt:MaximumMember
QLGN:SeriesCWarrantsMember
2022-05-26
0001460702
srt:MinimumMember
QLGN:SeriesCWarrantsMember
2022-05-26
0001460702
QLGN:SeriesCWarrantsMember
2022-05-23
2022-05-26
0001460702
srt:MaximumMember
QLGN:SeriesCWarrantsMember
2022-12-22
0001460702
srt:MinimumMember
QLGN:SeriesCWarrantsMember
2022-12-22
0001460702
QLGN:SeriesCWarrantsMember
2022-12-19
2022-12-22
0001460702
QLGN:SeriesCWarrantsMember
QLGN:AlphaCapitalMember
2022-12-22
0001460702
QLGN:SeriesCWarrantsMember
QLGN:AlphaCapitalMember
2022-12-19
2022-12-22
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
2022-12-31
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
srt:MinimumMember
2022-12-31
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
srt:MaximumMember
2022-12-31
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
2023-01-01
2023-06-30
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
2023-06-30
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
srt:MinimumMember
2023-06-30
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
srt:MaximumMember
2023-06-30
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
2021-12-31
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
2022-01-01
2022-06-30
0001460702
QLGN:SeriesCWarrantsMember
QLGN:CommonStockWarrantsMember
2022-06-30
0001460702
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001460702
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001460702
us-gaap:FairValueInputsLevel3Member
2022-12-31
0001460702
us-gaap:FairValueInputsLevel1Member
2023-01-01
2023-06-30
0001460702
us-gaap:FairValueInputsLevel2Member
2023-01-01
2023-06-30
0001460702
us-gaap:FairValueInputsLevel3Member
2023-01-01
2023-06-30
0001460702
us-gaap:FairValueInputsLevel1Member
2023-06-30
0001460702
us-gaap:FairValueInputsLevel2Member
2023-06-30
0001460702
us-gaap:FairValueInputsLevel3Member
2023-06-30
0001460702
srt:MinimumMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-06-30
0001460702
srt:MaximumMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2023-06-30
0001460702
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:WeightedAverageMember
2023-06-30
0001460702
srt:MinimumMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-06-30
0001460702
srt:MaximumMember
us-gaap:MeasurementInputRiskFreeInterestRateMember
2022-06-30
0001460702
us-gaap:MeasurementInputRiskFreeInterestRateMember
srt:WeightedAverageMember
2022-06-30
0001460702
srt:MinimumMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-06-30
0001460702
srt:MaximumMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-06-30
0001460702
srt:WeightedAverageMember
us-gaap:MeasurementInputPriceVolatilityMember
2023-06-30
0001460702
srt:MinimumMember
us-gaap:MeasurementInputPriceVolatilityMember
2022-06-30
0001460702
srt:MaximumMember
us-gaap:MeasurementInputPriceVolatilityMember
2022-06-30
0001460702
srt:WeightedAverageMember
us-gaap:MeasurementInputPriceVolatilityMember
2022-06-30
0001460702
srt:MinimumMember
us-gaap:MeasurementInputExpectedTermMember
2023-06-30
0001460702
srt:MaximumMember
us-gaap:MeasurementInputExpectedTermMember
2023-06-30
0001460702
srt:WeightedAverageMember
us-gaap:MeasurementInputExpectedTermMember
2023-06-30
0001460702
srt:MinimumMember
us-gaap:MeasurementInputExpectedTermMember
2022-06-30
0001460702
srt:MaximumMember
us-gaap:MeasurementInputExpectedTermMember
2022-06-30
0001460702
srt:WeightedAverageMember
us-gaap:MeasurementInputExpectedTermMember
2022-06-30
0001460702
us-gaap:MeasurementInputExpectedDividendRateMember
2023-06-30
0001460702
us-gaap:MeasurementInputExpectedDividendRateMember
srt:WeightedAverageMember
2023-06-30
0001460702
us-gaap:MeasurementInputExpectedDividendRateMember
2022-06-30
0001460702
us-gaap:MeasurementInputExpectedDividendRateMember
srt:WeightedAverageMember
2022-06-30
0001460702
QLGN:AlphaCapitalMember
QLGN:SeniorConvertibleDebentureMember
2022-12-19
2022-12-22
0001460702
QLGN:AlphaCapitalMember
QLGN:SeniorConvertibleDebentureMember
2022-12-22
0001460702
QLGN:SeniorConvertibleDebentureMember
2022-12-19
2022-12-22
0001460702
2022-12-22
0001460702
QLGN:AlphaCapitalMember
2022-12-22
0001460702
QLGN:AlphaCapitalMember
2022-12-30
0001460702
QLGN:AlphaCapitalOtherThirdPartiesMember
2023-01-01
2023-06-30
0001460702
QLGN:AlphaCapitalOtherThirdPartiesMember
2023-06-30
0001460702
2023-01-09
2023-01-12
0001460702
2023-01-12
0001460702
QLGN:SeniorSecuredConvertibleDebtMember
2023-06-30
0001460702
QLGN:SeniorSecuredConvertibleDebtMember
2022-12-31
0001460702
QLGN:SharesOfCommonStockSubjectToOutstandingOptionsMember
2023-01-01
2023-06-30
0001460702
QLGN:SharesOfCommonStockSubjectToOutstandingOptionsMember
2022-01-01
2022-06-30
0001460702
QLGN:SharesOfCommonStockSubjectToOutstandingWarrantsMember
2023-01-01
2023-06-30
0001460702
QLGN:SharesOfCommonStockSubjectToOutstandingWarrantsMember
2022-01-01
2022-06-30
0001460702
2021-12-15
0001460702
2021-12-14
2021-12-15
0001460702
QLGN:FirstTwelveMonthsMember
2021-12-14
2021-12-15
0001460702
2022-04-04
2022-04-05
0001460702
QLGN:LongtermOperatingLeaseAgreementMember
2022-12-31
0001460702
QLGN:LongtermOperatingLeaseAgreementMember
2023-01-01
2023-06-30
0001460702
QLGN:LongtermOperatingLeaseAgreementMember
2023-06-30
0001460702
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2018-06-01
2022-04-30
0001460702
srt:MinimumMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2018-06-01
2022-04-30
0001460702
srt:MaximumMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2018-06-01
2022-04-30
0001460702
QLGN:PhaseOneClinicalTrialMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2018-06-01
2022-04-30
0001460702
QLGN:PhaseTwoClinicalTrialMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2018-06-01
2022-04-30
0001460702
QLGN:PhaseThreeClinicalTrialMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2018-06-01
2022-04-30
0001460702
QLGN:LicensedProductSalesMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2018-06-01
2022-04-30
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2018-06-01
2022-04-30
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
2023-04-01
2023-06-30
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
2022-04-01
2022-06-30
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
2023-01-01
2023-06-30
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
2022-01-01
2022-06-30
0001460702
QLGN:SponsoredResearchAgreementsAndLicenseMember
2023-01-01
2023-06-30
0001460702
QLGN:SponsoredResearchAgreementsAndLicenseMember
2022-01-01
2022-06-30
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2019-03-01
2019-03-31
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2021-02-01
2021-02-28
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2022-03-01
2022-03-31
0001460702
QLGN:SponsoredResearchAgreementAndLicenseMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-07-01
2020-07-31
0001460702
srt:MinimumMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-07-01
2020-07-31
0001460702
srt:MaximumMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-07-01
2020-07-31
0001460702
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
QLGN:PhaseOneClinicalTrialMember
2020-07-01
2020-07-31
0001460702
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
QLGN:PhaseTwoClinicalTrialMember
2020-07-01
2020-07-31
0001460702
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
QLGN:PhaseThreeClinicalTrialMember
2020-07-01
2020-07-31
0001460702
QLGN:LicensedProductSalesMember
QLGN:LicenseAndSponsoredResearchAgreementsMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-07-01
2020-07-31
0001460702
srt:MinimumMember
QLGN:SponsoredResearchAgreementAndLicenseMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-07-31
0001460702
srt:MaximumMember
QLGN:SponsoredResearchAgreementAndLicenseMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-07-31
0001460702
QLGN:SponsoredResearchAgreementsAndLicenseMember
2023-04-01
2023-06-30
0001460702
QLGN:SponsoredResearchAgreementsAndLicenseMember
2022-04-01
2022-06-30
0001460702
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-06-30
0001460702
srt:MinimumMember
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-06-01
2020-06-30
0001460702
srt:MinimumMember
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-11-01
2020-11-30
0001460702
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-06-01
2020-06-30
0001460702
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
srt:MaximumMember
2020-06-01
2020-06-30
0001460702
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
QLGN:PhaseOneClinicalTrialMember
2020-06-01
2020-06-30
0001460702
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
QLGN:PhaseTwoClinicalTrialMember
2020-06-01
2020-06-30
0001460702
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
QLGN:PhaseThreeClinicalTrialMember
2020-06-01
2020-06-30
0001460702
QLGN:LicensedProductSalesMember
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-06-01
2020-06-30
0001460702
srt:MinimumMember
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-06-30
0001460702
srt:MaximumMember
QLGN:LicenseAgreementMember
QLGN:UniversityOfLouisvilleResearchFoundationMember
2020-06-30
0001460702
QLGN:YiXinZhenDuanJishuLtdMember
2021-12-31
0001460702
QLGN:YiXinZhenDuanJishuLtdMember
2023-06-30
0001460702
QLGN:YiXinZhenDuanJishuLtdMember
2022-06-30
0001460702
QLGN:UpfrontPaymentMember
QLGN:LicenseAgreementMember
2022-01-01
2022-01-31
0001460702
QLGN:LicenseAgreementMember
2022-01-01
2022-01-31
0001460702
QLGN:LicenseAgreementMember
2023-04-01
2023-06-30
0001460702
QLGN:LicenseAgreementMember
2022-04-01
2022-06-30
0001460702
QLGN:LicenseAgreementMember
2023-01-01
2023-06-30
0001460702
QLGN:LicenseAgreementMember
2022-01-01
2022-06-30
0001460702
us-gaap:ProductMember
QLGN:PredictionBiosciencesSASMember
2023-04-01
2023-06-30
0001460702
us-gaap:ProductMember
QLGN:PredictionBiosciencesSASMember
2023-01-01
2023-06-30
0001460702
us-gaap:ProductMember
QLGN:PredictionBiosciencesSASMember
2022-01-01
2022-06-30
0001460702
us-gaap:StockOptionMember
QLGN:TwoThousandTwentyStockIncentivePlanMember
2023-06-30
0001460702
us-gaap:StockOptionMember
QLGN:TwoThousandTwentyStockIncentivePlanMember
2022-12-31
0001460702
us-gaap:EmployeeStockOptionMember
2023-01-01
2023-06-30
0001460702
us-gaap:EmployeeStockOptionMember
2022-01-01
2022-06-30
0001460702
us-gaap:StockOptionMember
QLGN:TwoThousandTwentyStockIncentivePlanMember
2023-01-01
2023-06-30
0001460702
QLGN:CompensatoryWarrantsMember
2023-01-01
2023-06-30
0001460702
QLGN:CompensatoryWarrantsMember
2023-06-30
0001460702
QLGN:CompensatoryWarrantsMember
2017-12-31
0001460702
2021-01-01
2021-12-31
0001460702
us-gaap:WarrantMember
2022-04-25
0001460702
us-gaap:WarrantMember
2022-04-23
2022-04-25
0001460702
us-gaap:GeneralAndAdministrativeExpenseMember
us-gaap:WarrantMember
2022-04-23
2022-04-25
0001460702
us-gaap:WarrantMember
2022-05-26
0001460702
us-gaap:WarrantMember
srt:MinimumMember
2022-04-25
0001460702
us-gaap:WarrantMember
srt:MinimumMember
2022-05-26
0001460702
us-gaap:WarrantMember
srt:MaximumMember
2022-04-25
0001460702
us-gaap:WarrantMember
srt:MaximumMember
2022-05-26
0001460702
us-gaap:AdditionalPaidInCapitalMember
us-gaap:WarrantMember
2022-05-23
2022-05-26
0001460702
us-gaap:WarrantMember
2022-12-22
0001460702
us-gaap:WarrantMember
srt:MinimumMember
2022-12-22
0001460702
us-gaap:WarrantMember
srt:MaximumMember
2022-12-22
0001460702
us-gaap:WarrantMember
2022-12-19
2022-12-22
0001460702
QLGN:CompensatoryWarrantActivityMember
2023-01-01
2023-06-30
0001460702
QLGN:CompensatoryWarrantActivityMember
2022-01-01
2022-06-30
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
2020-05-31
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
2020-12-01
2020-12-31
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
QLGN:AlphaCapitalMember
2020-07-31
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
2020-07-31
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
QLGN:AlphaCapitalMember
us-gaap:WarrantMember
2020-08-31
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
QLGN:AlphaCapitalMember
2020-12-31
0001460702
2020-12-31
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
2022-05-31
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
2021-11-29
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
us-gaap:WarrantMember
2021-11-29
0001460702
QLGN:NoncompensatoryEquityClassifiedWarrantsMember
2023-01-01
2023-06-30
0001460702
QLGN:NanoSynexMember
2022-04-25
0001460702
QLGN:NanoSynexMember
2022-04-23
2022-04-25
0001460702
QLGN:NanoSynexMember
2022-05-26
0001460702
QLGN:NanoSynexMember
2022-05-23
2022-05-26
0001460702
QLGN:NanoSynexMember
2022-12-22
0001460702
QLGN:NanoSynexMember
2022-12-19
2022-12-22
0001460702
QLGN:NonCompensatoryWarrantActivityMember
2023-01-01
2023-06-30
0001460702
us-gaap:StockOptionMember
2023-06-30
0001460702
us-gaap:WarrantMember
2023-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
2022-12-31
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MinimumMember
2022-12-31
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MaximumMember
2022-12-31
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
2023-01-01
2023-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MinimumMember
2023-01-01
2023-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MaximumMember
2023-01-01
2023-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
2023-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MinimumMember
2023-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MaximumMember
2023-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
2021-12-31
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MinimumMember
2021-12-31
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MaximumMember
2021-12-31
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
2022-01-01
2022-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MinimumMember
2022-01-01
2022-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MaximumMember
2022-01-01
2022-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
2022-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MinimumMember
2022-06-30
0001460702
QLGN:EmployeesAndNonemployeeServiceProviderMember
srt:MaximumMember
2022-06-30
0001460702
us-gaap:GeneralAndAdministrativeExpenseMember
2023-01-01
2023-06-30
0001460702
us-gaap:GeneralAndAdministrativeExpenseMember
2022-01-01
2022-06-30
0001460702
us-gaap:ResearchAndDevelopmentExpenseMember
2023-01-01
2023-06-30
0001460702
us-gaap:ResearchAndDevelopmentExpenseMember
2022-01-01
2022-06-30
0001460702
QLGN:CompensatoryWarrantActivityMember
2022-12-31
0001460702
QLGN:CompensatoryWarrantActivityMember
srt:MinimumMember
2022-12-31
0001460702
QLGN:CompensatoryWarrantActivityMember
srt:MaximumMember
2022-12-31
0001460702
QLGN:CompensatoryWarrantActivityMember
2022-01-01
2022-12-31
0001460702
QLGN:CompensatoryWarrantActivityMember
2023-06-30
0001460702
QLGN:CompensatoryWarrantActivityMember
srt:MinimumMember
2023-06-30
0001460702
QLGN:CompensatoryWarrantActivityMember
srt:MaximumMember
2023-06-30
0001460702
QLGN:CompensatoryWarrantActivityMember
2021-12-31
0001460702
QLGN:CompensatoryWarrantActivityMember
srt:MinimumMember
2021-12-31
0001460702
QLGN:CompensatoryWarrantActivityMember
srt:MaximumMember
2021-12-31
0001460702
QLGN:CompensatoryWarrantActivityMember
2021-01-01
2021-12-31
0001460702
QLGN:CompensatoryWarrantActivityMember
2022-06-30
0001460702
QLGN:CompensatoryWarrantActivityMember
srt:MinimumMember
2022-06-30
0001460702
QLGN:CompensatoryWarrantActivityMember
srt:MaximumMember
2022-06-30
0001460702
QLGN:NonCompensatoryWarrantActivityMember
2022-12-31
0001460702
srt:MinimumMember
QLGN:NonCompensatoryWarrantActivityMember
2022-12-31
0001460702
srt:MaximumMember
QLGN:NonCompensatoryWarrantActivityMember
2022-12-31
0001460702
QLGN:NonCompensatoryWarrantActivityMember
2022-01-01
2022-12-31
0001460702
QLGN:NonCompensatoryWarrantActivityMember
2023-01-01
2023-06-30
0001460702
QLGN:NonCompensatoryWarrantActivityMember
2023-06-30
0001460702
QLGN:NonCompensatoryWarrantActivityMember
srt:MinimumMember
2023-06-30
0001460702
QLGN:NonCompensatoryWarrantActivityMember
srt:MaximumMember
2023-06-30
0001460702
QLGN:NonCompensatoryWarrantActivityMember
2021-12-31
0001460702
QLGN:NonCompensatoryWarrantActivityMember
2022-01-01
2022-06-30
0001460702
QLGN:NonCompensatoryWarrantActivityMember
2022-06-30
0001460702
QLGN:NonCompensatoryWarrantActivityMember
srt:MinimumMember
2022-06-30
0001460702
QLGN:NonCompensatoryWarrantActivityMember
srt:MaximumMember
2022-06-30
0001460702
QLGN:MasterLaboratoryServicesAgreementMember
us-gaap:SubsequentEventMember
QLGN:MLMMedicalLabsMember
2023-07-13
2023-07-13
0001460702
QLGN:StockPurchaseAgreementMember
us-gaap:SubsequentEventMember
2023-07-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
xbrli:pure
utr:sqft
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
10-Q
☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the quarterly period ended June 30, 2023
Or
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For
the transition period from _____________ to _____________
Qualigen
Therapeutics, Inc.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-37428 |
|
26-3474527 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
2042
Corte Del Nogal, Carlsbad, California 92011
(Address
of principal executive offices) (Zip Code)
(760)
918-9165
(Registrant’s
telephone number, including area code)
n/a
(Former
name or former address, if changed since last report)
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
Common
Stock, par value $.001 per share |
|
QLGN |
|
The
Nasdaq Capital Market of The Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. ☒ Yes ☐ No
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). ☒ Yes ☐ No
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large
accelerated filer |
☐ |
Accelerated
filer |
☐ |
Non-accelerated
filer |
☒ |
Smaller
reporting company |
☒ |
|
|
Emerging
growth company |
☐ |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No
As
of August 10, 2023, there were 5,052,463 shares of the registrant’s common stock, par value $0.001 per share, outstanding.
TABLE
OF CONTENTS
ITEM
1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
QUALIGEN
THERAPEUTICS, INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
(Unaudited)
| |
June 30, 2023 | | |
December 31, 2022 | |
ASSETS | |
| | | |
| | |
Current assets | |
| | | |
| | |
Cash | |
$ | 1,341,659 | | |
$ | 7,034,434 | |
Accounts receivable, net | |
| 679,380 | | |
| 538,587 | |
Inventory, net | |
| 1,563,399 | | |
| 1,586,297 | |
Prepaid expenses and other current assets | |
| 1,278,077 | | |
| 1,661,220 | |
Total current assets | |
| 4,862,515 | | |
| 10,820,538 | |
Restricted cash | |
| 5,434 | | |
| 5,690 | |
Right-of-use assets | |
| 1,305,970 | | |
| 1,422,538 | |
Property and equipment, net | |
| 498,647 | | |
| 345,087 | |
Intangible assets, net | |
| 5,833,070 | | |
| 5,845,702 | |
Goodwill | |
| 625,602 | | |
| 625,602 | |
Other assets | |
| 18,334 | | |
| 18,334 | |
Total Assets | |
$ | 13,149,572 | | |
$ | 19,083,491 | |
| |
| | | |
| | |
LIABILITIES AND STOCKHOLDERS’ EQUITY | |
| | | |
| | |
Current liabilities | |
| | | |
| | |
Accounts payable | |
$ | 1,756,183 | | |
$ | 857,311 | |
Accrued vacation | |
| 332,617 | | |
| 467,948 | |
Accrued expenses and other current liabilities | |
| 1,980,555 | | |
| 1,511,856 | |
R&D grant liability | |
| 151,620 | | |
| 780,682 | |
Deferred revenue, current portion | |
| 94,474 | | |
| 116,161 | |
Operating lease liability, current portion | |
| 257,155 | | |
| 240,645 | |
Short term debt-related party | |
| 965,155 | | |
| 950,722 | |
Warrant liabilities | |
| 133,500 | | |
| 788,100 | |
Warrant liabilities - related party | |
| 2,010,180 | | |
| 2,834,547 | |
Convertible debt - related party | |
| 812,419 | | |
| 60,197 | |
Total current liabilities | |
| 8,493,858 | | |
| 8,608,169 | |
Operating lease liability, net of current portion | |
| 1,168,653 | | |
| 1,301,919 | |
Deferred revenue, net of current portion | |
| 28,648 | | |
| 49,056 | |
Deferred tax liability | |
| 150,369 | | |
| 357,757 | |
Total liabilities | |
| 9,841,528 | | |
| 10,316,901 | |
Commitments and Contingencies (Note 12) | |
| - | | |
| - | |
Stockholders’ equity | |
| | | |
| | |
Qualigen Therapeutics, Inc. stockholders’ equity: | |
| | | |
| | |
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,052,463 and 4,210,737 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively | |
| 42,952 | | |
| 42,110 | |
Additional paid-in capital | |
| 112,554,830 | | |
| 110,528,050 | |
Accumulated other comprehensive income | |
| 131,891 | | |
| 50,721 | |
Accumulated deficit | |
| (110,695,598 | ) | |
| (103,385,172 | ) |
Total Qualigen Therapeutics, Inc. stockholders’ equity | |
| 2,034,075 | | |
| 7,235,709 | |
Noncontrolling interest | |
| 1,273,969 | | |
| 1,530,881 | |
Total Stockholders’ Equity | |
| 3,308,044 | | |
| 8,766,590 | |
Total Liabilities & Stockholders’ Equity | |
$ | 13,149,572 | | |
$ | 19,083,491 | |
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
QUALIGEN
THERAPEUTICS, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE LOSS
(Unaudited)
| |
| | |
| | |
| | |
| |
| |
For the Three Months Ended June 30, | | |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | | |
2023 | | |
2022 | |
REVENUES | |
| | |
| | |
| | |
| |
Net product sales | |
$ | 1,627,031 | | |
$ | 1,430,534 | | |
$ | 3,234,201 | | |
$ | 2,152,563 | |
Total revenues | |
| 1,627,031 | | |
| 1,430,534 | | |
| 3,234,201 | | |
| 2,152,563 | |
| |
| | | |
| | | |
| | | |
| | |
EXPENSES | |
| | | |
| | | |
| | | |
| | |
Cost of product sales | |
| 1,016,542 | | |
| 1,099,677 | | |
| 2,281,368 | | |
| 1,928,524 | |
General and administrative | |
| 2,665,849 | | |
| 2,660,857 | | |
| 4,380,283 | | |
| 5,559,608 | |
Research and development | |
| 1,326,544 | | |
| 1,506,227 | | |
| 3,448,095 | | |
| 3,370,972 | |
Sales and marketing | |
| 169,223 | | |
| 305,103 | | |
| 368,337 | | |
| 443,426 | |
Total expenses | |
| 5,178,158 | | |
| 5,571,864 | | |
| 10,478,083 | | |
| 11,302,530 | |
| |
| | | |
| | | |
| | | |
| | |
LOSS FROM OPERATIONS | |
| (3,551,127 | ) | |
| (4,141,330 | ) | |
| (7,243,882 | ) | |
| (9,149,967 | ) |
| |
| | | |
| | | |
| | | |
| | |
OTHER EXPENSE (INCOME), NET | |
| | | |
| | | |
| | | |
| | |
Gain on change in fair value of warrant liabilities | |
| (440,294 | ) | |
| (14,800 | ) | |
| (1,478,967 | ) | |
| (698,042 | ) |
Interest expense (income), net | |
| 377,416 | | |
| (4,824 | ) | |
| 921,652 | | |
| (11,132 | ) |
Loss on voluntary conversion of convertible debt | |
| — | | |
| — | | |
| 1,077,287 | | |
| — | |
Loss on disposal of equipment held for lease | |
| 63,302 | | |
| — | | |
| 63,302 | | |
| — | |
Other income, net | |
| (5,680 | ) | |
| 376 | | |
| (10,559 | ) | |
| 341 | |
Loss on fixed asset disposal | |
| — | | |
| — | | |
| 300 | | |
| — | |
Total other expense (income), net | |
| (5,256 | ) | |
| (19,248 | ) | |
| 573,015 | | |
| (708,833 | ) |
| |
| | | |
| | | |
| | | |
| | |
| |
| | | |
| | | |
| | | |
| | |
(BENEFIT) PROVISION FOR INCOME TAXES | |
| (38,182 | ) | |
| 5,438 | | |
| (201,959 | ) | |
| 6,173 | |
| |
| | | |
| | | |
| | | |
| | |
NET LOSS | |
| (3,507,689 | ) | |
| (4,127,520 | ) | |
| (7,614,938 | ) | |
| (8,447,307 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to noncontrolling interest | |
| (43,484 | ) | |
| (4,116 | ) | |
| (304,512 | ) | |
| (4,116 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss attributable to Qualigen Therapeutics, Inc. | |
$ | (3,464,205 | ) | |
$ | (4,123,404 | ) | |
$ | (7,310,426 | ) | |
$ | (8,443,191 | ) |
| |
| | | |
| | | |
| | | |
| | |
Net loss per common share, basic and diluted | |
$ | (0.69 | ) | |
$ | (1.12 | ) | |
$ | (1.46 | ) | |
$ | (2.35 | ) |
Net loss per common share, basic | |
$ | (0.69 | ) | |
$ | (1.12 | ) | |
$ | (1.46 | ) | |
$ | (2.35 | ) |
Weighted—average number of shares outstanding, basic and diluted | |
| 5,052,463 | | |
| 3,668,016 | | |
| 5,006,050 | | |
| 3,599,093 | |
Weighted—average number of shares outstanding, basic | |
| 5,052,463 | | |
| 3,668,016 | | |
| 5,006,050 | | |
| 3,599,093 | |
| |
| | | |
| | | |
| | | |
| | |
Other comprehensive loss, net of tax | |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (3,507,689 | ) | |
$ | (4,127,520 | ) | |
$ | (7,614,938 | ) | |
$ | (8,447,307 | ) |
Foreign currency translation adjustment | |
| (56,747 | ) | |
| 65,540 | | |
| 119,473 | | |
| 65,540 | |
Other comprehensive loss | |
| (3,564,436 | ) | |
| (4,061,980 | ) | |
| (7,495,465 | ) | |
| (8,381,767 | ) |
Comprehensive loss attributable to noncontrolling interest | |
| (43,484 | ) | |
| (4,116 | ) | |
| (304,512 | ) | |
| (4,116 | ) |
Comprehensive loss attributable to Qualigen Therapeutics, Inc. | |
$ | (3,520,952 | ) | |
$ | (4,057,864 | ) | |
$ | (7,190,953 | ) | |
$ | (8,377,651 | ) |
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
QUALIGEN
THERAPEUTICS, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(Unaudited)
| |
| | |
| | |
| | |
| | |
| | |
| | |
| | |
| |
| |
| | |
| | |
| | |
| | |
| | |
Total | | |
| | |
| |
| |
| | |
| | |
| | |
| | |
| | |
Qualigen | | |
| | |
| |
| |
| | |
| | |
Additional | | |
Accumulated
Other | | |
| | |
Therapeutics, Inc. | | |
| | |
Total | |
| |
Common Stock | | |
Paid-In | | |
Comprehensive | | |
Accumulated | | |
Stockholders’ | | |
Noncontrolling | | |
Stockholders’ | |
| |
Shares | | |
Amount | | |
Capital | | |
Income | | |
Deficit | | |
Equity | | |
Interest | | |
Equity | |
Balance at December 31, 2022 | |
| 4,210,737 | | |
$ | 42,110 | | |
$ | 110,528,050 | | |
$ | 50,721 | | |
$ | (103,385,172 | ) | |
$ | 7,235,709 | | |
$ | 1,530,881 | | |
$ | 8,766,590 | |
Voluntary conversion of convertible debt into common stock | |
| 841,726 | | |
| 842 | | |
| 1,111,740 | | |
| — | | |
| — | | |
| 1,112,582 | | |
| — | | |
| 1,112,582 | |
Stock-based compensation | |
| — | | |
| — | | |
| 247,657 | | |
| — | | |
| — | | |
| 247,657 | | |
| 4,569 | | |
| 252,226 | |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| 119,723 | | |
| — | | |
| 119,723 | | |
| 56,497 | | |
| 176,220 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| (3,846,221 | ) | |
| (3,846,221 | ) | |
| (261,028 | ) | |
| (4,107,249 | ) |
Balance at March 31, 2023 | |
| 5,052,463 | | |
$ | 42,952 | | |
$ | 111,887,447 | | |
$ | 170,444 | | |
$ | (107,231,393 | ) | |
$ | 4,869,450 | | |
$ | 1,330,919 | | |
$ | 6,200,369 | |
Stock-based compensation | |
| — | | |
| — | | |
| 667,383 | | |
| — | | |
| — | | |
| 667,383 | | |
| 4,728 | | |
| 672,111 | |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| (38,553 | ) | |
| — | | |
| (38,553 | ) | |
| (18,194 | ) | |
| (56,747 | ) |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| (3,464,205 | ) | |
| (3,464,205 | ) | |
| (43,484 | ) | |
| (3,507,689 | ) |
Balance at June 30, 2023 | |
| 5,052,463 | | |
$ | 42,952 | | |
$ | 112,554,830 | | |
$ | 131,891 | | |
$ | (110,695,598 | ) | |
$ | 2,034,075 | | |
$ | 1,273,969 | | |
$ | 3,308,044 | |
| |
| | |
| | |
Additional | | |
Other | | |
| | |
Therapeutics, Inc. | | |
| | |
Total | |
| |
Common Stock | | |
Paid-In | | |
Comprehensive | | |
Accumulated | | |
Stockholders’ | | |
Noncontrolling | | |
Stockholders’ | |
| |
Shares | | |
Amount $ | | |
Capital | | |
Income | | |
Deficit | | |
Equity | | |
Interest | | |
Equity | |
Balance at December 31, 2021 | |
| 3,529,018 | | |
$ | 35,290 | | |
$ | 101,274,073 | | |
$ | — | | |
$ | (84,744,629 | ) | |
$ | 16,564,734 | | |
$ | — | | |
$ | 16,564,734 | |
Stock issued upon exercise of warrants | |
| 536 | | |
| 5 | | |
| 4,711 | | |
| — | | |
| — | | |
| 4,716 | | |
| — | | |
| 4,716 | |
Stock-based compensation | |
| — | | |
| — | | |
| 1,267,166 | | |
| — | | |
| — | | |
| 1,267,166 | | |
| — | | |
| 1,267,166 | |
Net Loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| (4,319,787 | ) | |
| (4,319,787 | ) | |
| — | | |
| (4,319,787 | ) |
Balance at March 31, 2022 | |
| 3,529,554 | | |
$ | 35,295 | | |
$ | 102,545,950 | | |
$ | — | | |
$ | (89,064,416 | ) | |
$ | 13,516,829 | | |
$ | — | | |
$ | 13,516,829 | |
Common stock issued for business acquisition | |
| 350,000 | | |
| 3,500 | | |
| 1,841,000 | | |
| — | | |
| — | | |
| 1,844,500 | | |
| — | | |
| 1,844,500 | |
Prefunded warrants issued for business acquisition | |
| — | | |
| — | | |
| 1,746,816 | | |
| — | | |
| — | | |
| 1,746,816 | | |
| — | | |
| 1,746,816 | |
Foreign currency translation adjustment | |
| — | | |
| — | | |
| — | | |
| 65,540 | | |
| — | | |
| 65,540 | | |
| — | | |
| 65,540 | |
Estimated fair value of noncontrolling interest related to business acquisition | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| — | | |
| 4,000,000 | | |
| 4,000,000 | |
Fair value of warrant modification for business acquisition | |
| — | | |
| — | | |
| 696 | | |
| — | | |
| — | | |
| 696 | | |
| — | | |
| 696 | |
Stock-based compensation | |
| — | | |
| — | | |
| 1,423,282 | | |
| — | | |
| — | | |
| 1,423,282 | | |
| — | | |
| 1,423,282 | |
Net loss | |
| — | | |
| — | | |
| — | | |
| — | | |
| (4,123,404 | ) | |
| (4,123,404 | ) | |
| (4,116 | ) | |
| (4,127,520 | ) |
Balance at June 30, 2022 | |
| 3,879,554 | | |
$ | 38,795 | | |
$ | 107,557,744 | | |
$ | 65,540 | | |
$ | (93,187,820 | ) | |
$ | 14,474,259 | | |
$ | 3,995,884 | | |
$ | 18,470,143 | |
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
QUALIGEN
THERAPEUTICS, INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
| |
| | |
| |
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
CASH FLOWS FROM OPERATING ACTIVITIES | |
| | | |
| | |
Net loss | |
$ | (7,614,938 | ) | |
$ | (8,447,307 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 122,523 | | |
| 66,258 | |
Amortization of right-of-use assets | |
| 116,567 | | |
| 109,803 | |
Accounts receivable reserves and allowances | |
| (133,278 | ) | |
| (75,295 | ) |
Inventory reserves | |
| (22,992 | ) | |
| (16,405 | ) |
Stock-based compensation | |
| 906,145 | | |
| 2,690,447 | |
Change in fair value of warrant liabilities | |
| (1,478,967 | ) | |
| (698,042 | ) |
Loss on voluntary conversion of convertible debt | |
| 1,077,287 | | |
| — | |
Accretion of discount on convertible debt | |
| 787,517 | | |
| — | |
Loss on disposal of fixed assets and equipment held for lease | |
| 63,602 | | |
| — | |
| |
| | | |
| | |
Changes in operating assets and liabilities: | |
| | | |
| | |
Accounts receivable | |
| (8,614 | ) | |
| 250,201 | |
Inventory and equipment held for lease | |
| (37,390 | ) | |
| (237,930 | ) |
Prepaid expenses and other assets | |
| 382,893 | | |
| (548,487 | ) |
Accounts payable | |
| 899,753 | | |
| 27,941 | |
Accrued expenses and other current liabilities | |
| 357,508 | | |
| (828,229 | ) |
R&D grant liability | |
| (613,793 | ) | |
| — | |
Operating lease liability | |
| (116,756 | ) | |
| (73,408 | ) |
Deferred revenue | |
| (42,095 | ) | |
| (47,345 | ) |
Deferred tax liability | |
| (207,388 | ) | |
| — | |
Net cash used in operating activities | |
| (5,562,416 | ) | |
| (7,827,798 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Purchases of property and equipment | |
| (246,418 | ) | |
| (63,483 | ) |
Net cash acquired in business combination | |
| — | | |
| 135,354 | |
Net cash (used in)/provided by investing activities | |
| (246,418 | ) | |
| 71,871 | |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Net proceeds from warrant exercises | |
| — | | |
| 3,859 | |
Net cash provided by financing activities | |
| — | | |
| 3,859 | |
| |
| | | |
| | |
Net change in cash and restricted cash | |
| (5,808,834 | ) | |
| (7,752,068 | ) |
Effect of exchange rate changes on cash and restricted cash | |
| 115,803 | | |
| (34,228 | ) |
Cash and restricted cash - beginning of period | |
| 7,040,124 | | |
| 17,538,272 | |
Cash and restricted cash - end of period | |
$ | 1,347,093 | | |
$ | 9,751,976 | |
| |
| | | |
| | |
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION | |
| | | |
| | |
Cash paid during the year for: | |
| | | |
| | |
Interest | |
$ | — | | |
$ | — | |
Taxes | |
$ | 6,293 | | |
$ | 3,501 | |
| |
| | | |
| | |
NONCASH FINANCING AND INVESTING ACTIVITIES: | |
| | | |
| | |
Net transfers to equipment held for lease from inventory | |
$ | 83,271 | | |
$ | — | |
Fair value of warrant liabilities on date of exercise | |
$ | — | | |
$ | 858 | |
Voluntary conversion of convertible debt into common stock | |
$ | 1,112,582 | | |
$ | — | |
The
accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
QUALIGEN
THERAPEUTICS, INC.
NOTES
TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(Unaudited)
NOTE
1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES
Organization
Qualigen,
Inc., a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and
was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the “Company”) operates in one business segment. In
May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (“Ritter”) and
Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.’s capital stock were exchanged for Qualigen Therapeutics,
Inc.’s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital
Market under the ticker symbol “RTTR,” commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted
basis, under the trading symbol “QLGN” on May 26, 2020.
On
May 26, 2022, the Company acquired 2,232,861 shares
of Series A-1 Preferred Stock of NanoSynex, Ltd. (“NanoSynex”) from Alpha Capital Anstalt (“Alpha Capital”),
a related party, in exchange for 350,000 reverse
split adjusted shares of the Company’s common stock and a prefunded warrant to purchase 331,464 reverse
split adjusted shares of the Company’s common stock at an exercise price of $0.001 per
share. These warrants were
subsequently exercised on September 13, 2022.
Concurrently with this transaction, the Company also purchased 381,786 shares
of Series B preferred stock from NanoSynex for a total purchase price of $600,000.
The transactions resulted in the Company acquiring a 52.8%
interest in NanoSynex (the “NanoSynex Acquisition”). NanoSynex is a micro-biologics diagnostics company domiciled in
Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the
“NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of
NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a
majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by
the NanoSynex Funding Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd.
).
Basis
of Presentation
The
accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally
accepted in the United States of America (“U.S. GAAP”), Regulation S-X and rules and regulations of the Securities and Exchange
Commission (“SEC”).
Principles
of Consolidation
The
accompanying condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All
intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is
meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional
currency of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency,
New Israeli Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign
currency translation adjustments are reflected as a component of accumulated other comprehensive income within the Company’s consolidated
statements of changes in stockholders’ equity.
Accounting
Estimates
Management
uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill,
warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and
returns, and warranty costs. Actual results could vary from the estimates that were used.
Reverse
Stock Split
On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company’s board of directors, reverse stock split of its
outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced the Company’s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional
shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and
the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common
stock and the par value per share remains unchanged.
Cash
The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.
The
Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S.
that are of high quality. Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail,
the Company could lose all or a portion of amounts held in excess of such insurance limitations. In March 2023, Silicon Valley Bank and
Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity concerns and taken over by the Federal
Deposit Insurance Corporation (FDIC). While the Company did not have an account at any of these banks, in the event of failure of any
of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would
be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely
affect our business and financial position.
Inventory,
Net
Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified
as excess or obsolete.
Impairment
of Long-Lived Assets
The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the three and six months ended June 30, 2023 and 2022,
no such impairment losses have been recorded.
Segment
Reporting
Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.
Accounts
Receivable, Net
The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.
The
Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company’s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.
Accounts
receivable, net is comprised of the following at:
SCHEDULE
OF ACCOUNTS RECEIVABLE
| |
June 30, 2023 | | |
December 31, 2022 | |
Accounts Receivable | |
$ | 733,964 | | |
$ | 726,449 | |
Less Reserves and Allowances | |
| (54,584 | ) | |
| (187,862 | ) |
Accounts receivable,
net | |
$ | 679,380 | | |
$ | 538,587 | |
Research
and Development
Except
for acquired in process research and development (IPR&D), the Company expenses research and development costs as incurred including
therapeutics license costs.
R&D
Grants
NanoSynex
has received R&D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding
to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants
in advance, the proceeds are recorded as a current or non-current R&D grant liability based on the time from the condensed consolidated
balance sheets date to the expected future date of recognition as a reduction to research and development expenses.
Patent
Costs
The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the condensed consolidated
statement of operations.
Shipping
and Handling Costs
The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales which totaled approximately $78,000 and $72,000, respectively, for the three
months ended June 30, 2023 and 2022, and approximately $144,000 and $111,000, respectively, for the six months ended June 30,
2023 and 2022. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing
expenses were $0 and $4,000 for the three months ended June 30, 2023 and 2022, respectively, and
approximately $4,000 and $8,000 for the six months ended June 30, 2023 and 2022, respectively.
Revenue
from Contracts with Customers
The
Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine
revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and
(v) recognition of revenue when (or as) the Company satisfies each performance obligation.
Product
Sales
The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, testosterone, thyroid disorders,
pregnancy, and Vitamin D.
The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (“analyzer”) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.
The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (“FOB”) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company’s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.
The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfill the promise to transfer the disposable products and not as a separate performance obligation.
The
Company’s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company’s
contracts.
Contract
Asset and Liability Balances
The
timing of the Company’s revenue recognition may differ from the timing of payment by the Company’s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are
satisfied.
Multiple
performance obligations include contracts that combine both the Company’s analyzer and a customer’s future reagent purchases
under a single contract. In some sales contracts, the Company provides analyzers at no charge to customers. Title to the analyzer is
maintained by the Company and the analyzer is returned by the customer to the Company at the end of the purchase agreement.
During
the three months ended June 30, 2023 and 2022, product sales are stated net of an allowance for estimated returns of approximately $28,000
and $10,000, respectively. During the six months ended June 30, 2023 and 2022, product sales are stated net of an allowance for estimated
returns of approximately $33,000 and $53,000, respectively.
Deferred
Revenue
Payments
received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales,
multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the
time from the condensed consolidated balance sheets date to the future date of revenue recognition.
Operating
Leases
Effective
April 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2018-11, Leases (Topic 842) Targeted Improvements
(“Topic 842”). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding
right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for
in a manner similar to the guidance for operating leases prior to the adoption of Topic 842. (See Note
12 - Commitments and Contingencies for more information).
Property
and Equipment, Net
Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:
SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT
Machinery and equipment | |
| 5 years | |
Computer equipment | |
| 3 years | |
Molds and tooling | |
| 5 years | |
Furniture and fixtures | |
| 5 years | |
Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.
The
Company’s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.
Business
Combinations
The
Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other
things, that results of operations of acquired companies are included in Qualigen’s financial results beginning on the respective acquisition
date, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired
in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions
about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant.
Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred
(the “purchase price”) over the fair values of the net assets acquired is recognized as goodwill. The fair value of assets
acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a
period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all
other acquisition-related costs are expensed when incurred.
Goodwill
Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets
acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized
but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the
goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value.
If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the
difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $4,239,000
non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the fiscal year
ended December 31, 2022. There were no
impairment losses during the three and six months ended June 30, 2023 and 2022.
Intangible
Assets
In
Process R&D
Acquired
in process R&D (IPR&D) represents the fair value assigned to the research and development assets that have not reached technological
feasibility. The value assigned to IPR&D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue
and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing the
new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature
and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate
with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition
of acquired IPR&D, an assessment is completed as to whether the acquisition constitutes an acquisition of a single asset or a group
of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence
of separate cash flows, the development process and stage of completion, quantitative significance, and the Company’s rationale for entering
into the transaction.
If
a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&D is capitalized as an intangible
asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the
acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development
expense in the Company’s condensed consolidated statements of operations and other comprehensive income (loss) as they are incurred.
IPR&D
is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value
of the acquired IPR&D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment
recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&D could
result in an impairment.
Other
Intangible Assets, Net
Other
intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible
assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate
that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be
recovered.
If
the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.
Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally 5 to 17
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has
been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.
Derivative
Financial Instruments and Warrant Liabilities
The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the condensed consolidated statements of operations and other comprehensive income (loss). Depending on the features of the derivative
financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative
instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments
should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 9- Warrant Liabilities).
Fair
Value Measurements
The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:
| ● | Level
1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or
liabilities that the Company has the ability to access at the measurement date; |
| ● | Level
2 - Inputs other than quoted prices that are observable for the assets or liability either
directly or indirectly, including inputs in markets that are not considered to be active;
and |
| ● | Level
3 - Inputs that are unobservable. |
Fair
Value of Financial Instruments
Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.
Comprehensive
Loss
Comprehensive
loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements
of operations and comprehensive loss and as a separate component in the statements of stockholders’ equity for all periods presented.
Stock-Based
Compensation
Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.
Income
Taxes
Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.
Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years.
Sales
and Excise Taxes
Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the condensed consolidated balance sheet as cash is collected from customers
and remitted to the tax authority.
Warranty
Costs
The
Company’s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company’s best estimates of analyzer failure rates
and costs to repair.
Accrued
warranty liabilities were approximately $140,000 and $138,000, respectively, as of June 30, 2023 and December 31, 2022 and
are included in accrued expenses and other current liabilities on the accompanying condensed consolidated balance sheets. Warranty costs
were approximately $63,000 and $22,000 for the three months ended June 30, 2023 and 2022, respectively, and approximately $104,000
and $41,000 for the six months ended June 30, 2023 and 2022, respectively, and are included in cost of product sales in the condensed
consolidated statements of operations and other comprehensive loss.
Foreign
Currency Translation
The
functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company’s newly acquired majority
owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange
rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations;
and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of
NanoSynex is reflected as a separate component of other comprehensive income (loss).
Other
comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was ($56,747) and $65,540 for the three months ending June 30, 2023 and 2022, respectively, and $119,473 and $65,540 for the six months ending June 30, 2023 and 2022, respectively.
War
in Ukraine
In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company’s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.
Inflation
and Global Economic Conditions
During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect
to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate
the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include aggregation
of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive
suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that
it will be successful in fully offsetting increased costs resulting from inflationary pressure. In
addition, the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global
recession in the near future. If the global economy slows, our business would be adversely affected.
Impact
of COVID-19 Pandemic
The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company’s business as well. During the height of
the pandemic sales of diagnostic products decreased significantly and the Company’s net loss increased significantly, as deferral
of patients’ non-emergency visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests.
For 2023 we continue to experience recovery in demand.
Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s
condensed consolidated financial statements.
NOTE
2 — LIQUIDITY
As
of June 30, 2023, we had approximately $1.3 million in cash and an accumulated deficit of $110.7 million. For the six months ended June
30, 2023 and year ended December 31, 2022, we used cash of $5.6 million and $13.2 million, respectively, in operations.
On
July 20, 2023, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics,
Inc. (“Chembio”), Biosynex, S.A. and Qualigen, Inc., a wholly-owned subsidiary of the Company (see Note 16 - Subsequent
Events). Pursuant to the Purchase Agreement, the Company agreed to sell to the Buyer all of the issued and outstanding shares of
common stock (collectively, the “Shares”) of Qualigen, Inc., which was the legal entity operating the Company’s
FastPack™ diagnostics business (the “Transaction”). The Transaction closed on July 20, 2023. Following the
consummation of the Transaction, our Qualigen, Inc. subsidiary became a wholly-owned subsidiary of Chembio.
The
aggregate net purchase price paid to the Company for the Shares was $5.2 million in cash, based on a base purchase price of $5.8 million,
subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by Qualigen, Inc. as of the closing
of the Transaction; (ii) net working capital of Qualigen, Inc. as of the closing of the Transaction, (iii) certain indebtedness of Qualigen,
Inc. as of the closing of the Transaction, and (iv) certain Transaction expenses as of the closing of the Transaction. Of the $5.2 million
in cash, $450,000 is being held in escrow to satisfy certain Company indemnification obligations (the “Indemnity Escrow”).
Any amounts remaining in the Indemnity Escrow that have not been offset or reserved for claims will be released to the Company within
five business days following the date that is 18 months after the closing.
The
Company’s cash balances as of the date that these financial statements were issued along with the proceeds from the above sale to Chembio, without additional financing, are
expected to fund operations into the first quarter of 2024. The Company expects to continue to have net losses and negative cash
flow from operations, which over time will challenge its liquidity. These factors raise substantial doubt about the Company’s
ability to continue as a going concern for the one-year period following the date that these financial statements were
issued.
There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute its business plan, the Company will require significant additional financing for planned research and development activities,
capital expenditures, clinical testing for its QN-302 clinical trials, preclinical development of RAS and QN-247, and
funding for NanoSynex operations, as well as commercialization activities.
Historically,
the Company’s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from
the issuance of debt. In December 2021, the Company raised $8.8 million from the issuance of common stock to several institutional investors,
and in December 2022 the Company raised $3.0 million from the sale of an 8% Senior Convertible Debenture (the “Debenture”)
to a related party (see Note 10 - Convertible Debt - Related Party). There can be no assurance that further financing can be obtained
on favorable terms, or at all. If we are unable to obtain funding, we could be required to delay, reduce or eliminate research and development
programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business prospects.
On
July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex
Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated
May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary
of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding
Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd. ).
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
In
the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction,
the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex
pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we originally paid
in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per share.
To
the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests
of its common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If the Company raises additional funds through government or other third-party funding, commercialization, marketing and distribution
arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable
rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be
favorable to the Company. Additional funding may not be available to the Company on acceptable terms, or at all. In addition, any future
financing (depending on the terms and conditions) may be subject to the approval of Alpha Capital, the holder of the Debenture, or trigger
certain adjustments to the Debenture or warrants held by Alpha Capital.
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements
NOTE
3— INVENTORY,
NET
Inventory,
net consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF INVENTORY
| |
June 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 1,027,455 | | |
$ | 949,796 | |
Work in process | |
| 177,591 | | |
| 200,318 | |
Finished goods | |
| 358,353 | | |
| 436,183 | |
Total
inventory | |
$ | 1,563,399 | | |
$ | 1,586,297 | |
NOTE
4 — PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid
expenses and other current assets consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
| |
June 30, 2023 | | |
December 31, 2022 | |
Prepaid insurance | |
$ | 938,106 | | |
$ | 1,377,323 | |
Prepaid manufacturing expenses | |
| 51,710 | | |
| 43,820 | |
Other prepaid expenses | |
| 65,288 | | |
| 227,451 | |
Prepaid research and development expenses | |
| 211,337 | | |
| — | |
Other current assets | |
| 11,636 | | |
| 12,626 | |
Prepaid expenses and
other current assets | |
$ | 1,278,077 | | |
$ | 1,661,220 | |
NOTE
5 — PROPERTY AND EQUIPMENT, NET
Property
and equipment, net consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF PROPERTY AND EQUIPMENT
| |
June 30, 2023 | | |
December 31, 2022 | |
Machinery and equipment | |
$ | 2,735,507 | | |
$ | 2,510,148 | |
Computer equipment | |
| 369,589 | | |
| 395,836 | |
Leasehold improvements | |
| 336,916 | | |
| 333,271 | |
Molds and tooling | |
| 260,002 | | |
| 260,002 | |
Furniture and fixtures | |
| 144,832 | | |
| 144,832 | |
Equipment held for lease | |
| 1,405,384 | | |
| 1,399,444 | |
Property and equipment, gross | |
| 5,252,230 | | |
| 5,043,533 | |
Accumulated depreciation | |
| (4,678,583 | ) | |
| (4,623,446 | ) |
Fixed asset impairment | |
| (75,000 | ) | |
| (75,000 | ) |
Property and equipment,
net | |
$ | 498,647 | | |
$ | 345,087 | |
Depreciation
expense relating to property and equipment was approximately $19,000 and $24,000 for the three months ended June 30, 2023 and 2022,
respectively, and $37,000 and $48,000 for the six months ended June 30, 2023 and 2022, respectively.
Upon
termination of the Sekisui Distribution Agreement on March 31, 2022, the Company had a commitment to purchase leased FastPack rental
systems back from Sekisui at Sekisui’s net book value, which was determined to be approximately $154,000. An assignment agreement
was executed by the parties on June 26, 2023 to legally transfer title to this equipment from Sekisui to the Company, and this amount
is included in accounts payable at June 30, 2023.
NOTE
6 — GOODWILL, IPR&D AND OTHER INTANGIBLES
SCHEDULE
OF GOODWILL AND OTHER INTANGIBLES
| |
| |
June 30, | | |
December 31, | |
| |
| |
2023 | | |
2022 | |
| |
Estimated Useful Lives | |
Gross carrying amounts | | |
Gross carrying amounts | |
| |
| |
| | |
| |
Goodwill | |
| |
$ | 625,602 | | |
$ | 625,602 | |
| |
| |
| | | |
| | |
Finite-lived intangible assets: | |
| |
| | | |
| | |
Developed-product-technology rights | |
8 - 17 years | |
$ | 479,103 | | |
$ | 479,103 | |
Licensing rights | |
10 years | |
| 418,836 | | |
| 418,836 | |
Less: Accumulated amortization | |
| |
| (764,869 | ) | |
| (752,237 | ) |
Total finite-lived intangible assets, net | |
| |
| 133,070 | | |
| 145,702 | |
Indefinite-lived intangible assets: | |
| |
| | | |
| | |
In-process research and development | |
| |
| 5,700,000 | | |
| 5,700,000 | |
Total other intangible assets, net | |
| |
$ | 5,833,070 | | |
$ | 5,845,702 | |
The
Company periodically reviews goodwill for impairment in accordance with relevant accounting standards. Goodwill is attributable to the
NanoSynex Acquisition. Goodwill and intangible assets are recognized at fair value during the period in which an acquisition is completed,
from updated estimates during the measurement period, or when they are considered to be impaired. These non-recurring fair value measurements,
primarily for goodwill and intangible assets acquired, were based on Level 3 inputs. The Company estimates the fair value of long-lived
assets on a non-recurring basis based on a market valuation approach, engaging independent valuation experts to assist in the determination
of fair value. In the fourth quarter of fiscal 2022, in conjunction with the annual impairment assessment, the Company determined that
the fair value of the reporting unit was less than the carrying value. In addition to continued losses in the reporting unit, the Company
considered macroeconomic conditions including a deterioration in the equity markets evidenced by sustained declines in the Company’s
stock price, peer companies, and major market indices since the acquisition date. The Company engaged independent valuation experts to
assist in determining the fair value of the reporting unit. As a result of this analysis, the Company recorded a $4,239,000 goodwill
and fixed asset impairment charge associated with the reporting unit for fiscal year ended December 31, 2022. There were no impairment
losses during the three and six months ended June 30, 2023 and 2022.
The
carrying value of the patents of approximately $131,000
and $140,000
at June 30, 2023 and December 31, 2022,
respectively, are stated net of accumulated amortization of approximately $348,000
and $339,000,
respectively. Amortization of patents charged to operations for the three months ended June 30, 2023 and 2022 was approximately
$9,000
and $5,000
respectively, and for the six months ended June 30,
2023 and 2022 was approximately $9,000
and $9,000,
respectively.
The
carrying value of the in-licenses of approximately $2,000
and $5,000
at June 30, 2023 and December 31, 2022,
respectively, are stated net of accumulated amortization of approximately $417,000
and $414,000,
respectively, and amortization of licenses charged to both the three months ended June 30, 2023 and 2022 was approximately $3,000.
Amortization of licenses charged to operations for both the six months ended June 30, 2023 and 2022 was approximately $3,000.
On
July 20, 2023, the Company entered into a Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc.,
a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued
and outstanding shares of common stock of Qualigen, Inc. (see Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics,
Inc. and Biosynex, S.A.). Therefore, there is no future estimated amortization of patent and license costs for the five succeeding
years.
NOTE
7 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued
expenses and other current liabilities consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
| |
June 30, 2023 | | |
December 31, 2022 | |
Board compensation | |
$ | 84,000 | | |
| 70,000 | |
Equipment held for lease | |
| — | | |
| 154,433 | |
Franchise, sales and use taxes | |
| 30,407 | | |
| 27,531 | |
Income taxes | |
| 6,921 | | |
| 4,663 | |
Interest (Convertible debt - related party) | |
| 50,101 | | |
| 2,829 | |
License fees | |
| 100,026 | | |
| 150,130 | |
Payroll | |
| 484,048 | | |
| 209,303 | |
Professional fees | |
| 368,032 | | |
| 238,211 | |
Research and development | |
| 523,490 | | |
| 322,987 | |
Royalties | |
| 16,383 | | |
| 13,158 | |
Warranty liability | |
| 140,370 | | |
| 137,568 | |
Other | |
| 176,777 | | |
| 181,043 | |
Accrued expenses and other current liabilities | |
$ | 1,980,555 | | |
$ | 1,511,856 | |
NOTE
8 – SHORT TERM DEBT-RELATED PARTY
NanoSynex
has four separate Notes Payable (‘the Notes”) outstanding to Alpha Capital, dated between March 26, 2020 and September 2, 2021,
aggregating to a total principal outstanding balance of $905,000,
and aggregate accrued interest of $60,155
for a total outstanding balance of $965,155
as of June 30, 2023. The Notes all accrue interest at 2.62%
per annum, accrued daily, and provide that the full amount of principal and interest under each Note shall be due immediately prior
to a Liquidation Event (the Maturity Date) unless due earlier in accordance with the terms of the Notes. “Liquidation
Event” means either i) the merger or consolidation of NanoSynex into any other entity, other than one in control or under
control of NanoSynex or NanoSynex’s majority shareholder; ii) a transaction or series of transactions resulting in the transfer of
all or substantially all of NanoSynex’s assets or issued and outstanding share capital (other than to a company under the control of
NanoSynex or NanoSynex’s majority shareholders; or iii) an underwritten public offering by NanoSynex of its ordinary shares.
Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt, or equity funding with gross proceeds of USD
$3,000,000
or more, then the unused portion of these Notes shall be due and payable upon the actual receipt of such funding. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex
Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May
26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary of the
Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement (see
Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd. ).
NOTE
9 – WARRANT LIABILITIES
In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the “Series C Warrants”). The Series C Warrants were subsequently extended and, upon closing of the reverse
recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant
terms as adjusted.
In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase shares of the
Company’s common stock at $7.195
per share, subject to adjustment. As of June 30, 2023, the Series C Warrants have remaining terms ranging from .40
to .99
years. The Series C Warrants were determined to be liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, based on
the inclusion of a leveraged ratchet provision for subsequent dilutive issuances. On April 25, 2022, the Series C Warrants were
repriced from $7.195
to $6.00
with 49,318
additional ratchet Warrants issued, and on May 26, 2022, the Series C Warrants were repriced from $6.00
to $5.136
with 49,952
additional ratchet Warrants issued. As a result of these repricings, 247,625 warrants were forfeited and 346,896 warrants were
reissued. On December 22, 2022, the Series C Warrants were repriced again from $5.136
to $1.32
with 1,002,717
additional ratchet Warrants issued.
Additionally,
on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha Capital (see Note 10 – Convertible Debt –
Related Party), the Company issued to Alpha Capital a warrant to purchase 2,500,000 shares of the Company’s common stock (the “Alpha
Warrant”). The exercise price of the Alpha Warrant is $1.65 (equal to 125% of the conversion price of the Debenture on the closing
date). The Alpha Warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after June 22, 2023 and before June
22, 2028, subject to certain terms and conditions described in the Alpha Warrant, including the Company’s receipt of the necessary
stockholder approvals.
The
following table summarizes the activity in liability classified warrants for the six months ended June 30, 2023:
SCHEDULE OF WARRANTS ACTIVITY
| |
Common Stock Warrants | |
| |
Shares | | |
Weighted– Average Exercise Price | | |
Range of Exercise Price | | |
Weighted– Average Remaining Life (Years) | |
Total outstanding – December 31, 2022 | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.9 | |
Exercised | |
| — | | |
| — | | |
| — | | |
| — | |
Forfeited | |
| — | | |
| — | | |
| — | | |
| — | |
Expired | |
| — | | |
| — | | |
| — | | |
| — | |
Granted | |
| — | | |
| — | | |
| — | | |
| — | |
Total outstanding – June 30, 2023 | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.41 | |
Exercisable | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.41 | |
The
following table summarizes the activity in liability classified warrants for the six months ended June 30, 2022:
| |
Common
Stock Warrants | |
| |
Shares | | |
Weighted–
Average Exercise Price | | |
Range
of Exercise Price | | |
Weighted–
Average Remaining Life (Years) | |
Total outstanding
–December 31, 2021 | |
| 248,161 | | |
$ | 7.20 | | |
| | | |
| 2.00 | |
Exercised | |
| (536 | ) | |
| 7.20 | | |
| | | |
| | |
Forfeited | |
| (247,625 | ) | |
| 7.20 | | |
| | | |
| | |
Expired | |
| — | | |
| — | | |
| | | |
| | |
Granted | |
| 346,896 | | |
| 5.10 | | |
| | | |
| | |
Total outstanding –
June 30, 2022 | |
| 346,896 | | |
$ | 5.10 | | |
| | | |
| | |
Exercisable | |
| 346,896 | | |
$ | 5.10 | | |
$ | 5.10 | | |
| 1.51 | |
The
following table presents the Company’s fair value hierarchy for its liabilities measured at fair value on a recurring basis as
of June 30, 2023:
SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES
| |
Quoted | | |
| | |
| | |
| |
| |
Market | | |
Significant | | |
| | |
| |
| |
Prices for | | |
Other | | |
Significant | | |
| |
| |
Identical | | |
Observable | | |
Unobservable | | |
| |
| |
Assets | | |
Inputs | | |
Inputs | | |
| |
Common Stock Warrant liabilities | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | | |
Total | |
Balance as of December 31, 2022 | |
$ | — | | |
$ | — | | |
$ | 3,622,647 | | |
$ | 3,622,647 | |
Exercises | |
| — | | |
| — | | |
| — | | |
| — | |
Gain on change in fair value of warrant liabilities | |
| — | | |
| — | | |
| (1,478,967 | ) | |
| (1,478,967 | ) |
Balance as of June 30, 2023 | |
$ | — | | |
$ | — | | |
$ | 2,143,680 | | |
$ | 2,143,680 | |
There
were no transfers of financial assets or liabilities between category levels for the three and six months ended June 30, 2023.
The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.
The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average
calculated based on the number of outstanding warrants on each issuance) as of June 30, 2023 and 2022:
SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES
|
|
June
30, 2023 |
|
June
30, 2022 |
|
|
|
Range |
|
Weighted
Average |
|
Range |
|
Weighted
Average |
|
Risk-free
interest rate |
|
4.05%
— 5.31% |
|
|
4.49 |
% |
2.80%
— 2.87% |
|
|
2.82 |
% |
Expected
volatility (peer group) |
|
66.3%
— 134% |
|
|
110.55 |
% |
74%
— 96% |
|
|
78.6 |
% |
Term
of warrants (in years) |
|
.39
— 4.98 |
|
3.41 |
|
1.39
— 1.99 |
|
1.51 |
|
Expected
dividend yield |
|
|
0.00 |
% |
|
0.00 |
% |
|
0.00 |
% |
|
0.00 |
% |
NOTE
10 — CONVERTIBLE DEBT- RELATED PARTY
On
December 22, 2022, the Company issued to Alpha Capital, an 8%
Senior Convertible Debenture in the aggregate principal amount of $3,300,000
for a purchase price of $3,000,000
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and
from time to time, at Alpha Capital’s option, into shares of common stock of the Company (the “Conversion
Shares”), at a price equal to $1.32
per share, subject to adjustment as described in the Debenture (the “Conversion Price”) and other terms and conditions
described in the Debenture, including the Company’s receipt of the necessary stockholder approvals. Additionally, on December
22, 2022, the Company issued to Alpha Capital a liability classified warrant to purchase 2,500,000
shares of the Company’s common stock (see Note 9 - Warrant Liabilities). The exercise price of the Alpha Warrant is $1.65
(equal to 125%
of the Conversion Price of the Debenture on the closing date). The Alpha Warrant may be exercised by Alpha Capital, in whole or in
part, at any time on or after June 22, 2023 and before June 22, 2028, subject to certain terms and conditions described in the Alpha
Warrant, including the Company’s receipt of the necessary stockholder approvals, which the Company obtained at its 2023 annual
meeting of stockholders.
The
proceeds from the transaction are being used to advance the Company’s QN-302 Investigative New Drug candidate towards clinical
trials and other working capital purposes.
Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a “Monthly Redemption Date”), the Company will redeem $110,000 plus accrued but unpaid
interest, liquidated damages and any amounts then owing under the Debenture (the “Monthly Redemption Amount”). The Monthly
Redemption Amount will be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a
portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a Conversion Price equal to the lesser of (i)
the then Conversion Price of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem
some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to 105% of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. The Company’s election to pay monthly redemptions in Conversion Shares or to effect an optional redemption is subject
to the satisfaction of the Equity Conditions (as defined in the Debenture), including the Company’s receipt of the necessary stockholder
approvals, which the Company obtained at its 2023 annual meeting of stockholders.
The
Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the
Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including the Company’s
receipt of the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of stockholders.
Both
the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and exercise price, respectively, in connection with
stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions.
Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha Capital upon
61 days’ notice to the Company.
The
Company filed a registration statement on Form S-3 (No. 333-269088) with the Securities and Exchange Commission on December 30, 2022
registering the resale by Alpha Capital of an aggregate of 5,157,087 shares of the Company’s common stock, which may be issuable
to Alpha Capital pursuant to the terms of the Debenture and the Alpha Warrant.
The
Company evaluated the Debenture and the Alpha Warrant and determined that the Alpha Warrant is a freestanding financial instrument. The
Alpha Warrant is not considered indexed to the Company’s own stock, because the settlement amount would not equal the difference
between the fair value of a fixed number of the Company’s equity shares and a fixed strike price and all of the adjustment features
in Section 3(b) of the warrant agreement are not down round provisions, as defined in ASU 2017-11. Accordingly, the Alpha Warrant is
classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.
The
proceeds from the Debenture were allocated to the initial fair value of the Alpha Warrant, with the residual balance allocated to the
initial carrying value of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized
as proceeds received after allocating the proceeds to the Alpha Warrant, and then allocating remaining proceeds to a suite of bifurcated
embedded derivative features (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event
of Default), with the resulting difference, if any, allocated to the loan host instrument. The suite of derivative features was measured
and determined to have no fair value.
The
original issue discount of $0.3 million, the initial fair value of the Warrant of $2.8 million, the initial fair value of the suite of
bifurcated embedded derivative features of $0, and the fees and costs paid to Alpha Capital and other third parties of $0.1 million comprised
the debt discount upon issuance. The debt discount is amortized to interest expense over the expected term of the Debenture using the
effective interest method, in accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured at
amortized cost using the effective interest method to accrete interest over its term to bring the Debenture’s initial carrying
value to the principal balance at maturity.
Between
January 9 and 12, 2023, the Company issued 841,726 shares of common stock upon Alpha Capital’s partial conversion of the Debenture
at $1.32 per share for a total of $1,111,078 principal. Upon conversion, the Company recognized a loss on conversion of convertible debt
of approximately $1.1 million, recorded to other expenses in the condensed consolidated statements of operations. During the three and
six months ended June 30, 2023, the Company recorded accrued interest of approximately $383,000 and $945,000, respectively (of which
approximately $364,000 and $898,000 was attributable to discount amortization, respectively) in other expenses in the condensed consolidated
statements of operations. As of June 30, 2023, the fair value of the Alpha Warrant was approximately $2.0 million, and the fair value
of the suite of bifurcated embedded derivative features was $0.
Convertible
debt-related party is comprised of the following as of June 30, 2023 and December 31, 2022:
SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT
| |
June 30, 2023 | | |
December 31, 2022 | |
Senior secured convertible debenture | |
$ | 2,078,922 | | |
$ | 3,300,000 | |
Discount on convertible debenture | |
| (1,266,503 | ) | |
| (3,239,803 | ) |
Total convertible debt-related party | |
$ | 812,419 | | |
$ | 60,197 | |
As
of June 30, 2023, there were no events of default or violation of any covenants under our financing obligations.
NOTE
11 — EARNINGS (LOSS) PER SHARE
Basic
loss per share (“EPS”) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted
EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of shares issuable from stock options and warrants.
The following potentially dilutive securities have been excluded from diluted net loss per share
as of June 30, 2023 and 2022 because their effect would be anti-dilutive:
SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE
| |
As of June 30, | |
| |
2023 | | |
2022 | |
Shares of common stock subject to outstanding options | |
| 445,163 | | |
| 476,783 | |
Shares of common stock subject to outstanding warrants | |
| 4,119,934 | | |
| 1,412,338 | |
Total common stock equivalents | |
| 4,565,097 | | |
| 1,889,121 | |
NOTE
12 — COMMITMENTS AND CONTINGENCIES
Leases
The
Company leases its facilities under a long-term operating lease agreement. On December 15, 2021, our wholly-owned subsidiary Qualigen,
Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment extended the Company’s triple-net leasehold on
the Company’s existing 22,624-square-feet headquarters/manufacturing facility at 2042 Corte del Nogal, Carlsbad, California for
the 61-month period of November 1, 2022 to November 30, 2027. Over the 61 months, the base rent payable by Qualigen, Inc. will total
$1,950,710; however, the base rent for the first 12 months of the 61-month period will be only $335,966. Additionally, under the Second
Amendment to Lease, Qualigen, Inc. is entitled to a $339,360 tenant improvement allowance.
The
tables below show the operating lease right-of-use assets and operating lease liabilities as of June 30, 2023, including the changes
during the periods:
SCHEDULE
OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES
| |
Operating lease right-of-use assets | |
Net right-of-use assets at December 31, 2022 | |
$ | 1,422,538 | |
Less amortization of operating lease right-of-use assets | |
| (116,568 | ) |
Operating lease right-of-use assets at June 30, 2023 | |
$ | 1,305,970 | |
| |
Operating lease liabilities | |
Lease liabilities at December 31, 2022 | |
$ | 1,542,564 | |
Less principal payments on operating lease liabilities | |
| (116,756 | ) |
Lease liabilities at June 30, 2023 | |
| 1,425,808 | |
Less non-current portion | |
| (1,168,653 | ) |
Current portion at June 30, 2023 | |
$ | 257,155 | |
As
of June 30, 2023, the Company’s operating leases have a weighted-average remaining lease term of 4.3 years and a weighted-average
discount rate of 8.9%.
As
of June 30, 2023, future minimum payments during the next five fiscal years and thereafter are as follows:
SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES
Year Ending December 31, | |
Amount | |
2023 (six months) | |
| 184,171 | |
2024 | |
| 379,392 | |
2025 | |
| 390,773 | |
2026 | |
| 402,497 | |
2027 | |
| 379,164 | |
Total | |
| 1,735,997 | |
Less present value discount | |
| (310,189 | ) |
Operating lease liabilities | |
$ | 1,425,808 | |
Total
lease expense was approximately $114,000 and $119,000 for the three months ended June 30, 2023 and 2022, respectively, and approximately
$230,000 and $233,000, respectively, for the six months ended June 30, 2023 and 2022. Lease expense was recorded in cost of product
sales, general and administrative expenses, research and development and sales and marketing expenses.
On
July 20, 2023, the Company entered into a Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc.,
a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued
and outstanding shares of common stock of Qualigen, Inc. The lease commitments described above transferred to Chembio upon the closing
of this transaction. (see Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. ).
NanoSynex
Funding Commitment
On
July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex Amendment”),
which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between
the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary of the Company, to, among other
things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement (see Note 16 - Subsequent Events:
Amendment and Settlement Agreement with NanoSynex Ltd. ).
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
In
the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a
fraction, the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance
to NanoSynex pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we
originally paid in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per
share.
The
Nanosynex Amendment supersedes any payments contemplated by the Original Nanosynex Agreement, such that except as described in the Nanosynex
Amendment, the Company will have no further payment obligations to NanoSynex under the Original Nanosynex Agreement or otherwise (including
by way of equity investment, loan financing or credit lines), and Nanosynex will have no further payment obligations to the Company for
advances previously received under the Original Nanosynex Agreement.
Litigation
and Other Legal Proceedings
On
November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (“Mediant”) in
the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with
Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company
filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in
favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $96,558,
at which time the amount was paid.
NOTE
13 — RESEARCH AND LICENSE AGREEMENTS
The
University of Louisville Research Foundation
Between
June 2018 and April 2022, the Company entered into license and sponsored research agreements with the University of Louisville Research
Foundation (“ULRF”) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements,
the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance
of the related intellectual property portfolio. In return, ULRF received a $50,000 convertible promissory note in payment of an upfront
license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored
research expenses of up to approximately $805,000 and prior patent costs of up to $200,000. In addition, the Company agreed to pay ULRF
(i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of
4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last
to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the
first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement,
and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs
associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments
ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the
first therapeutic indication would be $100,000 for first dosing in a Phase 1 clinical trial, $200,000 for first dosing in a Phase 2 clinical
trial, $350,000 for first dosing in a Phase 3 clinical trial, $500,000 for regulatory marketing approval and $5,000,000 upon achieving
a cumulative $500,000,000 of Licensed Product sales. The Company also agreed to pay another $500,000 milestone payment for any additional
regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also pay ULRF shortfall payments
if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable
annual minimum (ranging from $10,000 to $50,000) for such year.
Sponsored
research expenses related to these agreements for the three months ended June 30, 2023 and 2022 were approximately $0 and $77,000,
respectively, and for the six months ended June 30, 2023 and 2022 were approximately $0 and $164,000, respectively, and these amounts
are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss.
License costs were approximately $1,000 and $14,000 related to these agreements for the three months ended June 30, 2023 and 2022,
respectively, and approximately $22,000 and $69,000 related to these agreements for the six months ended June 30, 2023 and 2022,
respectively, and are included in research and development expenses in the condensed consolidated statements of operations and other
comprehensive loss.
In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of
several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company agreed to reimburse
ULRF for sponsored research expenses of up to $693,000 for this program. In February 2021 and March 2022, the Company extended the term
of this agreement until January 2023 and increased the amount that the Company will reimburse ULRF for sponsored research expenses to
approximately $2.7 million. In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor
drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates
from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000
for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on
patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales
above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed
Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF
license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted
in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be
$50,000 for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing
in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed
Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty
sublicensee income for any year is less than the applicable annual minimum (ranging from $20,000 to $100,000) for such year.
Sponsored
research expenses related to these agreements for the three months ended June 30, 2023 and 2022 were approximately $333,000 and
$220,000, respectively, and for the six months ended June 30, 2023 and 2022 were approximately $556,000 and $405,000, respectively,
and are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive
loss. License costs related to these agreements for the three months ended June 30, 2023 and 2022 were approximately $15,000 and
$16,000, respectively, and for the six months ended June 30, 2023 and 2022 were approximately $29,000 and $18,000, respectively,
and are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive
loss.
In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a
treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the compound
(for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received
approximately $24,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required to enter
into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $250,000. In November 2020,
the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately
$430,000 in research which satisfied this requirement. This sponsored research agreement expired in November 2021.
In
addition, under the exclusive license agreement the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated
with the commercialization of QN-165 as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net
sales above a cumulative $250,000,000), until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by
Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones. Milestone payments would be $50,000 for first dosing in a Phase
1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing in a Phase 3 clinical trial, $300,000
for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales. The Company must
also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for
any year is less than the applicable annual minimum (ranging from $5,000 to $50,000) for such year.
There
were no sponsored research expenses or license costs related to these agreements for the three months ended June 30, 2023 and 2022,
or for the six months ended June 30, 2023 and 2022.
Yi
Xin
In
October 2020, through its wholly-owned diagnostics subsidiary Qualigen, Inc., the Company entered into a Technology Transfer Agreement
with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (“Yi Xin”), of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations
of diagnostic test systems based on the Company’s core FastPack technology. In addition, the Technology Transfer Agreement authorizes
Yi Xin to manufacture and sell the Company’s current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.
The
Company will receive low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin.
Under the Technology Transfer Agreement, during the fiscal year ended December 31, 2021 we recognized revenues of approximately $670,000.
There were no revenues under this agreement for the three months ended June 30, 2023, and the three months ended June 30, 2022. The Company
provided technology transfer and patent/know-how license rights to facilitate Yi Xin’s development and commercialization.
The
Company gave Yi Xin the exclusive rights for China, which is a market it has not otherwise entered, both for Yi Xin’s new generations
of FastPack-based products and for Yi Xin-manufactured versions of our existing FastPack product lines. Yi Xin also has the right to
sell its new generations of FastPack-based diagnostic test systems throughout the world (but not to or toward current customers of the
Company’s existing generations of FastPack products). After March 31, 2022, Yi Xin has the right to sell Yi Xin-manufactured versions
of existing FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-US
customers of those products), as well as the right to buy Qualigen-manufactured FastPack 1.0, IP and PRO products from us at distributor
prices for resale in and for the United States (but not to or toward current U.S. customers of those products). The Company did not license
Yi Xin to sell in the U.S. market any Yi Xin-manufactured versions of those legacy FastPack 1.0, IP and PRO product lines. In the Technology
Transfer Agreement the Company also confirmed that after March 31, 2022 it would not seek new FastPack customers outside the United States,
European Union, Canada and Mexico.
On July 20, 2023, the Company entered into a Purchase
Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company. Pursuant
to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued and outstanding shares of common stock of Qualigen,
Inc. The Technology Transfer Agreement with Yi Xin described above transferred to Chembio upon the closing of this transaction. See Note
16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. to our unaudited condensed consolidated
financial statements for additional details.
UCL
Business Limited
In
January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a
genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London,
including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for
University College London.) The program’s lead compound is now being developed at Qualigen under the name QN-302 as a candidate
for treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. The License Agreement
required a $150,000 upfront payment, reimbursement of past patent prosecution expenses (approximately $160,000), and (if and when applicable)
tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty
sublicensing consideration paid to Qualigen.
For
both the three months ended June 30, 2023 and 2022, there were license costs of $0, and for the six months ended June 30, 2023
and 2022, there were license costs of approximately $0 and $310,000, respectively, related to this agreement which are included in research
and development expenses in the condensed consolidated statements of operations and other comprehensive loss.
Prediction
Biosciences
In
November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS to develop and manufacture
diagnostic tests for use in the stroke Physician Office Laboratory (POL) market. The Company recognizes development revenue and product
sales over the performance period of the contract. Product sales related to this agreement for the three months ended June 30, 2023
and 2022 were $0 for both periods, and for the six months ended June 30, 2023 and 2022 were approximately $86,000 and $0, respectively,
and are recorded in net product sales in the condensed consolidated statements of operations and other comprehensive loss.
QN-302 Phase 1 Study
In
June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC
(“TD2”) where TD2 agreed to perform certain clinical research and development services for the Company including but not
limited to trial management, side identification and selection, site monitoring/management, medical monitoring, project management,
data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory
affairs consulting and submissions, strategic consulting, and/or other related services. From time to time, the Company shall enter
into Statements of Work (“SOW”) with TD2 for the performance of specific services under this Master Clinical Research
Services Agreement (see Note 16 - Subsequent Events: QN-302 Phase 1 Study).
In
June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (“MLM”) where MLM
agreed to perform certain clinical research and development services for the Company including but not limited to laboratory,
supply, testing, validation, data management, and storage services. From time to time, the Company shall enter into work orders with
MLM for the performance of specific services under this Master Laboratory Services Agreement (see Note 16 - Subsequent Events:
QN-302 Phase 1 Study).
In
June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc.
(“Clinigen”) where Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the
Company shall enter into Statements of Work (“SOW”) with Clinigen for the performance of specific services under this
Master Services Agreement (see Note 16 - Subsequent Events: QN-302 Phase 1 Study).
NOTE
14 — STOCKHOLDERS’ EQUITY
As
of June 30, 2023 and December 31, 2022, the Company had two classes of authorized capital stock: common stock and preferred
stock.
Common
Stock
Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any
remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any
preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.
On
December 22, 2022, the Company issued to Alpha Capital, an 8%
Senior Convertible Debenture in the aggregate principal amount of $3,300,000
for a purchase price of $3,000,000
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and
from time to time, at Alpha Capital’s option, into shares of common stock of the Company, at a price equal to $1.32
per share, and other terms and conditions described in the Debenture (see Note 10 - Convertible Debt - Related Party). As part of
this transaction, the Company issued to Alpha Capital a warrant to purchase 2,500,000
shares of the Company’s common stock (see Note 9 - Warrant Liabilities). Between January 9 and 12, 2023, Alpha Capital
voluntarily converted $1,111,078
of its outstanding the Debenture principal into 841,726
shares of common stock at a conversion price of $1.32
per share.
At
June 30, 2023, the Company has reserved 4,565,097 shares of authorized but unissued common stock for possible future issuance. At
June 30, 2023, shares were reserved in connection with the following:
SCHEDULE
OF RESERVED SHARES
| |
| | |
Exercise of issued and future grants of stock options | |
| 445,163 | |
Exercise of stock warrants | |
| 4,119,934 | |
Total | |
| 4,565,097 | |
Preferred
Stock
At
June 30, 2023 and December 31, 2022, there were no shares of preferred stock outstanding.
Stock
Options and Warrants
Stock
Options
The
Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting
period.
In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of incentive
or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service
providers. At June 30, 2023 and December 31, 2022, there were 445,163 and 608,012 outstanding stock options, respectively,
under the 2020 Plan and on such dates there were 310,539 and 147,690 shares reserved under the 2020 Plan, respectively, for future grant.
The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that are outstanding at June 30, 2023, and changes during the six-month period then ended:
SCHEDULE
OF STOCK OPTION ACTIVITY
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range of Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
608,012 |
|
$ |
35.02 |
|
|
$5.14
- $51.30 |
|
|
8.09 |
|
Granted |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Expired |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Forfeited |
|
|
(162,849 |
) |
|
36.01 |
|
|
5.14
- 51.30 |
|
|
— |
|
Total
outstanding – June 30, 2023 |
|
|
445,163 |
|
$ |
34.68 |
|
|
$5.14
— $51.30 |
|
|
7.59 |
|
Exercisable
(vested) |
|
|
323,355 |
|
$ |
44.79 |
|
|
$5.14
— $51.30 |
|
|
7.13 |
|
Non-Exercisable
(non-vested) |
|
|
121,808 |
|
$ |
7.83 |
|
|
$5.14
- $35.20 |
|
|
8.85 |
|
There
was approximately $0.9 and $2.7 million of compensation cost related to outstanding stock options for the six months ended June 30,
2023 and 2022, respectively. As of June 30, 2023, there was approximately $0.5 million of total unrecognized compensation cost related
to unvested stock-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.47 years.
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range of Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
484,186 |
|
$ |
60.70 |
|
$12.40 — $14,657.50 |
|
|
8.52 |
|
Granted |
|
|
2,500 |
|
|
10.50 |
|
|
10.50 |
|
|
9.54 |
|
Expired |
|
|
(9,386 |
) |
|
935.90 |
|
|
57.50
- 14,657.50 |
|
|
— |
|
Forfeited |
|
|
(517 |
) |
|
35.10 |
|
|
12.40
- 49.70 |
|
|
— |
|
Total
outstanding – June 30, 2022 |
|
|
476,783 |
|
$ |
43.30 |
|
|
$10.50
— $51.30 |
|
|
8.19 |
|
Exercisable
(vested) |
|
|
264,366 |
|
$ |
48.40 |
|
|
$12.40
— $50.13 |
|
|
8.00 |
|
Non-Exercisable
(non-vested) |
|
|
212,417 |
|
$ |
36.80 |
|
|
$10.50
— $51.30 |
|
|
8.48 |
|
The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant. The options awarded under the 2020 Plan
will vest as determined by the Board of Directors but will not exceed a ten-year period.
Fair
Value of Equity Awards
The
Company utilizes the Black-Scholes option pricing model to value awards under its equity plans. Key valuation assumptions include:
● | Expected
dividend yield. The expected dividend is assumed to be zero, as the Company has never
paid dividends and has no current plans to pay any dividends on the Company’s common
stock. |
● | Expected
stock-price volatility. The Company’s expected volatility is derived from the average
historical volatilities of publicly traded companies within the Company’s industry
that the Company considers to be comparable to the Company’s business over a period
approximately equal to the expected term. |
● | Risk-free
interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect
at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal
to the expected term. |
● | Expected
term. The expected term represents the period that the stock-based awards are expected
to be outstanding. The Company’s historical share option exercise experience does not
provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient
data. Therefore, the Company estimates the expected term by using the simplified method provided
by the SEC. The simplified method calculates the expected term as the average of the time-to-vesting
and the contractual life of the options. |
The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:
SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
Expected dividend yield | |
| 0.00 | % | |
| 0.00 | % |
Expected stock-price volatility | |
| — | | |
| 102 | % |
Risk-free interest rate | |
| — | | |
1.58% — 1.67 | % |
Expected average term of options (in years) | |
| — | | |
| 6.00 | |
Stock price | |
$ | — | | |
$ | 1.05 | |
The
Company recorded share-based compensation expense and classified it in the unaudited condensed consolidated statements of operations
as follows:
SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE
| |
2023 | | |
2022 | |
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
General and administrative | |
$ | 807,980 | | |
$ | 2,329,418 | |
Research and development | |
| 98,165 | | |
| 361,029 | |
Total | |
$ | 906,145 | | |
$ | 2,690,447 | |
Equity
Classified Compensatory Warrants
In
connection with the $4.0 million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued
common stock warrants to an advisor and its designees for the purchase of 81,143 reverse split adjusted shares of the Company’s
common stock at a reverse split adjusted exercise price of $11.10 per share. The issuance cost of these warrants was charged to additional
paid-in capital, and did not result in expense in the Company’s condensed consolidated statements of operations and comprehensive
loss.
In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier for the purchase of 66,802
reverse split adjusted shares of Company common stock (originally exercisable to purchase Series C convertible preferred stock) at a
weighted average exercise price of $23.40
per share. These are to be differentiated from the Series C Warrants described in Note 9 - Warrant Liabilities.
During
the year ended December 31, 2021, the Company issued equity classified compensatory warrants to a service provider for the purchase of
60,000 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $13.20 per share. The fair
value issuance cost of approximately $0.3 million using the Black-Scholes options pricing model for these warrants was charged to general
and administrative expenses in the Company’s condensed consolidated statements of operations and comprehensive loss. On April 25,
2022, 60,000 warrants were repriced from $13.20 to a reverse split adjusted exercise price of $6.00 and extended from June 3, 2023 to September 14, 2023. The increase in fair value of $67,370 using a Monte Carlo pricing model for the modification of these warrants was
charged to general and administrative expenses in the Company’s condensed consolidated statements of operations and comprehensive
loss. On April 25, 2022 and May 26, 2022 an additional 67,619 reverse split adjusted warrants were repriced from a reverse split adjusted
exercise price of $11.10 to $5.136. The increase in fair value of $31,010 using a Monte Carlo pricing model for the modification of these
warrants was charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements
of operations and comprehensive loss. On December 22, 2022, 67,620 warrants were repriced from a reverse split adjusted exercise price
of $5.136 to $1.32. The increase in fair value of $8,548 using a Monte Carlo pricing model for the modification of these warrants was
charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations
and comprehensive loss.
No
compensatory warrants were issued during the six months ended June 30, 2023.
The
following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June
30, 2023:
SCHEDULE
OF WARRANT ACTIVITY
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
1.73 |
|
Granted
to advisor and its designees |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2023 |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
1.24 |
|
Exercisable |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
|
1.24 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
The
following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June 30,
2022:
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
179,065 |
|
$ |
15.20 |
|
$11.10
— $25.40 |
|
2.64 |
|
Granted
to advisor and its designees |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2022 |
|
|
179,065 |
|
$ |
10.60 |
|
$5.14
— $25.40 |
|
2.23 |
|
Exercisable |
|
|
179,065 |
|
$ |
10.60 |
|
$5.14
— $25.40 |
|
|
2.23 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
There
were no compensation costs related to outstanding equity classified compensatory warrants for the six months ended June 30, 2023
and $67,370 for the six months ended June 30, 2022.
Noncompensatory
Equity Classified Warrants
In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha Capital (a related party) for the
purchase of 27,048 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $11.10 per share
(of which warrants for 20,000 shares were subsequently exercised in December 2020). In July 2020, the Company issued noncompensatory
equity classified warrants to Alpha Capital for the purchase of 78,019 reverse split adjusted shares of Company common stock at a reverse
split adjusted exercise price of $0.01 per share (which were subsequently exercised in July 2020), and 192,068 reverse split adjusted
shares of Company common stock at a reverse split adjusted exercise price of $52.50 per share. In August 2020, the Company issued noncompensatory
equity classified warrants to Alpha Capital for the purchase of 128,783 reverse split adjusted shares of Company common stock at a reverse
split adjusted exercise price of $60.00 per share. In December 2020, the Company issued noncompensatory equity classified warrants to
Alpha Capital for the purchase of 100,000 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $0.10 per share (which were exercised in February 2021) and 219,101 reverse split adjusted shares of Company common stock at
a reverse split adjusted exercise price of $40.70 per share. In May 2022, the Company issued noncompensatory equity classified warrants
to Alpha Capital for the purchase of 331,464 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $0.01 per share.
On
November 29, 2021, with the exception of the warrants to purchase reverse split adjusted shares of the Company’s common
stock at a reverse split adjusted exercise price of $11.10 per share, the exercise prices of all outstanding warrants to purchase a total
of 539,951 reverse split adjusted shares of the Company’s common stock were modified to a reverse split adjusted exercise price
of $20.00 per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant
modifications of approximately $2.3 million was charged to additional paid-in capital and did not result in expense on the Company’s
condensed consolidated statements of operations and comprehensive loss. In May 2022, pre-funded warrants to purchase 331,464 reverse
split adjusted shares of the Company’s common stock at a reverse split adjusted exercise price of $0.01 per share with no expiration
date were issued. These warrants were subsequently exercised during the period ended September 30, 2022.
In
conjunction with the NanoSynex Acquisition, on April 25, 2022 the exercise price of 7,048 reverse split adjusted
outstanding warrants with an exercise price of $11.10 per share was modified to a reverse split adjusted exercise price of $6.00. The
increase in fair value of $2,533, using a Monte Carlo pricing model for the modification of these warrants, was charged to additional
paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations and comprehensive
loss. On May 26, 2022, the reverse split adjusted exercise price of these warrants was modified again to $5.136, and the increase in
fair value of $696, using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred
in the NanoSynex Acquisition. On December 22, 2022, the exercise price of these warrants was modified again to $1.32. The increase in
fair value of $891, using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital
and did not result in expense on the Company’s condensed consolidated statements of operations and comprehensive loss.
No
noncompensatory equity classified warrants were issued during the six months ended June 30, 2023.
The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2023:
SCHEDULE
OF WARRANT ACTIVITY
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
547,003 |
|
$ |
19.76 |
|
$1.32
- $20.00 |
|
0.33 |
|
Legacy
Ritter warrants |
|
|
— |
|
|
— |
|
|
|
|
|
Granted |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
(455,685 |
) |
|
20.00 |
|
|
20.00 |
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2023 |
|
|
91,318 |
|
$ |
18.56 |
|
|
|
- |
|
Exercisable |
|
|
91,318 |
|
$ |
18.56 |
|
$1.32
— $20.00 |
|
|
0.58 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2022:
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
554,914 |
|
$ |
20.10 |
|
|
|
|
|
Legacy
Ritter warrants |
|
|
— |
|
|
— |
|
|
|
|
|
Granted |
|
|
331,464 |
|
|
0.01 |
|
|
0.01 |
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2022 |
|
|
886,378 |
|
$ |
12.60 |
|
|
|
|
|
Exercisable |
|
|
886,378 |
|
$ |
12.60 |
|
$0.01
— $37.70 |
|
|
0.82 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
NOTE
15 — RELATED PARTY TRANSACTIONS
Convertible
Debt
On
December 22, 2022, the Company issued to Alpha Capital, an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000
for a purchase price of $3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is
convertible, at any time, and from time to time, at Alpha Capital’s option, into shares of common stock of the Company, at a price
equal to $1.32 per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture,
including the Company’s receipt of the necessary stockholder approvals (See Note 10 - Convertible Debt - Related Party). Between
January 9 and 12, 2023, Alpha Capital voluntarily converted $1,111,078 of the Debenture principal into 841,726 shares of common stock
at a conversion price of $1.32 per share.
Short-Term
Debt
NanoSynex
has four separate notes payable outstanding to Alpha Capital, issued between March 26, 2020 and September 2, 2021, aggregating to a total
principal outstanding balance of $905,000, and aggregate accrued interest of $60,155 for a total outstanding balance of $965,155 as of
June 30, 2023. The Notes all accrue interest at 2.62% per annum, accrued daily, and provide that the full amount of principal and interest
under each Note shall be due immediately prior to a Liquidation Event (the Maturity Date) unless due earlier in accordance with the terms
of the Notes. “Liquidation Event” means either (i) the merger or consolidation of NanoSynex into any other entity, other
than one in control or under control of NanoSynex or NanoSynex’s majority shareholder; (ii) a transaction or series of transactions
resulting in the transfer of all or substantially all of NanoSynex’s assets or issued and outstanding share capital (other than
to a company under the control of NanoSynex or NanoSynex’s majority shareholders; or (iii) an underwritten public offering by NanoSynex
of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt, or equity funding with gross
proceeds of USD $3,000,000 or more, then the unused portion of these Notes shall be due and payable upon the actual receipt of such funding
(See Note 8 - Short-Term Debt - Related Party).
NanoSynex
Acquisition
The
Company acquired a 52.8% voting equity interest in NanoSynex on May 26, 2022 through: (1) the purchase of 2,232,861 shares Preferred
A-1 Stock of NanoSynex from Alpha Capital (a related party) for 350,000 reverse split adjusted shares of the Company’s common stock
and a prefunded warrant to purchase 331,464 reverse split adjusted shares of the Company’s common stock at a purchase price of
$0.001 per share (these warrants were subsequently exercised on September 13, 2022), and (2) the purchase of 381,786 shares of Series
B preferred stock of NanoSynex from NanoSynex in exchange for $600,000.
NOTE
16 — SUBSEQUENT EVENTS
QN-302
Phase 1 Study
Between
July 5-13, 2023, pursuant to the Master Clinical Research Services Agreement with TD2, Master Services Agreement with Clinigen, and
Master Laboratory Services Agreement with MLM (see Note 13 - Research and License Agreements), the Company entered into work orders
with these vendors to provide clinical trial services for the conduct of the QN-302 Phase 1 study. The estimated project timeline
was set to start in July 2023 and continue until July 2026. The total amount to be paid under these work orders is currently
expected to be approximately $7.6 million over the term of the QN-302 Phase 1 study.
Stock
Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A.
On
July 20, 2023, the Company entered into the Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc.,
a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued
and outstanding shares of common stock of Qualigen, Inc., which was the legal entity operating the Company’s FastPack™ diagnostics
business. The Transaction closed on July 20, 2023. Following the consummation of the Transaction, Qualigen, Inc. became a wholly-owned
subsidiary of Chembio.
The aggregate net purchase price paid to the Company for the Shares was $5.2 million in cash, based on a base purchase price of $5.8
million, subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by Qualigen, Inc. as of the
closing of the Transaction; (ii) net working capital of Qualigen, Inc. as of the closing of the Transaction, (iii) certain indebtedness
of Qualigen, Inc. as of the closing of the Transaction, and (iv) certain Transaction expenses as of the closing of the Transaction. Of
the $5.2 million in cash, $450,000 is being held in escrow to satisfy certain Company indemnification obligations. Any amounts remaining
in the Indemnity Escrow that have not been offset or reserved for claims will be released to the Company within five business days following
the date that is 18 months after the closing.
Amendment and Settlement Agreement with NanoSynex Ltd.
On
July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the NanoSynex Funding Agreement with NanoSynex, to, among
other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement.
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
In
the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction,
the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex
pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we originally paid
in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per share.
The NanoSynex Amendment
supersedes any payments contemplated by the Original NanoSynex Agreement, such that except as described in the NanoSynex Amendment, the
Company will have no further payment obligations to NanoSynex under the Original NanoSynex Agreement or otherwise (including by way of
equity investment, loan financing or credit lines), and NanoSynex will have no further payment obligations to the Company for advances
previously received under the Original NanoSynex Agreement.
Stockholder
Approval of Alpha Stock Issuance Proposal
On
July 13, 2023, the Company held its 2023 annual meeting of stockholders, at which the issuance to Alpha Capital of common stock pursuant
to the terms and conditions of (a) the Debenture and (b) the Alpha Warrant were approved in accordance with Nasdaq Listing Rule 5635(d),
which requires stockholder approval prior to the issuance of more than 20% of the Company’s issued and outstanding common stock.
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The
following discussion and analysis should be read in conjunction with our interim unaudited condensed consolidated financial statements
and related notes included in this Quarterly Report on Form 10-Q (this “Quarterly Report”) and the audited financial statements
and notes thereto as of and for the twelve months ended December 31, 2022, which are contained in our Annual Report on Form 10-K filed
with the Securities and Exchange Commission (“SEC”) on May 2, 2023, as amended by Amendment No. 1 filed with the SEC on July
7, 2023 ( the “2022 Annual Report.) As used in this Quarterly Report, unless the context suggests otherwise, “we,”
“us,” “our,” or “Qualigen” refer to Qualigen Therapeutics, Inc. In addition to historical information,
this discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions.
Cautionary
Note Regarding Forward Looking Statements
This
Quarterly Report contains forward-looking statements by the Company that involve risks and uncertainties and reflect the Company’s
judgment as of the date of this Report. These statements generally relate to future events or the Company’s future financial or
operating performance. In some cases, you can identify forward-looking statements because they contain words such as “may,”
“will,” “should,” “expects,” “plans,” “anticipates,” “could,”
“intends,” “target,” or “continue” or the negative of these words or other similar terms or expressions
that concern the Company’s expectations, strategy, plans or intentions. Such forward-looking statements may relate to, among other
things, potential future development, testing and launch of products and product candidates. Actual events or results may differ from
our expectations.
Some
of the factors that we believe could cause actual results to differ from those anticipated or predicted include:
| ● | there
can be no assurance that we will successfully develop any drugs or therapeutic devices; |
| ● | there
can be no assurance that preclinical or clinical development of our candidate drugs or therapeutic
devices will be successful; |
| ● | there
can be no assurance that clinical trials will be approved to begin by or will actually begin
by or will proceed as contemplated by any projected timeline; |
| ● | there
can be no assurance that clinical trials will complete enrollment as contemplated by any
projected timeline; |
| ● | there
can be no assurance that future clinical trial data will be favorable or that such trials
will confirm any improvements over other products or lack negative impacts; |
| ● | there
can be no assurance that any of our candidate drugs or therapeutic devices will receive the
required regulatory approvals or that they will be commercially successful; |
| ● | there
can be no assurance that we will be able to procure or earn sufficient working capital to
complete the development, testing and launch of our prospective candidate drugs therapeutic
products; |
| ● | there
can be no assurance that patents will issue on our owned and in-licensed patent applications; |
| ● | there
can be no assurance that such patents, if any, and our current owned and in-licensed patents
would prevent competition; |
By
their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics, and healthcare,
regulatory and scientific developments and depend on the economic circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement
contained in this Quarterly Report, we caution you that forward-looking statements are not guarantees of future performance and that
our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ
materially from the forward-looking statements contained in this Quarterly Report. In addition, even if our results of operations, financial
condition and liquidity, and the development of the industry in which we operate, are consistent in some future periods with the forward-looking
statements contained in this Quarterly Report, they may not be predictive of results or developments in other future periods.
Future
filings with the SEC, future press releases and future oral or written statements made by us or with our approval, which are not statements
of historical fact, may also contain forward-looking statements. Because such statements include risks and uncertainties, many of which
are beyond our control, actual results may differ materially from those expressed or implied by such forward-looking statements. The
forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update such statements
to reflect events that occur or circumstances that exist after the date on which they are made.
Overview
We
are a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug
designation.
Our
cancer therapeutics pipeline includes QN-302, RAS and QN-247.
Our
lead oncology therapeutics program, QN-302, is an investigational small molecule G4-selective transcription inhibitor with strong binding
affinity to G4s prevalent in cancer cells. Such binding could, by stabilizing the G4s against DNA “unwinding,” help inhibit
cancer cell proliferation. QN-302 is currently undergoing Good Laboratory Practice (GLP) toxicology studies.
Our
Pan-RAS portfolio consists of a family of RAS oncogene protein-protein interaction inhibitor small molecules believed to inhibit or block
mutated RAS genes’ proteins from binding to their effector proteins. Preventing this binding could stop tumor growth, especially
in RAS-driven tumors such as pancreatic, colorectal and lung cancers.
Our
investigational QN-247 compound binds nucleolin, a key multi-functional regulatory phosphoprotein that is overexpressed in cancer cells.
Such binding could inhibit the cancer cells’ proliferation. The foundational aptamer of QN-247 is QN-165 (formerly referred to
as AS1411), which the Company has deprioritized as a drug candidate for treating COVID-19 and other viral-based infectious diseases.
On
November 23, 2022, we effected a 1-for-10, as determined by our board of directors, reverse stock split of our outstanding shares of
common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced our shares of outstanding common stock, stock options,
and warrants to purchase shares of our common stock. Fractional shares of common stock that would have otherwise resulted from the Reverse
Stock Split were rounded down to the nearest whole share and cash in lieu of fractional shares was paid to stockholders. All share and
per share data for all periods presented in this section and the accompanying financial statements and related disclosures have been
adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common stock and the par value per share
remains unchanged.
On
May 26, 2022, we acquired 2,232,861 shares of Series A-1 Preferred Stock of NanoSynex Ltd. (“NanoSynex”) from Alpha Capital
Anstalt (“Alpha Capital”) in exchange for 350,000 shares of our common stock and a prefunded warrant to purchase 331,464
shares of our common stock at an exercise price of $0.001 per share. These warrants were subsequently exercised on September 13, 2022.
Concurrently with this transaction, we also purchased 381,786 shares of Series B preferred stock from NanoSynex for a total purchase
price of $600,000. The transactions resulted in our acquiring a 52.8% interest in NanoSynex (the “NanoSynex Acquisition”).
NanoSynex is a micro-biologics diagnostics company domiciled in Israel.
We
do not expect to be profitable before products from our therapeutics pipeline are commercialized. To experience losses while therapeutic
products are still under development is, of course, typical for biotechnology companies.
Recent
Developments
FDA
Clearance of IND Application for QN-302
On
August 1, 2023, the Company announced that the U.S. Food and Drug Administration has cleared the Company’s investigational new
drug (IND) application for QN-302, allowing us to commence our Phase 1 clinical trial for QN-302.
Sale
of FastPack™ Diagnostics Business
On
July 20, 2023, we sold all of the issued and outstanding shares of common stock of our wholly-owned subsidiary, Qualigen, Inc., which
was the legal entity operating our FastPack™ diagnostics business, to Chembio Diagnostics, Inc. (“Chembio”), a wholly-owned
subsidiary of Biosynex, S.A. (the “Transaction”). The aggregate net purchase price
paid to us for the shares was $5.2 million in cash, based on a base purchase price of $5.8 million, subject to certain post-closing adjustments,
upward or downward, as applicable. Of the $5.2 million, $450,000 is being held in escrow to satisfy certain indemnification obligations.
Any amounts remaining in the Indemnity Escrow that have not been offset or reserved for claims will be released to us within five
business days following the date that is 18 months after the closing. Following the consummation of the Transaction, Qualigen, Inc. became
a wholly-owned subsidiary of Chembio.
Amendment
and Settlement Agreement with NanoSynex Ltd.
On
July 20, 2023, we entered into an Amendment and Settlement Agreement with Nanosynex (the “NanoSynex Amendment”), which amended
the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd. (the “NanoSynex Funding Agreement”)
with NanoSynex and our payment obligations to NanoSynex under such agreement. See “Contractual Obligations and Commitments”
below.
Critical
Accounting Policies and Estimates
Our
condensed consolidated financial statements do not separate our diagnostics-related activities from our therapeutics-related activities.
Although to date all of our reported revenue is diagnostics-related, our reported expenses represent the total of our diagnostics-related
and therapeutics-related expenses.
This
discussion and analysis is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S.
GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates and judgments that affect the
reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in our condensed
consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to impairment
of goodwill and other intangible assets, fair value of warrant liabilities, stock-based compensation, amortization and depreciation,
inventory reserves, allowances for doubtful accounts and returns, and warranty costs. We base our estimates on historical experience,
known trends and events and various other factors we believe to be reasonable under the circumstances, the results of which form the
basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual
results may differ from these estimates under different assumptions or conditions.
While
our significant accounting policies are more fully described in Note 1 - Organization And Summary Of Significant Accounting Policies
And Estimates to our unaudited condensed consolidated financial statements appearing in “Item 1. Condensed Consolidated Financial
Statements (Unaudited),” we believe that the following accounting policies are the most critical to aid you in fully understanding
and evaluating our financial condition and results of operations:
| ● | Research
and development |
| ● | Allowance
for doubtful accounts and returns |
| ● | Impairment
of long-lived assets |
| ● | Derivative
financial instruments and warrant liabilities |
| ● | Stock-based
compensation |
Warrant
Liabilities
In
2004, Qualigen, Inc. issued Series C preferred stock warrants to investors and brokers in connection with a private placement. These
warrants were subsequently extended and survived the May 2020 Ritter reverse recapitalization transaction and are now exercisable for
Qualigen Therapeutics common stock. These warrants contain a provision that if we issue shares (except in certain defined scenarios)
at a price below the warrants’ exercise price, the exercise price will be re-set to such new price and the number of shares underlying
the warrants will be increased in the same proportion as the exercise price decrease. For accounting purposes, such warrants give rise
to warrant liabilities. The operation of the “double-ratchet” provisions in these warrants in connection with the NanoSynex
Acquisition and the convertible debenture financing transaction in December 2022 now allow the holders to exercise for a significantly
higher number of shares than before. Accounting principles generally accepted in the United States of America (“U.S. GAAP”)
require us to recognize the fair value of these warrants as warrant liabilities on our condensed consolidated balance sheets and to reflect
period-to-period changes in the fair value of the warrant liabilities on our condensed consolidated Statements of Operations. The estimated
fair value of these warrant liabilities was $0.1 million and $0.8 million at June 30, 2023 and December 31, 2022, respectively. There
were 1,349,571 of these warrants outstanding at June 30, 2023 and December 31, 2022.
On
December 22, 2022, as part of the convertible debenture financing, the Company issued to Alpha Capital a common stock warrant for 2,500,000
shares of common stock of the Company (the “Alpha Warrant”). The exercise price of the Alpha Warrant is $1.65. The Alpha
Warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after June 22, 2023 and before June 22, 2028. U.S.
GAAP requires us to recognize the fair value of this warrant as a warrant liability on our condensed consolidated balance sheets and
to reflect period-to-period changes in the fair value of the warrant liability on our condensed consolidated statements of operations.
The estimated fair value of this warrant liability was $2.0 million and $2.8 million at June 30, 2023 and December 31, 2022, respectively.
Because
the fair value of the above liability classified warrants will be determined each quarter on a “mark-to-market” basis, it
could result in significant variability in our future quarterly and annual consolidated statement of operations and consolidated balance
sheets based on changes in our public market common stock price. Pursuant to U.S. GAAP, a quarter-to-quarter increase in our stock price
would result in an increase (possibly quite large) in the fair value of the warrant liabilities and a quarter-to-quarter decrease in
our stock price would result in a decrease (possibly quite large) in the fair value of the warrant liabilities.
Results
of Operations
Comparison
of the Three Months Ended June 30, 2023 and 2022
The
following table summarizes our results of operations for the three months ended June 30, 2023 and 2022:
| |
For the Three Months Ended June 30, | |
| |
2023 | | |
2022 | |
REVENUES | |
| | |
| |
Net product sales | |
$ | 1,627,031 | | |
$ | 1,430,534 | |
Total revenues | |
| 1,627,031 | | |
| 1,430,534 | |
| |
| | | |
| | |
EXPENSES | |
| | | |
| | |
Cost of product sales | |
| 1,016,542 | | |
| 1,099,677 | |
General and administrative | |
| 2,665,849 | | |
| 2,660,857 | |
Research and development | |
| 1,326,544 | | |
| 1,506,227 | |
Sales and marketing | |
| 169,223 | | |
| 305,103 | |
Total expenses | |
| 5,178,158 | | |
| 5,571,864 | |
| |
| | | |
| | |
LOSS FROM OPERATIONS | |
| (3,551,127 | ) | |
| (4,141,330 | ) |
| |
| | | |
| | |
OTHER EXPENSE (INCOME), NET | |
| | | |
| | |
Gain on change in fair value of warrant liabilities | |
| (440,294 | ) | |
| (14,800 | ) |
Interest expense (income), net | |
| 377,416 | | |
| (4,823 | ) |
Loss on disposal of equipment held for lease | |
| 63,302 | | |
| — | |
Other income, net | |
| (5,680 | ) | |
| 376 | |
Total other expense (income), net | |
| (5,256 | ) | |
| (19,247 | ) |
| |
| | | |
| | |
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES | |
| (3,545,871 | ) | |
| (4,122,082 | ) |
| |
| | | |
| | |
(BENEFIT) PROVISION FOR INCOME TAXES | |
| (38,182 | ) | |
| 5,438 | |
| |
| | | |
| | |
NET LOSS | |
| (3,507,689 | ) | |
| (4,127,520 | ) |
| |
| | | |
| | |
Net loss attributable to noncontrolling interest | |
| (43,484 | ) | |
| (4,116 | ) |
| |
| | | |
| | |
Net loss attributable to Qualigen Therapeutics, Inc. | |
$ | (3,464,205 | ) | |
$ | (4,123,404 | ) |
| |
| | | |
| | |
Other comprehensive loss, net of tax | |
| | | |
| | |
Net loss | |
$ | (3,507,689 | ) | |
$ | (4,127,520 | ) |
Foreign currency translation adjustment | |
| (56,747 | ) | |
| 65,540 | |
Other comprehensive loss | |
| (3,564,436 | ) | |
| (4,061,980 | ) |
Comprehensive loss attributable to noncontrolling interest | |
| (43,484 | ) | |
| (4,116 | ) |
Comprehensive loss attributable to Qualigen Therapeutics, Inc. | |
$ | (3,520,952 | ) | |
$ | (4,057,864 | ) |
Revenues
Net
product sales
Net
product sales are primarily generated from sales of diagnostic tests. Net product sales during the three-month periods ended June 30,
2023 and 2022 were approximately $1.6 million and $1.4 million, respectively, representing an increase of approximately $0.2 million,
or 14%. This increase was primarily due to growth in sales volumes and higher average unit selling prices.
Expenses
Cost
of Product Sales
Cost
of product sales decreased during the three months ended June 30, 2023, to $1.0 million, or 62% of net product sales, compared
to approximately $1.1 million, or 77% of net product sales, during the three months ended June 30, 2022. This decrease of $0.1
million, and decrease as a percentage of sales was primarily due to a reduction in force implemented in January 2023.
General
and Administrative Expenses
General
and administrative expenses remained the same at $2.7 million, for the three months ended June 30, 2023 and 2022.
Research
and Development Costs
Research
and development costs include therapeutic and diagnostic research and product development costs. Research and development costs
decreased from $1.5 million for the three months ended June 30, 2022 to $1.3 million for the three months ended June 30,
2023. Of the $1.3 million of research and development costs for the three months ended June 30, 2023, approximately $1.2
million (89%) was attributable to therapeutics and $0.2 million (11%) was attributable to diagnostics. Of the $1.5 million of
research and development costs for the three months ended June 30, 2022, $1.1 million (73%) was attributable to therapeutics
and $0.4 million (27%) was attributable to diagnostics.
The
$0.1 million increase in therapeutics research and development costs during the three months ended June 30, 2023 compared to the
three months ended June 30, 2022 was primarily due to an increase of $0.5 million in preclinical research costs for QN-302, offset
by a decrease of $0.4 million in preclinical research costs for QN-247.
The
$0.2 million decrease in diagnostics research and development costs during the three months ended June 30, 2023 compared to the
three months ended June 30, 2022 was primarily due to a $0.2 million decrease in stock-based compensation expense and a $0.1
million decrease in payroll expenses related to FastPack due to the January 2023 reduction in force, offset by an increase of $0.1
million in research and development expenses for NanoSynex.
For
the future, we expect our therapeutic research and development costs to be relatively lower in periods when we are focusing on preclinical
activities and meaningfully higher in periods when we are provisioning for and conducting clinical trials, if any.
Sales
and Marketing Expenses
Sales
and marketing expenses were approximately $0.2 million for the three months ended June 30, 2023, a decrease of $0.1 million or 45%,
from the three months ended June 30, 2022. This decrease was primarily due to reduced payroll expenses related
to the January 2023 reduction in force.
Other
Income (Expense), Net
Change
in Fair Value of Warrant Liabilities
During
three months ended June 30, 2023 we experienced a $0.4 million gain on change in fair value of warrant
liabilities arising from our liability classified warrants described above. The estimated fair value of these warrants decreased to $2.1
million as of June 30, 2023 from $3.6 million as of December 31, 2022, primarily due to a reduction in our stock price and shorter remaining
outstanding life of the warrants.
Because
the fair value of the warrant liabilities will be determined each quarter on a “mark-to-market” basis, this item is likely
to continue to result in significant variability in our future quarterly and annual consolidated statements of operations based on unpredictable
changes in our public market common stock price and the number of warrants outstanding at the end of each quarter.
Interest
Expense (Income), Net
Interest
expense, net during the three months ended June 30, 2023 was approximately $377,000 due to accrued interest on the convertible
debt, as compared to interest income, net of approximately $5,000 during the three months ended June 30, 2022.
Loss
on Disposal of Equipment Held for Lease
Loss
on disposal of equipment held for lease during the three months ended June 30, 2023 was $63,000, compared to $0 during the three
months ended June 30, 2022. This increase of $63,000 was due to a write off of discontinued FastPack analyzers that were acquired
from Sekisui.
Other
Income, Net
Other
income was immaterial during the three months ended June 30, 2023 and 2022.
Comparison
of the Six Months Ended June 30, 2023 and 2022
The
following table summarizes our results of operations for the six months ended June 30, 2023 and 2022:
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
REVENUES | |
| | |
| |
Net product sales | |
$ | 3,234,201 | | |
$ | 2,152,563 | |
Total revenues | |
| 3,234,201 | | |
| 2,152,563 | |
| |
| | | |
| | |
EXPENSES | |
| | | |
| | |
Cost of product sales | |
| 2,281,368 | | |
| 1,928,524 | |
General and administrative | |
| 4,380,283 | | |
| 5,559,608 | |
Research and development | |
| 3,448,095 | | |
| 3,370,972 | |
Sales and marketing | |
| 368,337 | | |
| 443,426 | |
Total expenses | |
| 10,478,083 | | |
| 11,302,530 | |
| |
| | | |
| | |
LOSS FROM OPERATIONS | |
| (7,243,882 | ) | |
| (9,149,967 | ) |
| |
| | | |
| | |
OTHER EXPENSE (INCOME), NET | |
| | | |
| | |
Gain on change in fair value of warrant liabilities | |
| (1,478,967 | ) | |
| (698,042 | ) |
Interest expense (income), net | |
| 921,652 | | |
| (11,132 | ) |
Loss on voluntary conversion of convertible debt | |
| 1,077,287 | | |
| — | |
Loss on disposal of equipment held for lease | |
| 63,302 | | |
| — | |
Other income, net | |
| (10,559 | ) | |
| 341 | |
Loss on fixed asset disposal | |
| 300 | | |
| — | |
Total other expense (income), net | |
| 573,015 | | |
| (708,833 | ) |
| |
| | | |
| | |
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES | |
| (7,816,897 | ) | |
| (8,441,134 | ) |
| |
| | | |
| | |
(BENEFIT) PROVISION FOR INCOME TAXES | |
| (201,959 | ) | |
| 6,173 | |
| |
| | | |
| | |
NET LOSS | |
| (7,614,938 | ) | |
| (8,447,307 | ) |
| |
| | | |
| | |
Net loss attributable to noncontrolling interest | |
| (304,512 | ) | |
| (4,116 | ) |
| |
| | | |
| | |
Net loss attributable to Qualigen Therapeutics, Inc. | |
$ | (7,310,426 | ) | |
$ | (8,443,191 | ) |
| |
| | | |
| | |
Other comprehensive loss, net of tax | |
| | | |
| | |
Net loss | |
$ | (7,614,938 | ) | |
$ | (8,447,307 | ) |
Foreign currency translation adjustment | |
| 119,473 | | |
| 65,540 | |
Other comprehensive loss | |
| (7,495,465 | ) | |
| (8,381,767 | ) |
Comprehensive loss attributable to noncontrolling interest | |
| (304,512 | ) | |
| (4,116 | ) |
Comprehensive loss attributable to Qualigen Therapeutics, Inc. | |
$ | (7,190,953 | ) | |
$ | (8,377,651 | ) |
Revenues
Net
product sales
Net
product sales are primarily generated from sales of diagnostic tests. Net product sales during the six-month periods ended June 30,
2023 and 2022 were approximately $3.2 million and $2.2 million, respectively, representing an increase of approximately $1.0 million,
or 50%. This increase was primarily due to the expiration of the Sekisui Distribution Agreement on March 31, 2022, at which time the
distribution services previously provided by Sekisui reverted to us, which resulted in our recognizing 100% of the revenue from sales
of our FastPack diagnostic test kits and instruments beginning in the second quarter of 2022.
Expenses
Cost
of Product Sales
Cost
of product sales increased during the six months ended June 30, 2023 to $2.3 million, or 71% of net product sales, compared to approximately
$1.9 million, or 90% of net product sales, during the six months ended June 30, 2022. This increase of $0.4 million, and decrease
as a percentage of sales was relative to the increase in sales volumes and higher average unit selling prices due to the termination of the Sekisui agreement on March
31, 2022 as well as a reduction in force implemented in January 2023.
General
and Administrative Expenses
General
and administrative expenses decreased from $5.6 million, during the six months ended June 30, 2022 to approximately $4.4 million
during the six months ended June 30, 2023, a decrease of $1.2 million or 21%. This decrease was primarily due to a $1.5 million
decrease in stock-based compensation expense due to the January 2023 reduction in force, partially offset by an increase in accounting fees of $0.3 million.
Research
and Development Costs
Research
and development costs include therapeutic and diagnostic research and product development costs. Research and development costs remained
approximately the same at $3.4 million for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. Of
the $3.4 million of research and development costs for the six months ended June 30, 2023, $2.4 million (71%) was attributable to
therapeutics and $1.0 million (29%) was attributable to diagnostics. Of the $3.4 million of research and development costs for the six
months ended June 30, 2022, $2.7 million (80%) was attributable to therapeutics and $0.7 million (20%) was attributable to diagnostics.
The
$0.3 million decrease in therapeutics research and development costs during the six months ended June 30, 2023 compared to the
six months ended June 30, 2022 was primarily due to a decrease of $0.9 million of preclinical research costs for our QN-247
program, a decrease of $0.1 million in RAS preclinical research costs, a $0.2 million decrease in payroll-related expenses, and a
$0.1 million decrease in preclinical research costs for QN-165, offset by an increase of $1.0 million in preclinical research costs
for QN-302.
The
$0.3 million increase in diagnostics research and developments costs during the six months ended June 30, 2023 compared to the six months
ended June 30, 2022 was due to an increase of $0.8 million in research and development expenses for NanoSynex, offset by a reduction of offset
by a reduction of $0.5 million in FastPack research and development expenses due to the January 2023 reduction in force.
For
the future, we expect our therapeutic research and development costs to be relatively lower in periods when we are focusing
on preclinical activities and meaningfully higher in periods when we are provisioning for and conducting clinical trials, if any.
Sales
and Marketing Expenses
Sales
and marketing expenses were approximately $0.4 million for the six months ended June 30, 2023, a decrease of $0.1 million or 17% from
the six months ended June 30, 2022. This decrease was primarily due to lower payroll costs as a result of the January 2023 reduction in force.
Other
Income (Expense), Net
Change
in Fair Value of Warrant Liabilities
During
six months ended June 30, 2023 we experienced a $1.5 million gain on change in fair value of warrant
liabilities arising from our liability classified warrants described above. The estimated fair value of these warrants decreased to $2.1
million as of June 30, 2023 from $3.6 million as of December 31, 2022, primarily due to a reduction in our stock price
and shorter remaining outstanding life of the warrants.
Because
the fair value of the warrant liabilities will be determined each quarter on a “mark-to-market” basis, this item is likely
to continue to result in significant variability in our future quarterly and annual statements of operations based on unpredictable changes
in our public market common stock price and the number of liability classified warrants outstanding at the end of each quarter.
Interest
Expense (Income), Net
Interest
expense, net during the six months ended June 30, 2023 was approximately $921,000 due to accrued interest on the convertible
debt, as compared to interest income, net of approximately $11,000 during the six months ended June 30, 2022.
Loss
on Voluntary Conversion of Convertible Debt
During the six months ended June 30, 2023, we recognized a $1.1 million loss due to a voluntary conversion by Alpha
Capital of approximately $1.1 million of convertible debt into 841,726 shares of common stock (see Note 10 - Convertible Debt - Related
Party to our condensed consolidated financial statements). We did not have any outstanding convertible debt for the six months ended June
30, 2022.
Loss
on Disposal of Equipment Held for Lease
Loss
on disposal of equipment held for lease during the six months ended June 30, 2023, was $63,000, compared to $0 during the
six months ended June 30, 2022. This increase of $63,000 was due to a write off of discontinued FastPack analyzers that were acquired
from Sekisui.
Other
Income, Net
Other
income was immaterial during the six months ended June 30, 2023 and 2022.
Liquidity
and Capital Resources
As
of June 30, 2023, we had approximately $1.3 million in cash and an accumulated deficit of $110.7 million. For the six months ended
June 30, 2023 and the year ended December 31, 2022, we used cash of $5.6 million and $13.2 million, respectively, in operations.
On
July 25, 2023, we received a cash payment of $4.7 million from Chembio for all of the outstanding
shares of common stock of Qualigen, Inc., which payment is subject to post-closing adjustments, upward or downward, as applicable,
for: (i) cash held by the Subsidiary as of the closing of the Transaction; (ii) net working capital of the Subsidiary as of the closing
of the Transaction, (iii) certain indebtedness of the Subsidiary as of the closing of the Transaction, and (iv) certain Transaction expenses
as of the closing of the Transaction. An additional $450,000 is being held in an escrow account
to satisfy certain indemnification obligations. Any amounts remaining in the Indemnity Escrow that have not been offset or reserved
for claims will be released to us within five business days following the date that is 18 months after the closing of the Transaction.
On
July 20, 2023, we entered into the NanoSynex Amendment with NanoSynex, which amended the NanoSynex Funding Agreement. See “Contractual
Obligations and Commitments” below.
The
Company’s cash balances as of the date that the accompanying financial statements were issued along with the proceeds from the above sale to Chembio, without additional financing,
are expected to fund operations into the first quarter of 2024. The Company expects to continue to have net losses and negative cash
flow from operations, which over time will challenge its liquidity. These factors raise substantial doubt about the Company’s
ability to continue as a going concern for the one-year period following the date that these financial statements were
issued.
There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute our business plan, we will require significant additional funding for planned research and development activities, capital
expenditures, clinical testing for our QN-302 clinical trials, preclinical development of RAS and QN-247, as well as
commercialization activities.
Historically,
our principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from the issuance
of debt. In December 2022 we raised $3.0 million from the sale of a convertible debt instrument (see Note 10-Convertible Debt - Related
Party to our unaudited condensed consolidated financial statements). There can be no assurance that further financing will be obtained
on favorable terms, or at all. If we are unable to obtain funding, we could be required to delay, reduce or eliminate research and development
programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business prospects.
The
accompanying financial statements have been prepared assuming that we will continue as a going concern. The financial statements do not
include any adjustments that would be necessary should we be unable to continue as a going concern, and therefore, be required to liquidate
our assets and discharge our liabilities in other than the normal course of business and at amounts that may differ from those reflected
in the accompanying financial statements.
Our
condensed consolidated balance sheet at June 30, 2023 includes $2.1 million of warrant liabilities. We do not consider the warrant
liabilities to constrain our liquidity, as a practical matter. Our current liabilities at June 30, 2023 include $1.8 million of
accounts payable, $2.0 million of accrued expenses and other current liabilities, a $0.2 million R&D grant liability, $0.3 million
of accrued vacation, $1.8 million in short term debt and convertible debt to a related party.
Contractual
Obligations and Commitments
We
have no material contractual obligations that are not fully recorded on our condensed consolidated balance sheets or fully disclosed
in the notes to the unaudited condensed consolidated financial statements.
Lease
Agreement with Bond Ranch LP
On
December 15, 2021, our wholly-owned subsidiary Qualigen, Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment
extended our triple-net leasehold on our existing 22,624-square-foot headquarters/manufacturing facility at 2042 Corte del Nogal, Carlsbad,
California for the 61-month period of November 1, 2022 to November 30, 2027. Over the 61 months, the base rent payable will total $1,950,710;
however, the base rent for the first 12 months of the 61-month period will be only $335,966. Additionally, Qualigen, Inc. was entitled
to a $339,360 tenant improvement allowance. On July 20, 2023, the Company entered into a Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”),
and Qualigen, Inc., a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio
all of the issued and outstanding shares of common stock of Qualigen, Inc. The lease commitments described above transferred to Chembio
upon the closing of this transaction. See Note 12 - Commitments and Contingencies and Note 16 - Subsequent Events: Stock Purchase Agreement
with Chembio Diagnostics, Inc. and Biosynex, S.A. to our unaudited condensed consolidated financial
statements for additional details.
License
and Sponsored Research Agreements
We
have obligations under various license and sponsored research agreements to make future payments to third parties that become due and
payable on the achievement of certain development, regulatory and commercial milestones (such as the start of a clinical trial, filing
for product approval with the FDA or other regulatory agencies, product approval by the FDA or other regulatory agencies, product launch
or product sales) or on the sublicense of our rights to another party. We have not included these commitments on our balance sheet because
the achievement and timing of these events is not determinable. Certain milestones are in advance of receipt of revenue from the sale
of products and, therefore, we may require additional debt or equity capital to make such payments.
We
have multiple license and sponsored research agreements with ULRF. Under these agreements, we have taken over development, regulatory
approval and commercialization of various drug compounds from ULRF and are responsible for maintenance of the related intellectual property
portfolio. For example, we agreed to reimburse ULRF for sponsored research expenses of up to $2.7 million and prior patent costs of up
to $112,000 for RAS. As of June 30, 2023, there was approximately $239,000 remaining due to ULRF under this sponsored research agreement
for RAS. We also agreed to reimburse ULRF for sponsored research expenses of up to $830,000 and prior patent costs of up to $200,000
for QN-247. As of June 30, 2023, there were no remaining un-expensed amounts due to ULRF under this sponsored research agreement
for QN-247 and the agreement was terminated effective August 31, 2022. Under the
terms of these agreements, we are required to make patent maintenance payments and payments based upon development, regulatory and commercial
milestones for any products covered by the in-licensed intellectual property. The maximum aggregate milestone payments we may be obligated
to make per product are $5 million. We will also be required to pay a royalty on net sales of products covered by the in-licensed intellectual
property in the low single digits. The royalty is subject to reduction for any third-party payments required to be made, with a minimum
floor in the low single digits. We have the right to sublicense our rights under these agreements, and we will be required to pay a percentage
of any sublicense income.
On
January 13, 2022, we entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic
quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including
lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University
College London.) The program’s lead compound is being developed by us under the name QN-302 as a candidate for treatment of pancreatic
ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. The Agreement requires (if and when applicable)
tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments, and a percentage of any non-royalty
sublicensing consideration paid to the Company.
Technology
Transfer Agreement with Yi Xin
Through
our wholly-owned diagnostics subsidiary Qualigen, Inc., we entered into a Technology Transfer Agreement, dated as of October 7, 2020,
with Yi Xin of Suzhou, China, which authorizes Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based
on our core FastPack technology. In addition, the Technology Transfer Agreement authorizes Yi Xin to manufacture and sell our current
generations of FastPack System diagnostic products (1.0, IP and PRO) in China. We have provided technology transfer and patent/know-how
license rights to facilitate Yi Xin’s development and commercialization.
Under
the terms of the Technology Transfer Agreement, we have provided Yi Xin the exclusive rights for China, which is a market we have not
otherwise entered, both for Yi Xin’s new generations of FastPack-based products and for Yi Xin-manufactured versions of our existing
FastPack product lines. Yi Xin has the right to sell its new generations of FastPack-based diagnostic test systems throughout the world
(but not to or toward current customers of our existing generations of FastPack products); provided that any non-China sales would, until
March 31, 2022, need to be through Sekisui. As of April 1, 2022, Yi Xin has right to sell Yi Xin-manufactured versions of existing FastPack
1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-US customers of those
products). Yi Xin also has the right, as of April 1, 2022, to buy Qualigen-manufactured FastPack 1.0, IP and PRO products from us at
distributor prices for resale in and for the United States (but not to or toward current U.S. customers of those products). We did not
license Yi Xin to sell in the United States market any Yi Xin-manufactured versions of those legacy FastPack product lines, even after
March 31, 2022. We agreed in the Technology Transfer Agreement that we would not, after March 31, 2022, seek new FastPack customers outside
the United States, European Union, Canada, and Mexico.
Under
the Technology Transfer Agreement, during the fiscal year ended December 31, 2021 we recognized revenues of approximately $670,000. There
were no revenues under this agreement for the six months ended June 30, 2023, and the six months ended June 30, 2022. We will receive
low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin.
Yi
Xin is a newly-formed company and is subject to many risks. There can be no assurance that Yi Xin will successfully commercialize any
products or that we will receive any royalties from Yi Xin.
On
July 20, 2023, the Company entered into a Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc.,
a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued
and outstanding shares of common stock of Qualigen, Inc. The Technology Transfer Agreement with Yi Xin described above transferred to
Chembio upon the closing of this transaction. See Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics,
Inc. and Biosynex, S.A. to our unaudited condensed consolidated financial statements for additional details.
Alpha
Convertible Debt
On
December 22, 2022, we issued an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000 (“the Debenture”)
to Alpha Capital for a purchase price of $3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022.
The Debenture is convertible, at any time, and from time to time, at Alpha Capital’s option, into shares of our common stock, at
a price equal to $1.32 per share, subject to adjustment as described in the Debenture and other terms and conditions described in the
Debenture, including the Company’s receipt of the necessary stockholder approvals, which were obtained at our 2023 annual meeting
of stockholders.
In
January 2023 Alpha Capital converted $1,111,078 of the Debenture principal into 841,726 shares of common stock at a conversion price
of $1.32 per share.
Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a “Monthly Redemption Date”), we must redeem $110,000 plus accrued but unpaid interest,
liquidated damages and any amounts then owing under the Debenture (the “Monthly Redemption Amount”). The Monthly Redemption
Amount must be paid in cash; provided that after the first two monthly redemptions, we may elect to pay all or a portion of a Monthly
Redemption Amount in shares of common stock, based on a conversion price equal to the lesser of (i) the then applicable conversion price
of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the Debenture) for the five consecutive trading days ending
on the trading day that is immediately prior to the applicable Monthly Redemption Date. We may also redeem some or all of the then outstanding
principal amount of the Debenture at any time for cash in an amount equal to 105% of the then outstanding principal amount of the Debenture
being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under the Debenture. Our election to pay
monthly redemptions in shares of common stock or to effect an optional redemption is subject to the satisfaction of the Equity Conditions
(as defined in the Debenture), including our receipt of the necessary stockholder approvals, which
we obtained at our 2023 annual meeting of stockholders.
The
Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the
Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including our receipt of the
necessary stockholder approvals, which we obtained at our 2023 annual meeting of stockholders.
During
the three and six months ended June 30, 2023, we recognized an extinguishment loss on voluntary conversion of convertible debt of $0
and approximately $1.1 million, respectively, and recorded accrued interest of approximately $383,000 and $945,000, respectively (of
which approximately $364,000 and $898,000 was a reduction to the discount, respectively) in other expenses in the condensed consolidated
statements of operations. In June 2023 we paid the first Monthly Redemption Amount of $110,000 in cash, and as of June 30, 2023 the remaining
Debenture principal balance was approximately $2.1 million, the remaining discount was approximately $1.3 million, the fair value of
the Alpha Warrant was approximately $2.0 million, and the fair value of the suite of bifurcated embedded derivative features was $0.
NanoSynex
Funding Agreement
As
a condition to the NanoSynex Acquisition, we entered into the Funding Agreement with NanoSynex, pursuant to which we agreed to fund NanoSynex
up to an aggregate of approximately $10.4 million over a three year period, subject to NanoSynex’s achievement of certain performance
milestones specified in the NanoSynex Funding Agreement and the satisfaction of other terms and conditions described in the NanoSynex
Funding Agreement.
These
funding commitments were to be made in the form of convertible promissory notes to be issued to us with a face value equal to the
amount paid by us to NanoSynex upon satisfaction of the applicable performance milestone, bearing interest at the rate of 9% per
annum on the principal balance from time to time outstanding under the particular promissory note, convertible at our option into
additional shares of NanoSynex in order for us to maintain at least a 50.1% controlling ownership interest in NanoSynex, should
NanoSynex issue additional shares. During the year ended December 31, 2022, a total of approximately $2.4 million was funded to
NanoSynex, and for the six months ended June 30, 2023 an additional $0.5 million was funded to NanoSynex under the Funding
Agreement.
On
July 20, 2023, we entered into the NanoSynex Amendment with NanoSynex, which amended the NanoSynex Funding Agreement and our payment
obligations under such agreement. Pursuant to the terms of the Nanosynex Amendment, we will make an initial payment of $380,000 to NanoSynex
by surrendering the Preferred B shares of NanoSynex held by us, resulting in our ownership in NanoSynex being reduced from approximately
52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex. In addition, we also agreed to (i) advance $560,000
to NanoSynex on or before November 30, 2023 (the “First Advance”), against which NanoSynex will issue a promissory note to
us with a face value in the amount of such funding, and (ii) advance $670,000 to NanoSynex on or before March 31, 2024 (the “Second
Advance,” and, together with the First Advance, the “New Advances”), against which NanoSynex will issue a promissory
note to us with a face value in the amount of such funding. In addition, $2,880,000 in promissory notes delivered by NanoSynex to us
for advances previously made by us to NanoSynex under the NanoSynex Funding Agreement were canceled.In
the event we fail to make the New Advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction,
the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex
pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we originally paid
in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per share.
The
NanoSynex Amendment supersedes any payments contemplated by the NanoSynex Funding Agreement, such that except as described in the NanoSynex
Amendment, we will have no further payment obligations to NanoSynex under the NanoSynex Funding Agreement or otherwise (including by
way of equity investment, loan financing or credit lines), and NanoSynex will have no further payment obligations to us for advances
previously received under the NanoSynex Funding Agreement.
Other
Service Agreements
We
enter into contracts in the normal course of business, including with clinical sites, contract research organizations, and other professional
service providers for the conduct of clinical trials, contract manufacturers for the production of our product candidates, contract research
service providers for preclinical research studies, professional consultants for expert advice and vendors for the sourcing of clinical
and laboratory supplies and materials. These contracts generally provide for termination on notice, and therefore are cancelable contracts.
Cash
Flows
The
following table sets forth the significant sources and uses of cash for the periods set forth below:
| |
For the Six Months Ended | |
| |
June 30, | |
| |
2023 | | |
2022 | |
Net cash (used in) provided by: | |
| | | |
| | |
Operating activities | |
$ | (5,562,416 | ) | |
$ | (7,827,798 | ) |
Investing activities | |
| (246,418 | ) | |
| 71,871 | |
Financing activities | |
| — | | |
| 3,859 | |
Effect of exchange rate on cash | |
| 115,803 | | |
| (34,228 | ) |
Net decrease in cash and restricted cash | |
$ | (5,693,031 | ) | |
$ | (7,786,296 | ) |
Net
Cash Used in Operating Activities
During
the six months ended June 30, 2023, operating activities used $5.6 million of cash, primarily resulting from a net loss of $7.6
million. Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2023 were positively
impacted by adjustments for a $1.1 million non cash loss on voluntary conversion of convertible debt, accretion of discount of $0.8
million on convertible debt, $0.9 million in stock-based compensation expense, a $0.9 million increase in accounts payable, a $0.4
million increase in accrued expenses and other current liabilities, a $0.4 million decrease in prepaid expenses and other assets,
and depreciation and amortization of $0.2 million. Cash flows from operating activities (as opposed to net loss) for the six months
ended June 30, 2023 were negatively impacted by adjustments for a $1.5 million decrease in fair value of warrant liabilities, a $0.2
million decrease in accounts receivable and inventory reserves and allowances, a $0.6 million decrease in R&D grant liability, a
$0.2 million decrease in deferred tax liability, and a $0.1 million decrease in operating lease liability.
During
the six months ended June 30, 2022, operating activities used $7.8 million of cash, primarily resulting from a net loss of $8.4 million.
Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2022 benefitted from $2.7 million in
stock-based compensation expense, a $0.2 million decrease in net accounts receivable, and depreciation and amortization of $0.2 million.
Cash flows from operating activities (as opposed to net loss) for the six months ended June 30, 2022 were negatively impacted by a $0.8
million decrease in accrued expenses and other current liabilities, a $0.6 million increase in prepaid expenses and other assets, $0.3
million increase in net inventory, a $0.7 million decrease in fair value of warrant liabilities and a $0.1 million decrease in operating
lease liability.
Net
Cash Provided by (Used in) Investing Activities
During
the six months ended June 30, 2023, net cash used in investing activities was approximately $0.2 million, due
to the purchase of property and equipment.
During
the six months ended June 30, 2022, net cash provided by investing activities was approximately $0.1 million, primarily due to $0.7 million
in cash acquired in the NanoSynex transaction, offset by the $0.6 million purchase of NanoSynex stock.
Net
Cash Provided by Financing Activities
Net
cash provided by financing activities for the six months ended June 30, 2023 was $0.
Net
cash provided by financing activities for the six months ended June 30, 2022 was approximately $4,000, due to net proceeds from exercise
of warrants.
ITEM
3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We
are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise
required under this Item.
ITEM
4. CONTROLS AND PROCEDURES
Evaluation
of Disclosure Controls and Procedures
Our
management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of
our disclosure controls and procedures as of June 30, 2023, the end of the period covered by this Quarterly Report.
Based
on this evaluation, our principal executive officer and principal financial officer have concluded that, due to the material weakness described below, our disclosure controls and procedures
as of June 30, 2023 were not effective to provide reasonable assurance that the information
required to be disclosed by us in reports filed under the Securities Exchange Act of 1934, as amended (the “Exchange Act’),
is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information
is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate,
to allow timely decisions regarding required disclosure. We believe that a disclosure controls system, no matter how well designed and
operated, cannot provide absolute assurance that the objectives of the disclosure controls system are met, and no evaluation of disclosure
controls can provide absolute assurance that all disclosure control issues, if any, within a company have been detected.
Changes
in Internal Control over Financial Reporting
Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f)
and 15d-15(f) under the Securities Exchange Act. Internal control over financial reporting is a process designed under the supervision
and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes
in accordance with U.S. GAAP. As of December 31, 2022, our management assessed the effectiveness of our internal control over financial
reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in Internal Control-Integrated
Framework, or 2013 Framework. Based on this assessment, our management concluded that, as of December 31, 2022, our internal control
over financial reporting was not effective because of a material weakness in our internal control over financial reporting related to
the lack of accounting department resources and/or policies and procedures to ensure recording and disclosure of items in compliance
with generally accepted accounting principles. We have taken and continue to take steps to remediate the material weakness, including
implementing additional procedures and utilizing external consulting resources with experience and expertise in U.S. GAAP and public
company accounting and reporting requirements to assist management with its accounting and reporting of complex and/or non-recurring
transactions and related disclosures.
Notwithstanding
the identified material weakness, our management believes that the condensed consolidated financial statements included in this Quarterly
Report fairly represent in all material respects our financial condition, results of operations and cash flows at and for the periods
presented in accordance with U.S. GAAP. Nonetheless, we also believe that an internal control system, no matter how well designed and
operated, cannot provide absolute assurance that the objectives of the internal control system are met, and no evaluation of internal
control can provide absolute assurance that all internal control issues and instances of fraud, if any, within a company are detected.
PART
II - OTHER INFORMATION
ITEM
1. LEGAL PROCEEDINGS
We
are not currently involved in any legal matters. From time to time, we could become involved in disputes and various litigation matters
that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract
law and employee relations matters.
ITEM
1A. RISK FACTORS
The
Company’s business, reputation, results of operations and financial condition, as well as the price of its stock, can be affected
by a number of factors, whether currently known or unknown, including those described in Part I, Item 1A of the Company’s 2022
Annual Report under the heading “Risk Factors.” When any one or more of these risks materialize, the Company’s business,
reputation, results of operations and financial condition, as well as the price of its stock, can be materially and adversely affected.
Except as described below, there have been no material changes to the Company’s risk factors since the 2022 Annual Report.
We
may be classified as a transient investment company.
We
are not engaged in the business of investing, reinvesting, or trading in securities, and we do not hold ourselves out as being engaged
in those activities. Under the Investment Company Act, however, a company may be deemed an investment company under Section 3(a)(1)(C)
of the Investment Company Act if the value of its investment securities is more than 40% of its total assets (exclusive of government
securities and cash items) on an unconsolidated basis.
We
have recently divested certain shares of NanoSynex Ltd. (“NanoSynex”) which has resulted in our ownership in NanoSynex being
reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex. Since we no longer
hold a controlling interest in NanoSynex, the investment securities we hold, including our minority interest in NanoSynex, could exceed
40% of our total assets, exclusive of government securities cash items, on an unconsolidated basis, and, accordingly, we could determine
that we have become a transient investment company.
A
transient investment company can avoid being classified as an investment company if it can rely on one of the exclusions under the Investment
Company Act. One such exclusion, Rule 3a-2 under the Investment Company Act, allows a transient investment company a grace period of
one year from the earlier of (a) the date on which an issuer owns securities and/or cash having a value exceeding 50% of the issuer’s
total assets on either a consolidated or unconsolidated basis and (b) the date on which an issuer owns or proposes to acquire investment
securities having a value exceeding 40% of the value of such issuer’s total assets (exclusive of government securities and cash
items) on an unconsolidated basis. We are in the process of performing a valuation of our minority investment in Nanosynex to determine
whether we need to invoke the grace period. We may take actions to cause the investment securities held by us to be less than 40% of
our total assets, which may include acquiring assets with our cash on hand or liquidating our investment securities.
As
Rule 3a-2 is available to a company no more than once every three years, and assuming no other exclusion were available to us, we would
have to keep within the 40% limit for at least three years after we cease being a transient investment company. This may limit our ability
to make certain investments or enter into joint ventures that could otherwise have a positive impact on our earnings. In any event, we
do not intend to become an investment company engaged in the business of investing and trading securities.
Classification
as an investment company under the Investment Company Act requires registration with the SEC. If an investment company fails to register,
it would have to stop doing almost all business, and its contracts would become voidable. Registration is time consuming and restrictive
and would require a restructuring of our operations, and we would be very constrained in the kind of business we could do as a registered
investment company. Further, we would become subject to substantial regulation concerning management, operations, transactions with affiliated
persons and portfolio composition, and would need to file reports under the Investment Company Act regime. The cost of such compliance
would result in our incurring substantial additional expenses, and the failure to register if required would have a materially adverse
impact to conduct our operations.
ITEM
2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Unregistered
Sales of Equity Securities
None
Purchases
of Equity Securities by the Issuer and Affiliated Purchasers
None
ITEM
3. DEFAULTS UPON SENIOR SECURITIES
None
ITEM
4. MINE SAFETY DISCLOSURES
Not
Applicable
ITEM
5. OTHER INFORMATION
None
ITEM
6. EXHIBITS
|
|
|
|
Incorporated
by Reference |
Exhibit
No. |
|
Description |
|
Form |
|
File
No. |
|
Exhibit |
|
Filing
Date |
|
|
|
|
|
|
|
|
|
|
|
2.1 |
|
Contingent Value Rights Agreement, dated May 22, 2020, among the Company, John Beck in the capacity of CVR Holders’ Representative and Andrew J. Ritter in his capacity as a consultant to the Company. |
|
8-K |
|
001-37428 |
|
2.4 |
|
5/29/2020 |
|
|
|
|
|
|
|
|
|
|
|
2.2 |
|
Stock Purchase Agreement, dated July 20, 2023, by and between Qualigen Therapeutics, Inc., Chembio Diagnostics, Inc., Biosynex, S.A., and Qualigen, Inc. |
|
8-K |
|
001-37428 |
|
2.1 |
|
7/26/2023 |
|
|
|
|
|
|
|
|
|
|
|
3.1 |
|
Amended and Restated Certificate of Incorporation |
|
8-K |
|
001-37428 |
|
3.1 |
|
7/1/2015 |
|
|
|
|
|
|
|
|
|
|
|
3.2 |
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation |
|
8-K |
|
001-37428 |
|
3.1 |
|
9/15/2017 |
|
|
|
|
|
|
|
|
|
|
|
3.3 |
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation |
|
8-K |
|
001-37428 |
|
3.1 |
|
3/22/2018 |
|
|
|
|
|
|
|
|
|
|
|
3.4 |
|
Certificate of Designation of Preferences, Rights and Limitations of Series Alpha Preferred Stock of the Company, filed with the Delaware Secretary of State on May 20, 2020 |
|
8-K |
|
001-37428 |
|
3.1 |
|
5/29/2020 |
|
|
|
|
|
|
|
|
|
|
|
3.5 |
|
Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [reverse stock split] |
|
8-K |
|
001-37428 |
|
3.2 |
|
5/29/2020 |
|
|
|
|
|
|
|
|
|
|
|
3.6 |
|
Certificate of Merger, filed with the Delaware Secretary of State on May 22, 2020 |
|
8-K |
|
001-37428 |
|
3.3 |
|
5/29/2020 |
|
|
|
|
|
|
|
|
|
|
|
3.7 |
|
Certificate of Amendment to the Certificate of Incorporation of the Company, filed with the Delaware Secretary of State on May 22, 2020 [name change] |
|
8-K |
|
001-37428 |
|
3.4 |
|
5/29/2020 |
|
|
|
|
|
|
|
|
|
|
|
3.8 |
|
Amended and Restated Bylaws of the Company, through August 10, 2021 |
|
10-Q |
|
001-37428 |
|
3.1 |
|
8/13/2021 |
|
|
|
|
|
|
|
|
|
|
|
3.9 |
|
Certificate of Amendment to the Amended and Restated Certificate of Incorporation, as amended |
|
8-K |
|
001-37428 |
|
3.1 |
|
11/22/2022 |
|
|
|
|
|
|
|
|
|
|
|
4.1 |
|
Warrant, issued by the Company in favor of Alpha Capital Anstalt, dated May 22, 2020 |
|
8-K |
|
001-37428 |
|
10.13 |
|
5/29/2020 |
|
|
|
|
|
|
|
|
|
|
|
4.2 |
|
Form of Warrant, issued by the Company in favor of GreenBlock Capital LLC and its designees, dated May 22, 2020 [post-Merger] |
|
8-K |
|
001-37428 |
|
10.10 |
|
5/29/2020 |
|
|
|
|
|
|
|
|
|
|
|
4.3 |
|
Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated July 10, 2020 |
|
8-K |
|
001-37428 |
|
10.2 |
|
7/10/2020 |
|
|
|
|
|
|
|
|
|
|
|
4.4 |
|
Common Stock Purchase Warrant in favor of Alpha Capital Anstalt, dated August 4, 2020 |
|
8-K |
|
001-37428 |
|
10.3 |
|
8/4/2020 |
|
|
|
|
|
|
|
|
|
|
|
4.5 |
|
“Two-Year” Common Stock Purchase Warrant for 1,348,314 shares in favor of Alpha Capital Anstalt, dated December 18, 2020 |
|
8-K |
|
001-37428 |
|
10.3 |
|
12/18/2020 |
4.6 |
|
“Deferred” Common Stock Purchase Warrant for 842,696 shares in favor of Alpha Capital Anstalt, dated December 18, 2020 |
|
8-K |
|
001-37428 |
|
10.4 |
|
12/18/2020 |
|
|
|
|
|
|
|
|
|
|
|
4.7 |
|
Form of liability classified Warrant to Purchase Common Stock |
|
10-K |
|
001-37428 |
|
4.13 |
|
3/31/2021 |
|
|
|
|
|
|
|
|
|
|
|
4.8 |
|
Form of “service provider” compensatory equity classified Warrant |
|
10-K |
|
001-37428 |
|
4.14 |
|
3/31/2021 |
|
|
|
|
|
|
|
|
|
|
|
4.9 |
|
Description of Common Stock |
|
10-K/A |
|
001-37428 |
|
4.9 |
|
7/7/2023 |
|
|
|
|
|
|
|
|
|
|
|
4.10 |
|
Amended and Restated Common Stock Purchase Warrant to GreenBlock Capital LLC, dated April 25, 2022 |
|
10-Q |
|
001-37428 |
|
4.15 |
|
5/13/2022 |
|
|
|
|
|
|
|
|
|
|
|
4.11 |
|
Amended and Restated Common Stock Purchase Warrant to Christopher Nelson, dated April 25, 2022 |
|
10-Q |
|
001-37428 |
|
4.16 |
|
5/13/2022 |
|
|
|
|
|
|
|
|
|
|
|
4.12 |
|
Common Stock Purchase Warrant for 2,500,000 shares in favor of Alpha Capital Anstalt, dated December 22, 2022 |
|
8-K |
|
001-37428 |
|
4.1 |
|
12/22/2022 |
|
|
|
|
|
|
|
|
|
|
|
10.1* |
|
Separation Agreement and General Release, dated June 20, 2023, by and between Qualigen Therapeutics, Inc. and Amy Broidrick |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10.2 |
|
Amendment and Settlement Agreement, dated July 20, 2023, by and between Qualigen Therapeutics, Inc. and NanoSynex Ltd. |
|
8-K |
|
001-37428 |
|
10.1 |
|
7/26/2023
|
|
|
|
|
|
|
|
|
|
|
|
31.1 |
|
Certificate of principal executive officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31.2 |
|
Certificate of principal financial officer pursuant to Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
32.1 |
|
Certificate of principal executive officer and principal financial officer pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
|
|
|
|
|
|
|
|
101.INS# |
|
Inline
XBRL Instance Document. |
|
|
|
101.SCH# |
|
Inline
XBRL Taxonomy Extension Schema Document. |
|
|
|
101.CAL# |
|
Inline
XBRL Taxonomy Extension Calculation Linkbase Document. |
|
|
|
101.DEF# |
|
Inline
XBRL Taxonomy Extension Definition Linkbase Document. |
|
|
|
101.LAB# |
|
Inline
XBRL Taxonomy Extension Label Linkbase Document. |
|
|
|
101.PRE# |
|
Inline
XBRL Taxonomy Extension Presentation Linkbase Document. |
|
|
|
104 |
|
Cover
page Interactive Data File (embedded within the Inline XBRL document) |
*
Filed or furnished herewith.
+
Indicates management contract or compensatory plan or arrangement.
#
XBRL (Extensible Business Reporting Language) information is furnished and not filed herewith, is not a part of a registration statement
or Prospectus for purposes of sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of section 18 of the
Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its
behalf by the undersigned thereunto duly authorized.
August
14, 2023 |
QUALIGEN
THERAPEUTICS, INC. |
|
|
|
|
By: |
/s/
Michael S. Poirier |
|
Name: |
Michael
S. Poirier |
|
Title: |
Chief
Executive Officer |
Exhibit 10.1
SEPARATION
AGREEMENT AND GENERAL RELEASE
| 1. | Purpose
of Agreement: The intent of this Separation Agreement and General Release (“Agreement”)
is to amicably and finally resolve and compromise all issues and claims surrounding the employment
of Amy Broidrick (“Employee”) with Qualigen, Inc. (“Employer”) and
the termination thereof. This Agreement becomes effective on the eighth day after it is executed
by Employee (“Effective Date”). |
| 2. | Termination
of Employment and Receipt of Compensation and Benefits: Employee’s employment with
Employer is terminated on June 16, 2023 (“Termination Date”). Employee acknowledges
that on the Termination Date Employee was paid for all unpaid salary and unused vacation
time earned through the Termination Date. As of the Termination Date, Employee is no longer
eligible to receive further compensation of any kind, including payments for wages, salary,
vacation or benefits, and will not represent herself as an employee, officer, agent, or representative
of Employer for any purpose. Employee will also no longer serve as a member of Employer’s
Board of Directors, or as a member of the Board of Directors of any of Employer’s subsidiaries. |
| 3. | Employer’s
Consideration for Agreement: In exchange for the release and agreements that Employee
is making in this Agreement, Employer will provide Employee with the following: |
| a) | Base
Termination Payments: (A) The total gross amount of $16,636.79, less applicable withholdings
for federal and state income and employment taxes, which represents an amount in cash equal
to Employee’s accrued but unpaid salary and vacation pay through the Termination Date,
and (B) Reimbursement of any expenses incurred by Employee under Section 4 of her Employment
Agreement and in accordance with Employer’s expense reimbursement policies. |
Base
Terminations Payments will be made in a lump sum within 15 business days of the Effective Date of this Agreement.
| b) | Severance
in the form of continued salary pay to Employee at the rate then in effect on the Termination
Date for a period of 12 months following the Termination Date, subject to applicable withholdings
and otherwise in accordance with Employer’s general payroll practices and policies. |
| c) | Payment
or reimbursement to Employee for the cost of COBRA continuation medical and dental insurance
coverage for the Employee for a 12 month period following the Termination Date (less any
required taxes or withholdings). |
| d) | Any
other rights or benefits, to the extent earned and vested as of the Termination Date, under
Employer’s employee benefit plans such as Restricted Stock, Stock Bonus, Stock Appreciation
Right, Restricted Stock Unit or Performance Awards (“Options”). Employee’s
right to exercise her Options ends three (3) months from the Termination Date as described
in Employee’s Stock Option Agreement (“Option Agreement”). No additional
rights or benefits shall vest after the Termination Date |
| 4. | Employee’s
Consideration for Agreement: Employee acknowledges and agrees but for Employee’s
execution of this Agreement, Employee would not otherwise be entitled to the benefits described
in Section 3. Employee represents and warrants that Employee has returned to Employer all
items of property paid for and/or provided for Employee’s use during employment with
Employer including, but not limited to, cameras, camera equipment, access badges, keys, books,
manuals, laptop, peripherals, smartphone, corporate credit card, software, and company information
and documents. Employee also warrants and represents that Employee has returned to Employer
all documents (electronic or paper) created and received by Employee during employment with
Employer, and that Employee has not retained any such documents, copies, summaries, or excerpts
of such documents, except Employee may keep Employee’s personal copies of documents
evidencing Employee’s hire, compensation and employee benefits and benefit plan participation,
and this letter. |
| 5. | Release
of Claims: Employee agrees that the benefits provided for in this Agreement represent
settlement in full of all outstanding obligations owed to Employee by Employer and its officers,
managers, supervisors, members, agents, and employees. Employee, on Employee’s own
behalf, and on behalf of Employee’s heirs, representatives, executors, administrators,
attorneys, family members, executors, agents, successors in interest, and assigns, hereby
fully, knowingly and forever releases Employer and its past, present and future owners, parents,
subsidiaries, divisions, affiliates, future affiliates, related entities, joint ventures,
partners and members, including but not limited to Qualigen Therapeutics, Inc., as well as
each of their respective past, present and future directors, officers, investors, shareholders,
administrators, agents, associates, representatives, employees, attorneys, predecessors,
successors and assigns, and any and all of them (the “Releasees”) from any and
all liability, actions, causes of action, claims, charges, complaints, demands, grievances,
promises, obligations, losses, damages, injuries and legal responsibilities, of any type
whatsoever, whether known or unknown, unforeseen, unanticipated, unsuspected or latent, that
are based upon, relate to or arise out of any matters of any kind (collectively, “Claims”),
that Employee may possess arising from any omissions, acts or facts that have occurred up
until and including the date of this Agreement including, without limitation: |
| a) | Any
and all claims for wrongful discharge, constructive discharge, or wrongful demotion; |
| b) | Any
and all claims relating to any contracts of employment, express or implied, or breach of
the covenant of good faith and fair dealing, express or implied; |
| c) | Any
and all tort claims of any nature, including but not limited to claims for negligence, defamation,
misrepresentation, fraud, or negligent or intentional infliction of emotional distress; |
| d) | Any
and all claims for wages, compensation, incentive equity or equity based awards, other benefits,
and associated penalties and interest, including but not limited to claims under the state
labor laws, state wage orders, and the federal Fair Labor Standards Act; |
| e) | Any
and all claims for retaliation or for discrimination or harassment based on sex, race, age,
color, national origin, sexual orientation, gender identity and expression, religion, disability,
marital status, veteran’s or military status, medical condition, or any other protected
characteristic under federal, state or municipal statutes or ordinances; and any and all
other employment-related claims whatsoever, including but not limited to claims under Title
VII of the Civil Rights Act of 1964, the Civil Rights Act of 1991, 42 U.S.C. Section 1981,
the Americans With Disabilities Act, the Employment Retirement Income Security Act, the Family
and Medical Leave Act, the Equal Pay Act, the Fair Credit Reporting Act, the Age Discrimination
in Employment Act of 1967, the Older Workers’ Benefit Protection Act, the Worker Adjustment
and Retraining Notification (WARN) Act and any similar state laws, the Immigration Reform
and Control Act, the Occupational Safety and Health Administration, the California Family
Rights Act, the California Fair Employment and Housing Act, and the California Labor Code,
the California Civil Code, the California Business & Professions Code, the Code of Federal
Regulations, the California Code of Regulations, the California Unruh Act, the California
Equal Pay Act, and any applicable California Industrial Welfare Commission Order, and any
other federal, state, local, or foreign law (statutory, regulatory, or otherwise) that may
be legally waived and released; and |
| f) | Any
and all claims for attorneys’ fees or costs. |
This
release is not intended to encompass claims for workers’ compensation, unemployment benefits, or COBRA rights. Nor is this release
intended to prevent Employee from filing a statutory claim concerning employment with Employer or the termination thereof with the federal
Equal Employment Opportunity Commission, the National Labor Relations Board, the California Civil Rights Department, or similar government
agencies. However, if Employee does so, or if any such claim is prosecuted in Employee’s name before any court or administrative
agency, Employee waives and agrees not to take any award of money or other damages from such suit (excepting only any monetary award
to which Employee may become entitled pursuant to Section 922 of the Dodd-Frank Wall Street Reform and Consumer Protection Act).
| 6. | Waiver
of Unknown Claims; Civil Code Section 1542: This Agreement is a general release of claims
and applies not only to known claims based on facts Employee is currently aware of but also
to unknown claims based on facts Employee is not aware of. Employee hereby elects to assume
all risks for claims that now exist in his or her favor, known or unknown,
arising from the subject matter of this Agreement. Employee confirms that it is Employee’s
intention in executing this Agreement to waive and relinquish all rights and benefits to
all claims whether presently known or unknown, including any claims that Employee does not
know or suspect to exist in his or her favor which, if known by him or her, would have materially
affected Employee’s decision to enter into this Agreement. |
Employee
represents that Employee is not aware of any claim by Employee other than the claims that are released by this Agreement. Employee acknowledges
that Employee has had the opportunity to be advised by legal counsel and is familiar with the provisions of California Civil Code Section
1542, which provides as follows:
A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR
AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE
DEBTOR OR RELEASED PARTY.
Employee,
being aware of said code section, agrees to expressly waive any rights Employee may have thereunder, as well as under any other statute
or common law principles of similar effect.
| 7. | Confidential
Information: Employee agrees not to, except as authorized by Employer in writing, or
as required by any law, rule, or regulation after providing prior written notice to Employer
with sufficient time for Employer to object to production or disclosure, or to quash subpoenas
related to the same, disclose to any other person, firm, company, or any other entity any
confidential and proprietary information, knowledge, or data of Employer or that of third
parties obtained by Employee during her employment with Employer. “Confidential and
proprietary information” includes, but is not limited to, know-how, trade secrets,
and technical, business and financial information and any other non-public information in
any way learned by Employee during her employment with Employer, including, but not limited
to (i) prices, renewal dates and other detailed terms of customer or supplier contracts and
proposals; (ii) information concerning Employer’s customers, clients, referral sources
and vendors, and potential customers, clients, referral sources and vendors, including, but
not limited to, names of these entities or their employees or representatives, preferences,
needs or requirements, purchasing or sales histories, or other customer or client-specific
information; (iii) supplier and distributor lists; (iv) pricing policies, methods of delivering
services and products, and marketing and sales plans or strategies; (v) products, product
know-how, product technology and product development strategies and plans; (vi) employee
personnel or payroll records or information (except as to Employee herself); (vii) forecasts,
budgets and other non-public financial information; (viii) expansion plans, management policies
and other business strategies; (ix) inventions, research, development, manufacturing, purchasing,
finance processes, technologies, machines, computer software, computer hardware, automated
systems, engineering, marketing, merchandising, and selling; and (x) any information whatsoever
about the business and practices of Employer that was obtained by Employee during the course
of her employment with Employer. |
| 8. | Confidentiality
of Agreement: Employee agrees that the terms and conditions of this Agreement are strictly
confidential. Employee shall not disclose, discuss or reveal the existence or the terms of
this Agreement to any persons, entities or organizations except as follows: (a) as required
by court order; (b) to Employee’s spouse; or (c) to Employee’s attorneys or accountants.
Employee understands and agrees that all prior confidentiality agreements between Employee
and Employer shall continue and will remain in full force and effect at all times after the
Termination Date. Notwithstanding the foregoing, nothing in this Agreement prevents Employee
from discussing or disclosing information about unlawful acts in the workplace, such as harassment
or discrimination or any other conduct that Employee has reason to believe is unlawful. |
Further,
Employee shall not be held criminally or civilly liable under any federal or state trade secret law for the disclosure of a trade secret
that: (A) is made (i) in confidence to a federal, state, or local government official, either directly or indirectly, or to an attorney
and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document
filed in a lawsuit or other proceeding, if such filing is made under seal. Further, in the event that Employee files a lawsuit for retaliation
by Employer for reporting a suspected violation of law, Employee may disclose the trade secret to Employee’s attorney and use the
trade secret information in the court proceeding, if Employee: (A) files any document containing the trade secret under seal; and (B)
does not disclose the trade secret, except pursuant to court order.
| 9. | Interpretation
and Construction of Agreement: This Agreement shall in all respects be interpreted, enforced,
and governed by and in accordance with the internal substantive laws (and not the laws of
choice of laws) of the state of California. Regardless of which party initially drafted this
Agreement, it shall not be construed against any one party, and shall be construed and enforced
as a mutually prepared Agreement. |
| 10. | No
Admission of Liability: By entering into this Agreement, Employer is not admitting to
any liability, wrongdoing or legal violation whatsoever with regard to the employment relationship
between the parties or with respect to any claims released herein. Employer expressly denies
any and all such liability and wrongdoing. |
| 11. | Acknowledgement
of Waiver of Claims Under ADEA; Waiting Period: Pursuant to the Age Discrimination in
Employment Act of 1967 (the “ADEA”) and the Older Workers’ Benefit Protection
Act, Employer hereby advises Employee to consult with an attorney prior to signing this Agreement.
Employer also advises Employee that Employee has up to forty-five (45) days within which
to consider whether Employee should sign this Agreement (and the parties agree that changes,
whether material or immaterial, do not restart the running of this forty-five (45) day period).
To the extent that Employee takes less than forty-five (45) days to consider this Agreement
prior to execution, Employee acknowledges that Employee had sufficient time to consider this
Agreement and that Employee expressly, voluntarily and knowingly waives any additional time.
In addition, should Employee choose to sign the Agreement, Employee shall have seven (7)
days following the date on which she signed the Agreement to revoke it, by delivering written
notice of the revocation to Qualigen, Inc. Attn: Chris Lotz, 2042 Corte Del Nogal Ste. B,
Carlsbad, CA 92011 (clotz@qualigeninc.com), for receipt within the seven-day period. This
Agreement does not become effective until after this seven-day period has elapsed. Nothing
in this Agreement prevents or precludes Employee from challenging or seeking a determination
in good faith of the validity of this waiver under the ADEA, nor does it impose any condition
precedent, penalties or costs from doing so, unless specifically authorized by federal law. |
| 12. | Non-disparagement:
Employee agrees that Employee will not, nor will cause or cooperate with others to, publicly
criticize, ridicule, disparage or defame the Employer or its products, services, policies,
directors, officers, managers, members, shareholders, or employees, or any other Releasees,
with or through any written or oral statement or image, including, but not limited to, any
statements made via websites, blogs, postings to the internet, or emails, whether or not
they are made anonymously or through the use of a pseudonym. Employee agrees to provide full
cooperation and assistance in assisting the Employer to investigate such statements if the
Employer reasonably believes that the Employee is the source of the statements. The foregoing
does not apply to statutorily privileged statements made to governmental or law enforcement
agencies. Additionally, Employee agrees Employee shall not visit the office or facility locations,
nor contact members of the Employer without prior written permission from/by the Chief Executive
Officer or Employer’s authorized representative. Notwithstanding the foregoing, nothing
in this Agreement prevents Employee from discussing or disclosing information about unlawful
acts in the workplace, such as harassment or discrimination or any other conduct that Employee
has reason to believe is unlawful. |
| 13. | Complete
and Voluntary Agreement: Employee acknowledges that Employee has read and understands
this Agreement; that Employee has had the opportunity to seek legal counsel of Employee’s
own choosing and to have the terms of the Agreement fully explained to Employee; that Employee
is not executing this Agreement in reliance on any promises, representations or inducements
other than those contained herein; and that Employee is executing this Agreement voluntarily,
free of any duress or coercion. Employee specifically understands that by entering into this
Agreement Employee is forever foreclosed from pursuing any of the claims Employee has waived
in Section 5 above. |
| 14. | Savings
Clause: Should any of the provisions of this Agreement be determined to be invalid or
unenforceable by a court or government agency of competent jurisdiction, it is agreed that
such determination shall not affect the enforceability of the other provisions herein. |
| 15. | Scope
of Agreement: This Agreement constitutes the entire understanding of the parties on the
subjects covered. Except as expressly provided herein, this Agreement supersedes and renders
null and void any and all prior agreements between Employee and Employer. |
| 16. | Waiver:
The failure of Employer or Employee to insist upon strict adherence to any term of this Agreement
on any occasion will not be considered a waiver thereof, or deprive that Party of the right
thereafter to insist upon strict adherence to that term or any other term of this Agreement.
|
| 17. | Attorneys’
Fees and Costs: Employer and Employee agree that they will bear their own respective
costs and fees, including attorneys’ fees, in connection with the negotiation and execution
of this Agreement. |
| 18. | Arbitration:
The parties agree that any controversy involving the construction or application of any terms,
covenants or conditions of this Agreement, or any claims arising out of or relating to this
Agreement or the breach thereof will be submitted to and settled by final and binding arbitration
before the American Arbitration Association (AAA) pursuant to its employment arbitration
rules and procedures, in accordance with the Federal Arbitration Act, with the arbitration
to take place in the state of California. Each side will bear its own attorneys’ fees
in any such arbitration, and the arbitrator shall not have authority to award attorneys’
fees unless a statutory section at issue in the dispute authorizes the award of attorneys’
fees to the prevailing party, in which case the arbitrator has the authority to make such
award as permitted by the statute in question. The parties agree that the prevailing party
in any arbitration shall be entitled to injunctive relief in any court of competent jurisdiction
to enforce the arbitration award. The parties hereby agree to waive their right to have any
dispute between them resolved in a court of law by a judge or jury. |
PLEASE
READ CAREFULLY. THIS AGREEMENT CONTAINS A FULL RELEASE OF LEGAL CLAIMS, BOTH KNOWN CLAIMS AND UNKNOWN CLAIMS. EMPLOYEE ACKNOWLEDGES THAT
HER SIGNATURE WILL NOT BE AFFIXED TO THIS AGREEMENT PRIOR TO HER TERMINATION DATE.
Dated: ___6/17/2023_________ |
______/s/
Amy Broidrick_____________ Employee Signature
______Amy
Broidrick_______________ Employee Name (Printed) |
Dated: ___6/20/2023_________
|
______/s/
Christopher Lotz____ Employer Representative Signature
Christopher
Lotz
Employer
Representative Signature (Printed) |
Exhibit
31.1
CERTIFICATION
OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002
I,
Michael S. Poirier, certify that:
1. | I
have reviewed this quarterly report on Form 10-Q of Qualigen Therapeutics, Inc., a Delaware
corporation; |
2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered
by this report; |
3. | Based
on my knowledge, the condensed consolidated financial statements, and other financial information
included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented
in this report; |
4. | The
registrant’s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have: |
| a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the
registrant is made known to us by others within those entities, particularly during the period
in which this report is being prepared; |
| b) | Designed
such control over financial reporting, or caused such internal control over financial reporting
to be designed under our supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of condensed consolidated financial statements
for external purposes with generally accepted accounting principles; |
| c) | Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed
in this report any change in the registrant’s internal control over financial reporting
that occurred during the registrant’s most recent fiscal quarter (the registrant’s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and |
5. | The
registrant’s other certifying officer(s) and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of the registrant’s board of directors (or persons performing
the equivalent functions): |
| a) | All
significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial information; and |
| b) | Any
fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant’s internal control over financial reporting. |
August
14, 2023 |
By: |
/s/
Michael S. Poirier |
|
Name: |
Michael
S. Poirier |
|
Title: |
Chief
Executive Officer |
Exhibit
31.2
CERTIFICATION
OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
SECTION
302 OF THE SARBANES-OXLEY ACT OF 2002
I,
Christopher L. Lotz, certify that:
1. | I
have reviewed this quarterly report on Form 10-Q of Qualigen Therapeutics, Inc., a Delaware
corporation; |
2. | Based
on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered
by this report; |
3. | Based
on my knowledge, the condensed consolidated financial statements, and other financial information
included in this report, fairly present in all material respects the financial condition,
results of operations and cash flows of the registrant as of, and for, the periods presented
in this report; |
4. | The
registrant’s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e))
and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have: |
| a) | Designed
such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the
registrant is made known to us by others within those entities, particularly during the period
in which this report is being prepared; |
| b) | Designed
such control over financial reporting, or caused such internal control over financial reporting
to be designed under our supervision, to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of condensed consolidated financial statements
for external purposes with generally accepted accounting principles; |
| c) | Evaluated
the effectiveness of the registrant’s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures,
as of the end of the period covered by this report based on such evaluation; and |
| d) | Disclosed
in this report any change in the registrant’s internal control over financial reporting
that occurred during the registrant’s most recent fiscal quarter (the registrant’s
fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over financial
reporting; and |
5. | The
registrant’s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant’s auditors
and the audit committee of the registrant’s board of directors (or persons performing
the equivalent functions): |
| a) | All
significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s
ability to record, process, summarize and report financial information; and |
| b) | Any
fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant’s internal control over financial reporting. |
August
14, 2023 |
By: |
/s/
Christopher L. Lotz |
|
Name: |
Christopher
L. Lotz |
|
Title: |
Chief
Financial Officer (Principal Financial Officer) |
Exhibit
32.1
CERTIFICATIONS
PURSUANT TO 18 U.S.C. SECTION 1350 AS ADOPTED PURSUANT TO
SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002
Each
of the undersigned, Michael S. Poirier, Chief Executive Officer of Qualigen Therapeutics, Inc., a Delaware corporation (the “Company”),
and Christopher L. Lotz, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant
to Section 906 of the Sarbanes- Oxley Act of 2002, that, to his knowledge (1) the quarterly report on Form 10-Q of the Company for the
three months ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”),
fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information
contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
August
14, 2023
|
By: |
/s/
Michael S. Poirier |
|
Name: |
Michael
S. Poirier |
|
Title: |
Chief
Executive Officer (Principal Executive Officer) |
August
14, 2023
|
By: |
/s/
Christopher L. Lotz |
|
Name: |
Christopher
L. Lotz |
|
Title: |
Chief
Financial Officer (Principal Financial Officer) |
These
certifications accompanying and being “furnished” with this Report, shall not be deemed “filed” by the Company
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and
shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the
Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation
language contained in such filing.
v3.23.2
Cover - shares
|
6 Months Ended |
|
Jun. 30, 2023 |
Aug. 10, 2023 |
Cover [Abstract] |
|
|
Document Type |
10-Q
|
|
Amendment Flag |
false
|
|
Document Quarterly Report |
true
|
|
Document Transition Report |
false
|
|
Document Period End Date |
Jun. 30, 2023
|
|
Document Fiscal Period Focus |
Q2
|
|
Document Fiscal Year Focus |
2023
|
|
Current Fiscal Year End Date |
--12-31
|
|
Entity File Number |
001-37428
|
|
Entity Registrant Name |
Qualigen
Therapeutics, Inc.
|
|
Entity Central Index Key |
0001460702
|
|
Entity Tax Identification Number |
26-3474527
|
|
Entity Incorporation, State or Country Code |
DE
|
|
Entity Address, Address Line One |
2042
Corte Del Nogal
|
|
Entity Address, City or Town |
Carlsbad
|
|
Entity Address, State or Province |
CA
|
|
Entity Address, Postal Zip Code |
92011
|
|
City Area Code |
(760)
|
|
Local Phone Number |
918-9165
|
|
Title of 12(b) Security |
Common
Stock, par value $.001 per share
|
|
Trading Symbol |
QLGN
|
|
Security Exchange Name |
NASDAQ
|
|
Entity Current Reporting Status |
Yes
|
|
Entity Interactive Data Current |
Yes
|
|
Entity Filer Category |
Non-accelerated Filer
|
|
Entity Small Business |
true
|
|
Entity Emerging Growth Company |
false
|
|
Entity Shell Company |
false
|
|
Entity Common Stock, Shares Outstanding |
|
5,052,463
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as an quarterly report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a
+ Details
Name: |
dei_DocumentQuarterlyReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true only for a form used as a transition report.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1
+ Details
Name: |
dei_DocumentTransitionReport |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405
+ Details
Name: |
dei_EntityInteractiveDataCurrent |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityShellCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicates that the company is a Smaller Reporting Company (SRC).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntitySmallBusiness |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Current assets |
|
|
Cash |
$ 1,341,659
|
$ 7,034,434
|
Accounts receivable, net |
679,380
|
538,587
|
Inventory, net |
1,563,399
|
1,586,297
|
Prepaid expenses and other current assets |
1,278,077
|
1,661,220
|
Total current assets |
4,862,515
|
10,820,538
|
Restricted cash |
5,434
|
5,690
|
Right-of-use assets |
1,305,970
|
1,422,538
|
Property and equipment, net |
498,647
|
345,087
|
Intangible assets, net |
5,833,070
|
5,845,702
|
Goodwill |
625,602
|
625,602
|
Other assets |
18,334
|
18,334
|
Total Assets |
13,149,572
|
19,083,491
|
Current liabilities |
|
|
Accounts payable |
1,756,183
|
857,311
|
Accrued vacation |
332,617
|
467,948
|
Accrued expenses and other current liabilities |
1,980,555
|
1,511,856
|
R&D grant liability |
151,620
|
780,682
|
Deferred revenue, current portion |
94,474
|
116,161
|
Operating lease liability, current portion |
257,155
|
240,645
|
Short term debt-related party |
965,155
|
950,722
|
Warrant liabilities |
133,500
|
788,100
|
Warrant liabilities - related party |
2,010,180
|
2,834,547
|
Convertible debt - related party |
812,419
|
60,197
|
Total current liabilities |
8,493,858
|
8,608,169
|
Operating lease liability, net of current portion |
1,168,653
|
1,301,919
|
Deferred revenue, net of current portion |
28,648
|
49,056
|
Deferred tax liability |
150,369
|
357,757
|
Total liabilities |
9,841,528
|
10,316,901
|
Commitments and Contingencies (Note 12) |
|
|
Qualigen Therapeutics, Inc. stockholders’ equity: |
|
|
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,052,463 and 4,210,737 shares issued and outstanding as of June 30, 2023 and December 31, 2022, respectively |
42,952
|
42,110
|
Additional paid-in capital |
112,554,830
|
110,528,050
|
Accumulated other comprehensive income |
131,891
|
50,721
|
Accumulated deficit |
(110,695,598)
|
(103,385,172)
|
Total Qualigen Therapeutics, Inc. stockholders’ equity |
2,034,075
|
7,235,709
|
Noncontrolling interest |
1,273,969
|
1,530,881
|
Total Stockholders’ Equity |
3,308,044
|
8,766,590
|
Total Liabilities & Stockholders’ Equity |
$ 13,149,572
|
$ 19,083,491
|
X |
- DefinitionResearch and development grant liability
+ References
+ Details
Name: |
QLGN_ResearchAndDevelopmentGrantLiability |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.
+ References
+ Details
Name: |
us-gaap_AccruedLiabilitiesAndOtherLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for unused vacation time owed to employees based on the entity's vacation benefit given to its employees. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 710 -SubTopic 10 -Section 25 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483070/710-10-25-3
+ Details
Name: |
us-gaap_AccruedVacationCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred income excluding obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 25 -Paragraph 2 -SubTopic 10 -Topic 470 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481174/470-10-25-2
+ Details
Name: |
us-gaap_DeferredIncomeCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenueNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Goodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying amount as of the balance sheet date of the liability arising from a financial instrument or a contract used to mitigate a specified risk (hedge), and which are expected to be converted into cash or otherwise disposed of within a year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_HedgingLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_Liabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7
Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_MinorityInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncurrent assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_RestrictedCashAndCashEquivalents |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ShortTermBorrowings |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15
Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16
Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Statement of Financial Position [Abstract] |
|
|
Common stock, par value |
$ 0.001
|
$ 0.001
|
Common stock, shares authorized |
225,000,000
|
225,000,000
|
Common stock, shares issued |
5,052,463
|
4,210,737
|
Common stock, shares outstanding |
5,052,463
|
4,210,737
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($)
|
3 Months Ended |
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
REVENUES |
|
|
|
|
Total revenues |
$ 1,627,031
|
$ 1,430,534
|
$ 3,234,201
|
$ 2,152,563
|
EXPENSES |
|
|
|
|
Cost of product sales |
1,016,542
|
1,099,677
|
2,281,368
|
1,928,524
|
General and administrative |
2,665,849
|
2,660,857
|
4,380,283
|
5,559,608
|
Research and development |
1,326,544
|
1,506,227
|
3,448,095
|
3,370,972
|
Sales and marketing |
169,223
|
305,103
|
368,337
|
443,426
|
Total expenses |
5,178,158
|
5,571,864
|
10,478,083
|
11,302,530
|
LOSS FROM OPERATIONS |
(3,551,127)
|
(4,141,330)
|
(7,243,882)
|
(9,149,967)
|
OTHER EXPENSE (INCOME), NET |
|
|
|
|
Gain on change in fair value of warrant liabilities |
(440,294)
|
(14,800)
|
(1,478,967)
|
(698,042)
|
Interest expense (income), net |
377,416
|
(4,824)
|
921,652
|
(11,132)
|
Loss on voluntary conversion of convertible debt |
|
|
1,077,287
|
|
Loss on disposal of equipment held for lease |
63,302
|
|
63,302
|
|
Other income, net |
(5,680)
|
376
|
(10,559)
|
341
|
Loss on fixed asset disposal |
|
|
300
|
|
Total other expense (income), net |
(5,256)
|
(19,248)
|
573,015
|
(708,833)
|
LOSS BEFORE (BENEFIT) PROVISION FOR INCOME TAXES |
(3,545,871)
|
(4,122,082)
|
(7,816,897)
|
(8,441,134)
|
(BENEFIT) PROVISION FOR INCOME TAXES |
(38,182)
|
5,438
|
(201,959)
|
6,173
|
Net loss |
(3,507,689)
|
(4,127,520)
|
(7,614,938)
|
(8,447,307)
|
Net loss attributable to noncontrolling interest |
(43,484)
|
(4,116)
|
(304,512)
|
(4,116)
|
Net loss attributable to Qualigen Therapeutics, Inc. |
$ (3,464,205)
|
$ (4,123,404)
|
$ (7,310,426)
|
$ (8,443,191)
|
Net loss per common share, basic |
$ (0.69)
|
$ (1.12)
|
$ (1.46)
|
$ (2.35)
|
Net loss per common share, diluted |
$ (0.69)
|
$ (1.12)
|
$ (1.46)
|
$ (2.35)
|
Weighted—average number of shares outstanding, basic |
5,052,463
|
3,668,016
|
5,006,050
|
3,599,093
|
Weighted-average number of shares outstanding, diluted |
5,052,463
|
3,668,016
|
5,006,050
|
3,599,093
|
Other comprehensive loss, net of tax |
|
|
|
|
Foreign currency translation adjustment |
$ (56,747)
|
$ 65,540
|
$ 119,473
|
$ 65,540
|
Other comprehensive loss |
(3,564,436)
|
(4,061,980)
|
(7,495,465)
|
(8,381,767)
|
Comprehensive loss attributable to noncontrolling interest |
(43,484)
|
(4,116)
|
(304,512)
|
(4,116)
|
Comprehensive loss attributable to Qualigen Therapeutics, Inc. |
(3,520,952)
|
(4,057,864)
|
(7,190,953)
|
(8,377,651)
|
Net Product Sales [Member] |
|
|
|
|
REVENUES |
|
|
|
|
Total revenues |
$ 1,627,031
|
$ 1,430,534
|
$ 3,234,201
|
$ 2,152,563
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(21)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
+ Details
Name: |
us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in the fair value of derivatives recognized in the income statement.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4A
+ Details
Name: |
us-gaap_DerivativeGainLossOnDerivativeNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5
+ Details
Name: |
us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7
+ Details
Name: |
us-gaap_EarningsPerShareDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of other assets.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnSaleOfOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionConsideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 40 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481194/470-20-40-16
+ Details
Name: |
us-gaap_InducedConversionOfConvertibleDebtExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe net amount of operating interest income (expense).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.10) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_InterestIncomeExpenseNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe total expense recognized in the period for promotion, public relations, and brand or product advertising.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_MarketingAndAdvertisingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4
Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B
Reference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of Net Income (Loss) attributable to noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
+ Details
Name: |
us-gaap_NetIncomeLossAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingCostsAndExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of income (expense) related to nonoperating activities, classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_OtherNonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_RevenuesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=QLGN_NetProductSalesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
|
Common Stock [Member] |
Additional Paid-in Capital [Member] |
AOCI Attributable to Parent [Member] |
Retained Earnings [Member] |
Parent [Member] |
Noncontrolling Interest [Member] |
Total |
Beginning balance, value at Dec. 31, 2021 |
$ 35,290
|
$ 101,274,073
|
|
$ (84,744,629)
|
$ 16,564,734
|
|
$ 16,564,734
|
Balance, shares at Dec. 31, 2021 |
3,529,018
|
|
|
|
|
|
|
Stock-based compensation |
|
1,267,166
|
|
|
1,267,166
|
|
1,267,166
|
Net loss |
|
|
|
(4,319,787)
|
(4,319,787)
|
|
(4,319,787)
|
Stock issued upon exercise of warrants |
$ 5
|
4,711
|
|
|
4,716
|
|
4,716
|
Stock issued upon exercise of warrants, shares |
536
|
|
|
|
|
|
|
Ending balance, value at Mar. 31, 2022 |
$ 35,295
|
102,545,950
|
|
(89,064,416)
|
13,516,829
|
|
13,516,829
|
Balance, shares at Mar. 31, 2022 |
3,529,554
|
|
|
|
|
|
|
Beginning balance, value at Dec. 31, 2021 |
$ 35,290
|
101,274,073
|
|
(84,744,629)
|
16,564,734
|
|
16,564,734
|
Balance, shares at Dec. 31, 2021 |
3,529,018
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
(8,447,307)
|
Ending balance, value at Jun. 30, 2022 |
$ 38,795
|
107,557,744
|
65,540
|
(93,187,820)
|
14,474,259
|
3,995,884
|
18,470,143
|
Balance, shares at Jun. 30, 2022 |
3,879,554
|
|
|
|
|
|
|
Beginning balance, value at Mar. 31, 2022 |
$ 35,295
|
102,545,950
|
|
(89,064,416)
|
13,516,829
|
|
13,516,829
|
Balance, shares at Mar. 31, 2022 |
3,529,554
|
|
|
|
|
|
|
Stock-based compensation |
|
1,423,282
|
|
|
1,423,282
|
|
1,423,282
|
Foreign currency translation adjustment |
|
|
65,540
|
|
65,540
|
|
65,540
|
Net loss |
|
|
|
(4,123,404)
|
(4,123,404)
|
(4,116)
|
(4,127,520)
|
Common stock issued for business acquisition |
$ 3,500
|
1,841,000
|
|
|
1,844,500
|
|
1,844,500
|
Common stock issued shares for business acquisition |
350,000
|
|
|
|
|
|
|
Prefunded warrants issued for business acquisition |
|
1,746,816
|
|
|
1,746,816
|
|
1,746,816
|
Estimated fair value of noncontrolling interest related to business acquisition |
|
|
|
|
|
4,000,000
|
4,000,000
|
Fair value of warrant modification for business acquisition |
|
696
|
|
|
696
|
|
696
|
Ending balance, value at Jun. 30, 2022 |
$ 38,795
|
107,557,744
|
65,540
|
(93,187,820)
|
14,474,259
|
3,995,884
|
18,470,143
|
Balance, shares at Jun. 30, 2022 |
3,879,554
|
|
|
|
|
|
|
Beginning balance, value at Dec. 31, 2022 |
$ 42,110
|
110,528,050
|
50,721
|
(103,385,172)
|
7,235,709
|
1,530,881
|
8,766,590
|
Balance, shares at Dec. 31, 2022 |
4,210,737
|
|
|
|
|
|
|
Voluntary conversion of convertible debt into common stock |
$ 842
|
1,111,740
|
|
|
1,112,582
|
|
1,112,582
|
Voluntary conversion of convertible debt into common stock, shares |
841,726
|
|
|
|
|
|
|
Stock-based compensation |
|
247,657
|
|
|
247,657
|
4,569
|
252,226
|
Foreign currency translation adjustment |
|
|
119,723
|
|
119,723
|
56,497
|
176,220
|
Net loss |
|
|
|
(3,846,221)
|
(3,846,221)
|
(261,028)
|
(4,107,249)
|
Ending balance, value at Mar. 31, 2023 |
$ 42,952
|
111,887,447
|
170,444
|
(107,231,393)
|
4,869,450
|
1,330,919
|
6,200,369
|
Balance, shares at Mar. 31, 2023 |
5,052,463
|
|
|
|
|
|
|
Beginning balance, value at Dec. 31, 2022 |
$ 42,110
|
110,528,050
|
50,721
|
(103,385,172)
|
7,235,709
|
1,530,881
|
8,766,590
|
Balance, shares at Dec. 31, 2022 |
4,210,737
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
(7,614,938)
|
Ending balance, value at Jun. 30, 2023 |
$ 42,952
|
112,554,830
|
131,891
|
(110,695,598)
|
2,034,075
|
1,273,969
|
3,308,044
|
Balance, shares at Jun. 30, 2023 |
5,052,463
|
|
|
|
|
|
|
Beginning balance, value at Mar. 31, 2023 |
$ 42,952
|
111,887,447
|
170,444
|
(107,231,393)
|
4,869,450
|
1,330,919
|
6,200,369
|
Balance, shares at Mar. 31, 2023 |
5,052,463
|
|
|
|
|
|
|
Stock-based compensation |
|
667,383
|
|
|
667,383
|
4,728
|
672,111
|
Foreign currency translation adjustment |
|
|
(38,553)
|
|
(38,553)
|
(18,194)
|
(56,747)
|
Net loss |
|
|
|
(3,464,205)
|
(3,464,205)
|
(43,484)
|
(3,507,689)
|
Ending balance, value at Jun. 30, 2023 |
$ 42,952
|
$ 112,554,830
|
$ 131,891
|
$ (110,695,598)
|
$ 2,034,075
|
$ 1,273,969
|
$ 3,308,044
|
Balance, shares at Jun. 30, 2023 |
5,052,463
|
|
|
|
|
|
|
X |
- DefinitionAmount of other increase (decrease) in additional paid in capital (APIC).
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481284/470-20-25-2
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in noncontrolling interest from a business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 1 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(2) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_NoncontrollingInterestIncreaseFromBusinessCombination |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued pursuant to acquisitions during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of shares of stock issued attributable to transactions classified as other.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueOther |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 23 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 5 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (h)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 20 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (i)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 848 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (a)(3)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 105 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 6 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 8 -Subparagraph (d)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 65 -Paragraph 15 -Subparagraph (f)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2
Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15
Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16
Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 55 -Paragraph 4I -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I
+ Details
Name: |
us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Mar. 31, 2023 |
Jun. 30, 2022 |
Mar. 31, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
CASH FLOWS FROM OPERATING ACTIVITIES |
|
|
|
|
|
|
|
Net loss |
$ (3,507,689)
|
$ (4,107,249)
|
$ (4,127,520)
|
$ (4,319,787)
|
$ (7,614,938)
|
$ (8,447,307)
|
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
122,523
|
66,258
|
|
Amortization of right-of-use assets |
|
|
|
|
116,567
|
109,803
|
|
Accounts receivable reserves and allowances |
|
|
|
|
(133,278)
|
(75,295)
|
|
Inventory reserves |
|
|
|
|
(22,992)
|
(16,405)
|
|
Stock-based compensation |
|
|
|
|
906,145
|
2,690,447
|
|
Change in fair value of warrant liabilities |
|
|
|
|
(1,478,967)
|
(698,042)
|
|
Loss on voluntary conversion of convertible debt |
|
|
|
|
1,077,287
|
|
|
Accretion of discount on convertible debt |
|
|
|
|
787,517
|
|
|
Loss on disposal of fixed assets and equipment held for lease |
|
|
|
|
63,602
|
|
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
Accounts receivable |
|
|
|
|
(8,614)
|
250,201
|
|
Inventory and equipment held for lease |
|
|
|
|
(37,390)
|
(237,930)
|
|
Prepaid expenses and other assets |
|
|
|
|
382,893
|
(548,487)
|
|
Accounts payable |
|
|
|
|
899,753
|
27,941
|
|
Accrued expenses and other current liabilities |
|
|
|
|
357,508
|
(828,229)
|
|
R&D grant liability |
|
|
|
|
(613,793)
|
|
|
Operating lease liability |
|
|
|
|
(116,756)
|
(73,408)
|
|
Deferred revenue |
|
|
|
|
(42,095)
|
(47,345)
|
|
Deferred tax liability |
|
|
|
|
(207,388)
|
|
|
Net cash used in operating activities |
|
|
|
|
(5,562,416)
|
(7,827,798)
|
$ (13,200,000)
|
CASH FLOWS FROM INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
Purchases of property and equipment |
|
|
|
|
(246,418)
|
(63,483)
|
|
Net cash acquired in business combination |
|
|
|
|
|
135,354
|
|
Net cash (used in)/provided by investing activities |
|
|
|
|
(246,418)
|
71,871
|
|
CASH FLOWS FROM FINANCING ACTIVITIES: |
|
|
|
|
|
|
|
Net proceeds from warrant exercises |
|
|
|
|
|
3,859
|
|
Net cash provided by financing activities |
|
|
|
|
|
3,859
|
|
Net change in cash and restricted cash |
|
|
|
|
(5,808,834)
|
(7,752,068)
|
|
Effect of exchange rate changes on cash and restricted cash |
|
|
|
|
115,803
|
(34,228)
|
|
Cash and restricted cash - beginning of period |
|
$ 7,040,124
|
|
$ 17,538,272
|
7,040,124
|
17,538,272
|
17,538,272
|
Cash and restricted cash - end of period |
$ 1,347,093
|
|
$ 9,751,976
|
|
1,347,093
|
9,751,976
|
$ 7,040,124
|
Cash paid during the year for: |
|
|
|
|
|
|
|
Interest |
|
|
|
|
|
|
|
Taxes |
|
|
|
|
6,293
|
3,501
|
|
NONCASH FINANCING AND INVESTING ACTIVITIES: |
|
|
|
|
|
|
|
Net transfers to equipment held for lease from inventory |
|
|
|
|
83,271
|
|
|
Fair value of warrant liabilities on date of exercise |
|
|
|
|
|
858
|
|
Voluntary conversion of convertible debt into common stock |
|
|
|
|
$ 1,112,582
|
|
|
X |
- DefinitionAccretion of discount on convertible debt.
+ References
+ Details
Name: |
QLGN_AccretionOfDiscountOnConvertibleDebt |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionFair value of warrant liabilities on date of exercise.
+ References
+ Details
Name: |
QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionResearch and development grant liability.
+ References
+ Details
Name: |
QLGN_IncreaseDecreaseInResearchAndDevelopmentGrantLiability |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLoss on voluntary conversion of convertible debt.
+ References
+ Details
Name: |
QLGN_LossOnVoluntaryConversionOfConvertibleDebt |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionTransfers of inventory from equipment held for lease.
+ References
+ Details
Name: |
QLGN_TransfersOfInventoryFromEquipmentHeldForLease |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionVoluntary conversion of convertible debt into common stock.
+ References
+ Details
Name: |
QLGN_VoluntaryConversionOfConvertibleDebtIntoCommonStock |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12
+ Details
Name: |
us-gaap_CashAcquiredFromAcquisition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1
+ Details
Name: |
us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_GainLossOnDispositionOfAssets1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsReceivable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the period in book value of long-lived assets that the reporting entity plans to sell within one year (or one business cycle).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInAssetsHeldForSale |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInContractWithCustomerLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionChange during the period in carrying value for all deferred liabilities due within one year or operating cycle.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInDeferredLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in obligation for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2
+ Details
Name: |
us-gaap_InterestPaidNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-2
+ Details
Name: |
us-gaap_InventoryWriteDown |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NoncashInvestingAndFinancingItemsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9
Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19
Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31
Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1
Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7
Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J
Reference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K
Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A
Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B
Reference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2
Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
Reference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A
+ Details
Name: |
us-gaap_ProfitLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_ProvisionForDoubtfulAccounts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES
|
6 Months Ended |
Jun. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES |
NOTE
1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES
Organization
Qualigen,
Inc., a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and
was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the “Company”) operates in one business segment. In
May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (“Ritter”) and
Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.’s capital stock were exchanged for Qualigen Therapeutics,
Inc.’s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital
Market under the ticker symbol “RTTR,” commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted
basis, under the trading symbol “QLGN” on May 26, 2020.
On
May 26, 2022, the Company acquired 2,232,861 shares
of Series A-1 Preferred Stock of NanoSynex, Ltd. (“NanoSynex”) from Alpha Capital Anstalt (“Alpha Capital”),
a related party, in exchange for 350,000 reverse
split adjusted shares of the Company’s common stock and a prefunded warrant to purchase 331,464 reverse
split adjusted shares of the Company’s common stock at an exercise price of $0.001 per
share. These warrants were
subsequently exercised on September 13, 2022.
Concurrently with this transaction, the Company also purchased 381,786 shares
of Series B preferred stock from NanoSynex for a total purchase price of $600,000.
The transactions resulted in the Company acquiring a 52.8%
interest in NanoSynex (the “NanoSynex Acquisition”). NanoSynex is a micro-biologics diagnostics company domiciled in
Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the
“NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of
NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a
majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by
the NanoSynex Funding Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd.
).
Basis
of Presentation
The
accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally
accepted in the United States of America (“U.S. GAAP”), Regulation S-X and rules and regulations of the Securities and Exchange
Commission (“SEC”).
Principles
of Consolidation
The
accompanying condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All
intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is
meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional
currency of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency,
New Israeli Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign
currency translation adjustments are reflected as a component of accumulated other comprehensive income within the Company’s consolidated
statements of changes in stockholders’ equity.
Accounting
Estimates
Management
uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill,
warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and
returns, and warranty costs. Actual results could vary from the estimates that were used.
Reverse
Stock Split
On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company’s board of directors, reverse stock split of its
outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced the Company’s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional
shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and
the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common
stock and the par value per share remains unchanged.
Cash
The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.
The
Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S.
that are of high quality. Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail,
the Company could lose all or a portion of amounts held in excess of such insurance limitations. In March 2023, Silicon Valley Bank and
Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity concerns and taken over by the Federal
Deposit Insurance Corporation (FDIC). While the Company did not have an account at any of these banks, in the event of failure of any
of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would
be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely
affect our business and financial position.
Inventory,
Net
Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified
as excess or obsolete.
Impairment
of Long-Lived Assets
The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the three and six months ended June 30, 2023 and 2022,
no such impairment losses have been recorded.
Segment
Reporting
Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.
Accounts
Receivable, Net
The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.
The
Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company’s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.
Accounts
receivable, net is comprised of the following at:
SCHEDULE
OF ACCOUNTS RECEIVABLE
| |
June 30, 2023 | | |
December 31, 2022 | |
Accounts Receivable | |
$ | 733,964 | | |
$ | 726,449 | |
Less Reserves and Allowances | |
| (54,584 | ) | |
| (187,862 | ) |
Accounts receivable,
net | |
$ | 679,380 | | |
$ | 538,587 | |
Research
and Development
Except
for acquired in process research and development (IPR&D), the Company expenses research and development costs as incurred including
therapeutics license costs.
R&D
Grants
NanoSynex
has received R&D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding
to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants
in advance, the proceeds are recorded as a current or non-current R&D grant liability based on the time from the condensed consolidated
balance sheets date to the expected future date of recognition as a reduction to research and development expenses.
Patent
Costs
The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the condensed consolidated
statement of operations.
Shipping
and Handling Costs
The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales which totaled approximately $78,000 and $72,000, respectively, for the three
months ended June 30, 2023 and 2022, and approximately $144,000 and $111,000, respectively, for the six months ended June 30,
2023 and 2022. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing
expenses were $0 and $4,000 for the three months ended June 30, 2023 and 2022, respectively, and
approximately $4,000 and $8,000 for the six months ended June 30, 2023 and 2022, respectively.
Revenue
from Contracts with Customers
The
Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine
revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and
(v) recognition of revenue when (or as) the Company satisfies each performance obligation.
Product
Sales
The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, testosterone, thyroid disorders,
pregnancy, and Vitamin D.
The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (“analyzer”) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.
The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (“FOB”) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company’s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.
The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfill the promise to transfer the disposable products and not as a separate performance obligation.
The
Company’s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company’s
contracts.
Contract
Asset and Liability Balances
The
timing of the Company’s revenue recognition may differ from the timing of payment by the Company’s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are
satisfied.
Multiple
performance obligations include contracts that combine both the Company’s analyzer and a customer’s future reagent purchases
under a single contract. In some sales contracts, the Company provides analyzers at no charge to customers. Title to the analyzer is
maintained by the Company and the analyzer is returned by the customer to the Company at the end of the purchase agreement.
During
the three months ended June 30, 2023 and 2022, product sales are stated net of an allowance for estimated returns of approximately $28,000
and $10,000, respectively. During the six months ended June 30, 2023 and 2022, product sales are stated net of an allowance for estimated
returns of approximately $33,000 and $53,000, respectively.
Deferred
Revenue
Payments
received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales,
multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the
time from the condensed consolidated balance sheets date to the future date of revenue recognition.
Operating
Leases
Effective
April 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2018-11, Leases (Topic 842) Targeted Improvements
(“Topic 842”). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding
right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for
in a manner similar to the guidance for operating leases prior to the adoption of Topic 842. (See Note
12 - Commitments and Contingencies for more information).
Property
and Equipment, Net
Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:
SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT
Machinery and equipment | |
| 5 years | |
Computer equipment | |
| 3 years | |
Molds and tooling | |
| 5 years | |
Furniture and fixtures | |
| 5 years | |
Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.
The
Company’s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.
Business
Combinations
The
Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other
things, that results of operations of acquired companies are included in Qualigen’s financial results beginning on the respective acquisition
date, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired
in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions
about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant.
Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred
(the “purchase price”) over the fair values of the net assets acquired is recognized as goodwill. The fair value of assets
acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a
period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all
other acquisition-related costs are expensed when incurred.
Goodwill
Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets
acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized
but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the
goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value.
If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the
difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $4,239,000
non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the fiscal year
ended December 31, 2022. There were no
impairment losses during the three and six months ended June 30, 2023 and 2022.
Intangible
Assets
In
Process R&D
Acquired
in process R&D (IPR&D) represents the fair value assigned to the research and development assets that have not reached technological
feasibility. The value assigned to IPR&D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue
and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing the
new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature
and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate
with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition
of acquired IPR&D, an assessment is completed as to whether the acquisition constitutes an acquisition of a single asset or a group
of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence
of separate cash flows, the development process and stage of completion, quantitative significance, and the Company’s rationale for entering
into the transaction.
If
a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&D is capitalized as an intangible
asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the
acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development
expense in the Company’s condensed consolidated statements of operations and other comprehensive income (loss) as they are incurred.
IPR&D
is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value
of the acquired IPR&D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment
recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&D could
result in an impairment.
Other
Intangible Assets, Net
Other
intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible
assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate
that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be
recovered.
If
the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.
Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally 5 to 17
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has
been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.
Derivative
Financial Instruments and Warrant Liabilities
The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the condensed consolidated statements of operations and other comprehensive income (loss). Depending on the features of the derivative
financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative
instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments
should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 9- Warrant Liabilities).
Fair
Value Measurements
The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:
| ● | Level
1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or
liabilities that the Company has the ability to access at the measurement date; |
| ● | Level
2 - Inputs other than quoted prices that are observable for the assets or liability either
directly or indirectly, including inputs in markets that are not considered to be active;
and |
| ● | Level
3 - Inputs that are unobservable. |
Fair
Value of Financial Instruments
Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.
Comprehensive
Loss
Comprehensive
loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements
of operations and comprehensive loss and as a separate component in the statements of stockholders’ equity for all periods presented.
Stock-Based
Compensation
Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.
Income
Taxes
Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.
Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years.
Sales
and Excise Taxes
Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the condensed consolidated balance sheet as cash is collected from customers
and remitted to the tax authority.
Warranty
Costs
The
Company’s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company’s best estimates of analyzer failure rates
and costs to repair.
Accrued
warranty liabilities were approximately $140,000 and $138,000, respectively, as of June 30, 2023 and December 31, 2022 and
are included in accrued expenses and other current liabilities on the accompanying condensed consolidated balance sheets. Warranty costs
were approximately $63,000 and $22,000 for the three months ended June 30, 2023 and 2022, respectively, and approximately $104,000
and $41,000 for the six months ended June 30, 2023 and 2022, respectively, and are included in cost of product sales in the condensed
consolidated statements of operations and other comprehensive loss.
Foreign
Currency Translation
The
functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company’s newly acquired majority
owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange
rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations;
and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of
NanoSynex is reflected as a separate component of other comprehensive income (loss).
Other
comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was ($56,747) and $65,540 for the three months ending June 30, 2023 and 2022, respectively, and $119,473 and $65,540 for the six months ending June 30, 2023 and 2022, respectively.
War
in Ukraine
In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company’s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.
Inflation
and Global Economic Conditions
During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect
to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate
the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include aggregation
of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive
suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that
it will be successful in fully offsetting increased costs resulting from inflationary pressure. In
addition, the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global
recession in the near future. If the global economy slows, our business would be adversely affected.
Impact
of COVID-19 Pandemic
The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company’s business as well. During the height of
the pandemic sales of diagnostic products decreased significantly and the Company’s net loss increased significantly, as deferral
of patients’ non-emergency visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests.
For 2023 we continue to experience recovery in demand.
Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s
condensed consolidated financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 275 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//275/tableOfContent
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContent
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
LIQUIDITY
|
6 Months Ended |
Jun. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
LIQUIDITY |
NOTE
2 — LIQUIDITY
As
of June 30, 2023, we had approximately $1.3 million in cash and an accumulated deficit of $110.7 million. For the six months ended June
30, 2023 and year ended December 31, 2022, we used cash of $5.6 million and $13.2 million, respectively, in operations.
On
July 20, 2023, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Chembio Diagnostics,
Inc. (“Chembio”), Biosynex, S.A. and Qualigen, Inc., a wholly-owned subsidiary of the Company (see Note 16 - Subsequent
Events). Pursuant to the Purchase Agreement, the Company agreed to sell to the Buyer all of the issued and outstanding shares of
common stock (collectively, the “Shares”) of Qualigen, Inc., which was the legal entity operating the Company’s
FastPack™ diagnostics business (the “Transaction”). The Transaction closed on July 20, 2023. Following the
consummation of the Transaction, our Qualigen, Inc. subsidiary became a wholly-owned subsidiary of Chembio.
The
aggregate net purchase price paid to the Company for the Shares was $5.2 million in cash, based on a base purchase price of $5.8 million,
subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by Qualigen, Inc. as of the closing
of the Transaction; (ii) net working capital of Qualigen, Inc. as of the closing of the Transaction, (iii) certain indebtedness of Qualigen,
Inc. as of the closing of the Transaction, and (iv) certain Transaction expenses as of the closing of the Transaction. Of the $5.2 million
in cash, $450,000 is being held in escrow to satisfy certain Company indemnification obligations (the “Indemnity Escrow”).
Any amounts remaining in the Indemnity Escrow that have not been offset or reserved for claims will be released to the Company within
five business days following the date that is 18 months after the closing.
The
Company’s cash balances as of the date that these financial statements were issued along with the proceeds from the above sale to Chembio, without additional financing, are
expected to fund operations into the first quarter of 2024. The Company expects to continue to have net losses and negative cash
flow from operations, which over time will challenge its liquidity. These factors raise substantial doubt about the Company’s
ability to continue as a going concern for the one-year period following the date that these financial statements were
issued.
There
is no assurance that profitable operations will ever be achieved, or, if achieved, could be sustained on a continuing basis. In order
to fully execute its business plan, the Company will require significant additional financing for planned research and development activities,
capital expenditures, clinical testing for its QN-302 clinical trials, preclinical development of RAS and QN-247, and
funding for NanoSynex operations, as well as commercialization activities.
Historically,
the Company’s principal sources of cash have included proceeds from the issuance of common and preferred equity and proceeds from
the issuance of debt. In December 2021, the Company raised $8.8 million from the issuance of common stock to several institutional investors,
and in December 2022 the Company raised $3.0 million from the sale of an 8% Senior Convertible Debenture (the “Debenture”)
to a related party (see Note 10 - Convertible Debt - Related Party). There can be no assurance that further financing can be obtained
on favorable terms, or at all. If we are unable to obtain funding, we could be required to delay, reduce or eliminate research and development
programs, product portfolio expansion or future commercialization efforts, which could adversely affect our business prospects.
On
July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex
Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated
May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary
of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding
Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd. ).
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
In
the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction,
the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex
pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we originally paid
in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per share.
To
the extent that the Company raises additional capital through the sale of equity or convertible debt securities, the ownership interests
of its common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely
affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or
restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.
If the Company raises additional funds through government or other third-party funding, commercialization, marketing and distribution
arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, it may have to relinquish valuable
rights to its technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be
favorable to the Company. Additional funding may not be available to the Company on acceptable terms, or at all. In addition, any future
financing (depending on the terms and conditions) may be subject to the approval of Alpha Capital, the holder of the Debenture, or trigger
certain adjustments to the Debenture or warrants held by Alpha Capital.
The
accompanying financial statements have been prepared assuming that the Company will continue as a going concern. The financial statements
do not include any adjustments that would be necessary should the Company be unable to continue as a going concern, and therefore, be
required to liquidate its assets and discharge its liabilities in other than the normal course of business and at amounts that may differ
from those reflected in the accompanying financial statements
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 40 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205-40/tableOfContent
+ Details
Name: |
us-gaap_SubstantialDoubtAboutGoingConcernTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INVENTORY, NET
|
6 Months Ended |
Jun. 30, 2023 |
Inventory Disclosure [Abstract] |
|
INVENTORY, NET |
NOTE
3— INVENTORY,
NET
Inventory,
net consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF INVENTORY
| |
June 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 1,027,455 | | |
$ | 949,796 | |
Work in process | |
| 177,591 | | |
| 200,318 | |
Finished goods | |
| 358,353 | | |
| 436,183 | |
Total
inventory | |
$ | 1,563,399 | | |
$ | 1,586,297 | |
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
+ Details
Name: |
us-gaap_InventoryDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
PREPAID EXPENSES AND OTHER CURRENT ASSETS
|
6 Months Ended |
Jun. 30, 2023 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
PREPAID EXPENSES AND OTHER CURRENT ASSETS |
NOTE
4 — PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid
expenses and other current assets consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
| |
June 30, 2023 | | |
December 31, 2022 | |
Prepaid insurance | |
$ | 938,106 | | |
$ | 1,377,323 | |
Prepaid manufacturing expenses | |
| 51,710 | | |
| 43,820 | |
Other prepaid expenses | |
| 65,288 | | |
| 227,451 | |
Prepaid research and development expenses | |
| 211,337 | | |
| — | |
Other current assets | |
| 11,636 | | |
| 12,626 | |
Prepaid expenses and
other current assets | |
$ | 1,278,077 | | |
$ | 1,661,220 | |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.
+ References
+ Details
Name: |
us-gaap_OtherAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
PROPERTY AND EQUIPMENT, NET
|
6 Months Ended |
Jun. 30, 2023 |
Property, Plant and Equipment [Abstract] |
|
PROPERTY AND EQUIPMENT, NET |
NOTE
5 — PROPERTY AND EQUIPMENT, NET
Property
and equipment, net consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF PROPERTY AND EQUIPMENT
| |
June 30, 2023 | | |
December 31, 2022 | |
Machinery and equipment | |
$ | 2,735,507 | | |
$ | 2,510,148 | |
Computer equipment | |
| 369,589 | | |
| 395,836 | |
Leasehold improvements | |
| 336,916 | | |
| 333,271 | |
Molds and tooling | |
| 260,002 | | |
| 260,002 | |
Furniture and fixtures | |
| 144,832 | | |
| 144,832 | |
Equipment held for lease | |
| 1,405,384 | | |
| 1,399,444 | |
Property and equipment, gross | |
| 5,252,230 | | |
| 5,043,533 | |
Accumulated depreciation | |
| (4,678,583 | ) | |
| (4,623,446 | ) |
Fixed asset impairment | |
| (75,000 | ) | |
| (75,000 | ) |
Property and equipment,
net | |
$ | 498,647 | | |
$ | 345,087 | |
Depreciation
expense relating to property and equipment was approximately $19,000 and $24,000 for the three months ended June 30, 2023 and 2022,
respectively, and $37,000 and $48,000 for the six months ended June 30, 2023 and 2022, respectively.
Upon
termination of the Sekisui Distribution Agreement on March 31, 2022, the Company had a commitment to purchase leased FastPack rental
systems back from Sekisui at Sekisui’s net book value, which was determined to be approximately $154,000. An assignment agreement
was executed by the parties on June 26, 2023 to legally transfer title to this equipment from Sekisui to the Company, and this amount
is included in accounts payable at June 30, 2023.
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//360/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
GOODWILL, IPR&D AND OTHER INTANGIBLES
|
6 Months Ended |
Jun. 30, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
GOODWILL, IPR&D AND OTHER INTANGIBLES |
NOTE
6 — GOODWILL, IPR&D AND OTHER INTANGIBLES
SCHEDULE
OF GOODWILL AND OTHER INTANGIBLES
| |
| |
June 30, | | |
December 31, | |
| |
| |
2023 | | |
2022 | |
| |
Estimated Useful Lives | |
Gross carrying amounts | | |
Gross carrying amounts | |
| |
| |
| | |
| |
Goodwill | |
| |
$ | 625,602 | | |
$ | 625,602 | |
| |
| |
| | | |
| | |
Finite-lived intangible assets: | |
| |
| | | |
| | |
Developed-product-technology rights | |
8 - 17 years | |
$ | 479,103 | | |
$ | 479,103 | |
Licensing rights | |
10 years | |
| 418,836 | | |
| 418,836 | |
Less: Accumulated amortization | |
| |
| (764,869 | ) | |
| (752,237 | ) |
Total finite-lived intangible assets, net | |
| |
| 133,070 | | |
| 145,702 | |
Indefinite-lived intangible assets: | |
| |
| | | |
| | |
In-process research and development | |
| |
| 5,700,000 | | |
| 5,700,000 | |
Total other intangible assets, net | |
| |
$ | 5,833,070 | | |
$ | 5,845,702 | |
The
Company periodically reviews goodwill for impairment in accordance with relevant accounting standards. Goodwill is attributable to the
NanoSynex Acquisition. Goodwill and intangible assets are recognized at fair value during the period in which an acquisition is completed,
from updated estimates during the measurement period, or when they are considered to be impaired. These non-recurring fair value measurements,
primarily for goodwill and intangible assets acquired, were based on Level 3 inputs. The Company estimates the fair value of long-lived
assets on a non-recurring basis based on a market valuation approach, engaging independent valuation experts to assist in the determination
of fair value. In the fourth quarter of fiscal 2022, in conjunction with the annual impairment assessment, the Company determined that
the fair value of the reporting unit was less than the carrying value. In addition to continued losses in the reporting unit, the Company
considered macroeconomic conditions including a deterioration in the equity markets evidenced by sustained declines in the Company’s
stock price, peer companies, and major market indices since the acquisition date. The Company engaged independent valuation experts to
assist in determining the fair value of the reporting unit. As a result of this analysis, the Company recorded a $4,239,000 goodwill
and fixed asset impairment charge associated with the reporting unit for fiscal year ended December 31, 2022. There were no impairment
losses during the three and six months ended June 30, 2023 and 2022.
The
carrying value of the patents of approximately $131,000
and $140,000
at June 30, 2023 and December 31, 2022,
respectively, are stated net of accumulated amortization of approximately $348,000
and $339,000,
respectively. Amortization of patents charged to operations for the three months ended June 30, 2023 and 2022 was approximately
$9,000
and $5,000
respectively, and for the six months ended June 30,
2023 and 2022 was approximately $9,000
and $9,000,
respectively.
The
carrying value of the in-licenses of approximately $2,000
and $5,000
at June 30, 2023 and December 31, 2022,
respectively, are stated net of accumulated amortization of approximately $417,000
and $414,000,
respectively, and amortization of licenses charged to both the three months ended June 30, 2023 and 2022 was approximately $3,000.
Amortization of licenses charged to operations for both the six months ended June 30, 2023 and 2022 was approximately $3,000.
On
July 20, 2023, the Company entered into a Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc.,
a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued
and outstanding shares of common stock of Qualigen, Inc. (see Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics,
Inc. and Biosynex, S.A.). Therefore, there is no future estimated amortization of patent and license costs for the five succeeding
years.
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for goodwill and intangible assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//350/tableOfContent
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
|
6 Months Ended |
Jun. 30, 2023 |
Payables and Accruals [Abstract] |
|
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES |
NOTE
7 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
Accrued
expenses and other current liabilities consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
| |
June 30, 2023 | | |
December 31, 2022 | |
Board compensation | |
$ | 84,000 | | |
| 70,000 | |
Equipment held for lease | |
| — | | |
| 154,433 | |
Franchise, sales and use taxes | |
| 30,407 | | |
| 27,531 | |
Income taxes | |
| 6,921 | | |
| 4,663 | |
Interest (Convertible debt - related party) | |
| 50,101 | | |
| 2,829 | |
License fees | |
| 100,026 | | |
| 150,130 | |
Payroll | |
| 484,048 | | |
| 209,303 | |
Professional fees | |
| 368,032 | | |
| 238,211 | |
Research and development | |
| 523,490 | | |
| 322,987 | |
Royalties | |
| 16,383 | | |
| 13,158 | |
Warranty liability | |
| 140,370 | | |
| 137,568 | |
Other | |
| 176,777 | | |
| 181,043 | |
Accrued expenses and other current liabilities | |
$ | 1,980,555 | | |
$ | 1,511,856 | |
|
X |
- DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
SHORT TERM DEBT-RELATED PARTY
|
6 Months Ended |
Jun. 30, 2023 |
Debt Disclosure [Abstract] |
|
SHORT TERM DEBT-RELATED PARTY |
NOTE
8 – SHORT TERM DEBT-RELATED PARTY
NanoSynex
has four separate Notes Payable (‘the Notes”) outstanding to Alpha Capital, dated between March 26, 2020 and September 2, 2021,
aggregating to a total principal outstanding balance of $905,000,
and aggregate accrued interest of $60,155
for a total outstanding balance of $965,155
as of June 30, 2023. The Notes all accrue interest at 2.62%
per annum, accrued daily, and provide that the full amount of principal and interest under each Note shall be due immediately prior
to a Liquidation Event (the Maturity Date) unless due earlier in accordance with the terms of the Notes. “Liquidation
Event” means either i) the merger or consolidation of NanoSynex into any other entity, other than one in control or under
control of NanoSynex or NanoSynex’s majority shareholder; ii) a transaction or series of transactions resulting in the transfer of
all or substantially all of NanoSynex’s assets or issued and outstanding share capital (other than to a company under the control of
NanoSynex or NanoSynex’s majority shareholders; or iii) an underwritten public offering by NanoSynex of its ordinary shares.
Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt, or equity funding with gross proceeds of USD
$3,000,000
or more, then the unused portion of these Notes shall be due and payable upon the actual receipt of such funding. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex
Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May
26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary of the
Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement (see
Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd. ).
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for short-term debt.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
+ Details
Name: |
us-gaap_ShortTermDebtTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
WARRANT LIABILITIES
|
6 Months Ended |
Jun. 30, 2023 |
Warrant Liabilities |
|
WARRANT LIABILITIES |
NOTE
9 – WARRANT LIABILITIES
In
2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a
private placement (the “Series C Warrants”). The Series C Warrants were subsequently extended and, upon closing of the reverse
recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant
terms as adjusted.
In
exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase shares of the
Company’s common stock at $7.195
per share, subject to adjustment. As of June 30, 2023, the Series C Warrants have remaining terms ranging from .40
to .99
years. The Series C Warrants were determined to be liability-classified pursuant to the guidance in ASC 480 and ASC 815-40, based on
the inclusion of a leveraged ratchet provision for subsequent dilutive issuances. On April 25, 2022, the Series C Warrants were
repriced from $7.195
to $6.00
with 49,318
additional ratchet Warrants issued, and on May 26, 2022, the Series C Warrants were repriced from $6.00
to $5.136
with 49,952
additional ratchet Warrants issued. As a result of these repricings, 247,625 warrants were forfeited and 346,896 warrants were
reissued. On December 22, 2022, the Series C Warrants were repriced again from $5.136
to $1.32
with 1,002,717
additional ratchet Warrants issued.
Additionally,
on December 22, 2022, in conjunction with the issuance of the Debenture to Alpha Capital (see Note 10 – Convertible Debt –
Related Party), the Company issued to Alpha Capital a warrant to purchase 2,500,000 shares of the Company’s common stock (the “Alpha
Warrant”). The exercise price of the Alpha Warrant is $1.65 (equal to 125% of the conversion price of the Debenture on the closing
date). The Alpha Warrant may be exercised by Alpha Capital, in whole or in part, at any time on or after June 22, 2023 and before June
22, 2028, subject to certain terms and conditions described in the Alpha Warrant, including the Company’s receipt of the necessary
stockholder approvals.
The
following table summarizes the activity in liability classified warrants for the six months ended June 30, 2023:
SCHEDULE OF WARRANTS ACTIVITY
| |
Common Stock Warrants | |
| |
Shares | | |
Weighted– Average Exercise Price | | |
Range of Exercise Price | | |
Weighted– Average Remaining Life (Years) | |
Total outstanding – December 31, 2022 | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.9 | |
Exercised | |
| — | | |
| — | | |
| — | | |
| — | |
Forfeited | |
| — | | |
| — | | |
| — | | |
| — | |
Expired | |
| — | | |
| — | | |
| — | | |
| — | |
Granted | |
| — | | |
| — | | |
| — | | |
| — | |
Total outstanding – June 30, 2023 | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.41 | |
Exercisable | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.41 | |
The
following table summarizes the activity in liability classified warrants for the six months ended June 30, 2022:
| |
Common
Stock Warrants | |
| |
Shares | | |
Weighted–
Average Exercise Price | | |
Range
of Exercise Price | | |
Weighted–
Average Remaining Life (Years) | |
Total outstanding
–December 31, 2021 | |
| 248,161 | | |
$ | 7.20 | | |
| | | |
| 2.00 | |
Exercised | |
| (536 | ) | |
| 7.20 | | |
| | | |
| | |
Forfeited | |
| (247,625 | ) | |
| 7.20 | | |
| | | |
| | |
Expired | |
| — | | |
| — | | |
| | | |
| | |
Granted | |
| 346,896 | | |
| 5.10 | | |
| | | |
| | |
Total outstanding –
June 30, 2022 | |
| 346,896 | | |
$ | 5.10 | | |
| | | |
| | |
Exercisable | |
| 346,896 | | |
$ | 5.10 | | |
$ | 5.10 | | |
| 1.51 | |
The
following table presents the Company’s fair value hierarchy for its liabilities measured at fair value on a recurring basis as
of June 30, 2023:
SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES
| |
Quoted | | |
| | |
| | |
| |
| |
Market | | |
Significant | | |
| | |
| |
| |
Prices for | | |
Other | | |
Significant | | |
| |
| |
Identical | | |
Observable | | |
Unobservable | | |
| |
| |
Assets | | |
Inputs | | |
Inputs | | |
| |
Common Stock Warrant liabilities | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | | |
Total | |
Balance as of December 31, 2022 | |
$ | — | | |
$ | — | | |
$ | 3,622,647 | | |
$ | 3,622,647 | |
Exercises | |
| — | | |
| — | | |
| — | | |
| — | |
Gain on change in fair value of warrant liabilities | |
| — | | |
| — | | |
| (1,478,967 | ) | |
| (1,478,967 | ) |
Balance as of June 30, 2023 | |
$ | — | | |
$ | — | | |
$ | 2,143,680 | | |
$ | 2,143,680 | |
There
were no transfers of financial assets or liabilities between category levels for the three and six months ended June 30, 2023.
The
value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo
simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the
fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a
public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common
stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and
does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher
or lower fair value measurements.
The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average
calculated based on the number of outstanding warrants on each issuance) as of June 30, 2023 and 2022:
SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES
|
|
June
30, 2023 |
|
June
30, 2022 |
|
|
|
Range |
|
Weighted
Average |
|
Range |
|
Weighted
Average |
|
Risk-free
interest rate |
|
4.05%
— 5.31% |
|
|
4.49 |
% |
2.80%
— 2.87% |
|
|
2.82 |
% |
Expected
volatility (peer group) |
|
66.3%
— 134% |
|
|
110.55 |
% |
74%
— 96% |
|
|
78.6 |
% |
Term
of warrants (in years) |
|
.39
— 4.98 |
|
3.41 |
|
1.39
— 1.99 |
|
1.51 |
|
Expected
dividend yield |
|
|
0.00 |
% |
|
0.00 |
% |
|
0.00 |
% |
|
0.00 |
% |
|
X |
- References
+ Details
Name: |
QLGN_DisclosureWarrantLiabilitiesAbstract |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWarrant Liabilities [Text Block]
+ References
+ Details
Name: |
QLGN_WarrantLiabilitiesTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
CONVERTIBLE DEBT- RELATED PARTY
|
6 Months Ended |
Jun. 30, 2023 |
Debt Disclosure [Abstract] |
|
CONVERTIBLE DEBT- RELATED PARTY |
NOTE
10 — CONVERTIBLE DEBT- RELATED PARTY
On
December 22, 2022, the Company issued to Alpha Capital, an 8%
Senior Convertible Debenture in the aggregate principal amount of $3,300,000
for a purchase price of $3,000,000
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and
from time to time, at Alpha Capital’s option, into shares of common stock of the Company (the “Conversion
Shares”), at a price equal to $1.32
per share, subject to adjustment as described in the Debenture (the “Conversion Price”) and other terms and conditions
described in the Debenture, including the Company’s receipt of the necessary stockholder approvals. Additionally, on December
22, 2022, the Company issued to Alpha Capital a liability classified warrant to purchase 2,500,000
shares of the Company’s common stock (see Note 9 - Warrant Liabilities). The exercise price of the Alpha Warrant is $1.65
(equal to 125%
of the Conversion Price of the Debenture on the closing date). The Alpha Warrant may be exercised by Alpha Capital, in whole or in
part, at any time on or after June 22, 2023 and before June 22, 2028, subject to certain terms and conditions described in the Alpha
Warrant, including the Company’s receipt of the necessary stockholder approvals, which the Company obtained at its 2023 annual
meeting of stockholders.
The
proceeds from the transaction are being used to advance the Company’s QN-302 Investigative New Drug candidate towards clinical
trials and other working capital purposes.
Commencing
June 1, 2023 and continuing on the first day of each month thereafter until the earlier of (i) December 22, 2025 and (ii) the full redemption
of the Debenture (each such date, a “Monthly Redemption Date”), the Company will redeem $110,000 plus accrued but unpaid
interest, liquidated damages and any amounts then owing under the Debenture (the “Monthly Redemption Amount”). The Monthly
Redemption Amount will be paid in cash; provided that after the first two monthly redemptions, the Company may elect to pay all or a
portion of a Monthly Redemption Amount in shares of common stock of the Company, based on a Conversion Price equal to the lesser of (i)
the then Conversion Price of the Debenture and (ii) 85% of the average of the VWAPs (as defined in the Debenture) for the five consecutive
trading days ending on the trading day that is immediately prior to the applicable Monthly Redemption Date. The Company may also redeem
some or all of the then outstanding principal amount of the Debenture at any time for cash in an amount equal to 105% of the then outstanding
principal amount of the Debenture being redeemed plus accrued but unpaid interest, liquidated damages and any amounts then owing under
the Debenture. The Company’s election to pay monthly redemptions in Conversion Shares or to effect an optional redemption is subject
to the satisfaction of the Equity Conditions (as defined in the Debenture), including the Company’s receipt of the necessary stockholder
approvals, which the Company obtained at its 2023 annual meeting of stockholders.
The
Debenture accrues interest at the rate of 8% per annum, which does not begin accruing until December 1, 2023, and will be payable on
a quarterly basis. Interest may be paid in cash or shares of common stock of the Company or a combination thereof at the option of the
Company; provided that interest may only be paid in shares if the Equity Conditions have been satisfied, including the Company’s
receipt of the necessary stockholder approvals, which the Company obtained at its 2023 annual meeting of stockholders.
Both
the Debenture and the Alpha Warrant provide for adjustments to the Conversion Price and exercise price, respectively, in connection with
stock dividends and splits, subsequent equity sales and rights offerings, pro rata distributions, and certain fundamental transactions.
Both the Debenture and the Alpha Warrant include a beneficial ownership blocker of 9.99%, which may only be waived by Alpha Capital upon
61 days’ notice to the Company.
The
Company filed a registration statement on Form S-3 (No. 333-269088) with the Securities and Exchange Commission on December 30, 2022
registering the resale by Alpha Capital of an aggregate of 5,157,087 shares of the Company’s common stock, which may be issuable
to Alpha Capital pursuant to the terms of the Debenture and the Alpha Warrant.
The
Company evaluated the Debenture and the Alpha Warrant and determined that the Alpha Warrant is a freestanding financial instrument. The
Alpha Warrant is not considered indexed to the Company’s own stock, because the settlement amount would not equal the difference
between the fair value of a fixed number of the Company’s equity shares and a fixed strike price and all of the adjustment features
in Section 3(b) of the warrant agreement are not down round provisions, as defined in ASU 2017-11. Accordingly, the Alpha Warrant is
classified as a liability and recognized at fair value, with subsequent changes in fair value recognized in earnings.
The
proceeds from the Debenture were allocated to the initial fair value of the Alpha Warrant, with the residual balance allocated to the
initial carrying value of the Debenture. The Company has not elected the fair value option for the Debenture. The Debenture was recognized
as proceeds received after allocating the proceeds to the Alpha Warrant, and then allocating remaining proceeds to a suite of bifurcated
embedded derivative features (conversion option, contingent acceleration upon an Event of Default, and contingent interest upon an Event
of Default), with the resulting difference, if any, allocated to the loan host instrument. The suite of derivative features was measured
and determined to have no fair value.
The
original issue discount of $0.3 million, the initial fair value of the Warrant of $2.8 million, the initial fair value of the suite of
bifurcated embedded derivative features of $0, and the fees and costs paid to Alpha Capital and other third parties of $0.1 million comprised
the debt discount upon issuance. The debt discount is amortized to interest expense over the expected term of the Debenture using the
effective interest method, in accordance with ASC 835-30. The debt host instrument of the Debenture will subsequently be measured at
amortized cost using the effective interest method to accrete interest over its term to bring the Debenture’s initial carrying
value to the principal balance at maturity.
Between
January 9 and 12, 2023, the Company issued 841,726 shares of common stock upon Alpha Capital’s partial conversion of the Debenture
at $1.32 per share for a total of $1,111,078 principal. Upon conversion, the Company recognized a loss on conversion of convertible debt
of approximately $1.1 million, recorded to other expenses in the condensed consolidated statements of operations. During the three and
six months ended June 30, 2023, the Company recorded accrued interest of approximately $383,000 and $945,000, respectively (of which
approximately $364,000 and $898,000 was attributable to discount amortization, respectively) in other expenses in the condensed consolidated
statements of operations. As of June 30, 2023, the fair value of the Alpha Warrant was approximately $2.0 million, and the fair value
of the suite of bifurcated embedded derivative features was $0.
Convertible
debt-related party is comprised of the following as of June 30, 2023 and December 31, 2022:
SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT
| |
June 30, 2023 | | |
December 31, 2022 | |
Senior secured convertible debenture | |
$ | 2,078,922 | | |
$ | 3,300,000 | |
Discount on convertible debenture | |
| (1,266,503 | ) | |
| (3,239,803 | ) |
Total convertible debt-related party | |
$ | 812,419 | | |
$ | 60,197 | |
As
of June 30, 2023, there were no events of default or violation of any covenants under our financing obligations.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
EARNINGS (LOSS) PER SHARE
|
6 Months Ended |
Jun. 30, 2023 |
Earnings Per Share [Abstract] |
|
EARNINGS (LOSS) PER SHARE |
NOTE
11 — EARNINGS (LOSS) PER SHARE
Basic
loss per share (“EPS”) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted
EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during
the period. Potentially dilutive common shares consist of shares issuable from stock options and warrants.
The following potentially dilutive securities have been excluded from diluted net loss per share
as of June 30, 2023 and 2022 because their effect would be anti-dilutive:
SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE
| |
As of June 30, | |
| |
2023 | | |
2022 | |
Shares of common stock subject to outstanding options | |
| 445,163 | | |
| 476,783 | |
Shares of common stock subject to outstanding warrants | |
| 4,119,934 | | |
| 1,412,338 | |
Total common stock equivalents | |
| 4,565,097 | | |
| 1,889,121 | |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for earnings per share.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3
+ Details
Name: |
us-gaap_EarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
COMMITMENTS AND CONTINGENCIES
|
6 Months Ended |
Jun. 30, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
COMMITMENTS AND CONTINGENCIES |
NOTE
12 — COMMITMENTS AND CONTINGENCIES
Leases
The
Company leases its facilities under a long-term operating lease agreement. On December 15, 2021, our wholly-owned subsidiary Qualigen,
Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment extended the Company’s triple-net leasehold on
the Company’s existing 22,624-square-feet headquarters/manufacturing facility at 2042 Corte del Nogal, Carlsbad, California for
the 61-month period of November 1, 2022 to November 30, 2027. Over the 61 months, the base rent payable by Qualigen, Inc. will total
$1,950,710; however, the base rent for the first 12 months of the 61-month period will be only $335,966. Additionally, under the Second
Amendment to Lease, Qualigen, Inc. is entitled to a $339,360 tenant improvement allowance.
The
tables below show the operating lease right-of-use assets and operating lease liabilities as of June 30, 2023, including the changes
during the periods:
SCHEDULE
OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES
| |
Operating lease right-of-use assets | |
Net right-of-use assets at December 31, 2022 | |
$ | 1,422,538 | |
Less amortization of operating lease right-of-use assets | |
| (116,568 | ) |
Operating lease right-of-use assets at June 30, 2023 | |
$ | 1,305,970 | |
| |
Operating lease liabilities | |
Lease liabilities at December 31, 2022 | |
$ | 1,542,564 | |
Less principal payments on operating lease liabilities | |
| (116,756 | ) |
Lease liabilities at June 30, 2023 | |
| 1,425,808 | |
Less non-current portion | |
| (1,168,653 | ) |
Current portion at June 30, 2023 | |
$ | 257,155 | |
As
of June 30, 2023, the Company’s operating leases have a weighted-average remaining lease term of 4.3 years and a weighted-average
discount rate of 8.9%.
As
of June 30, 2023, future minimum payments during the next five fiscal years and thereafter are as follows:
SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES
Year Ending December 31, | |
Amount | |
2023 (six months) | |
| 184,171 | |
2024 | |
| 379,392 | |
2025 | |
| 390,773 | |
2026 | |
| 402,497 | |
2027 | |
| 379,164 | |
Total | |
| 1,735,997 | |
Less present value discount | |
| (310,189 | ) |
Operating lease liabilities | |
$ | 1,425,808 | |
Total
lease expense was approximately $114,000 and $119,000 for the three months ended June 30, 2023 and 2022, respectively, and approximately
$230,000 and $233,000, respectively, for the six months ended June 30, 2023 and 2022. Lease expense was recorded in cost of product
sales, general and administrative expenses, research and development and sales and marketing expenses.
On
July 20, 2023, the Company entered into a Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc.,
a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued
and outstanding shares of common stock of Qualigen, Inc. The lease commitments described above transferred to Chembio upon the closing
of this transaction. (see Note 16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. ).
NanoSynex
Funding Commitment
On
July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the “NanoSynex Amendment”),
which amended the Master Funding Agreement for the Operational and Technology Funding of NanoSynex Ltd., dated May 26, 2022, by and between
the Company and NanoSynex (the “NanoSynex Funding Agreement”), a majority owned subsidiary of the Company, to, among other
things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement (see Note 16 - Subsequent Events:
Amendment and Settlement Agreement with NanoSynex Ltd. ).
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
In
the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a
fraction, the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance
to NanoSynex pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we
originally paid in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per
share.
The
Nanosynex Amendment supersedes any payments contemplated by the Original Nanosynex Agreement, such that except as described in the Nanosynex
Amendment, the Company will have no further payment obligations to NanoSynex under the Original Nanosynex Agreement or otherwise (including
by way of equity investment, loan financing or credit lines), and Nanosynex will have no further payment obligations to the Company for
advances previously received under the Original Nanosynex Agreement.
Litigation
and Other Legal Proceedings
On
November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (“Mediant”) in
the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with
Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company
filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in
favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $96,558,
at which time the amount was paid.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContent
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
RESEARCH AND LICENSE AGREEMENTS
|
6 Months Ended |
Jun. 30, 2023 |
Research And License Agreements |
|
RESEARCH AND LICENSE AGREEMENTS |
NOTE
13 — RESEARCH AND LICENSE AGREEMENTS
The
University of Louisville Research Foundation
Between
June 2018 and April 2022, the Company entered into license and sponsored research agreements with the University of Louisville Research
Foundation (“ULRF”) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements,
the Company took over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance
of the related intellectual property portfolio. In return, ULRF received a $50,000 convertible promissory note in payment of an upfront
license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored
research expenses of up to approximately $805,000 and prior patent costs of up to $200,000. In addition, the Company agreed to pay ULRF
(i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of
4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last
to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the
first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement,
and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs
associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments
ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the
first therapeutic indication would be $100,000 for first dosing in a Phase 1 clinical trial, $200,000 for first dosing in a Phase 2 clinical
trial, $350,000 for first dosing in a Phase 3 clinical trial, $500,000 for regulatory marketing approval and $5,000,000 upon achieving
a cumulative $500,000,000 of Licensed Product sales. The Company also agreed to pay another $500,000 milestone payment for any additional
regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company must also pay ULRF shortfall payments
if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable
annual minimum (ranging from $10,000 to $50,000) for such year.
Sponsored
research expenses related to these agreements for the three months ended June 30, 2023 and 2022 were approximately $0 and $77,000,
respectively, and for the six months ended June 30, 2023 and 2022 were approximately $0 and $164,000, respectively, and these amounts
are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive loss.
License costs were approximately $1,000 and $14,000 related to these agreements for the three months ended June 30, 2023 and 2022,
respectively, and approximately $22,000 and $69,000 related to these agreements for the six months ended June 30, 2023 and 2022,
respectively, and are included in research and development expenses in the condensed consolidated statements of operations and other
comprehensive loss.
In
March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of
several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company agreed to reimburse
ULRF for sponsored research expenses of up to $693,000 for this program. In February 2021 and March 2022, the Company extended the term
of this agreement until January 2023 and increased the amount that the Company will reimburse ULRF for sponsored research expenses to
approximately $2.7 million. In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor
drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates
from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000
for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on
patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales
above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed
Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF
license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted
in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be
$50,000 for first dosing in a Phase 1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing
in a Phase 3 clinical trial, $300,000 for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed
Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty
sublicensee income for any year is less than the applicable annual minimum (ranging from $20,000 to $100,000) for such year.
Sponsored
research expenses related to these agreements for the three months ended June 30, 2023 and 2022 were approximately $333,000 and
$220,000, respectively, and for the six months ended June 30, 2023 and 2022 were approximately $556,000 and $405,000, respectively,
and are recorded in research and development expenses in the condensed consolidated statements of operations and other comprehensive
loss. License costs related to these agreements for the three months ended June 30, 2023 and 2022 were approximately $15,000 and
$16,000, respectively, and for the six months ended June 30, 2023 and 2022 were approximately $29,000 and $18,000, respectively,
and are included in research and development expenses in the condensed consolidated statements of operations and other comprehensive
loss.
In
June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a
treatment for COVID-19. Under the agreement, the Company took over development, regulatory approval and commercialization of the compound
(for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received
approximately $24,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required to enter
into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $250,000. In November 2020,
the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately
$430,000 in research which satisfied this requirement. This sponsored research agreement expired in November 2021.
In
addition, under the exclusive license agreement the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated
with the commercialization of QN-165 as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net
sales above a cumulative $250,000,000), until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by
Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones. Milestone payments would be $50,000 for first dosing in a Phase
1 clinical trial, $100,000 for first dosing in a Phase 2 clinical trial, $150,000 for first dosing in a Phase 3 clinical trial, $300,000
for regulatory marketing approval and $5,000,000 upon achieving a cumulative $500,000,000 of Licensed Product sales. The Company must
also pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for
any year is less than the applicable annual minimum (ranging from $5,000 to $50,000) for such year.
There
were no sponsored research expenses or license costs related to these agreements for the three months ended June 30, 2023 and 2022,
or for the six months ended June 30, 2023 and 2022.
Yi
Xin
In
October 2020, through its wholly-owned diagnostics subsidiary Qualigen, Inc., the Company entered into a Technology Transfer Agreement
with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (“Yi Xin”), of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations
of diagnostic test systems based on the Company’s core FastPack technology. In addition, the Technology Transfer Agreement authorizes
Yi Xin to manufacture and sell the Company’s current generations of FastPack System diagnostic products (1.0, IP and PRO) in China.
The
Company will receive low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin.
Under the Technology Transfer Agreement, during the fiscal year ended December 31, 2021 we recognized revenues of approximately $670,000.
There were no revenues under this agreement for the three months ended June 30, 2023, and the three months ended June 30, 2022. The Company
provided technology transfer and patent/know-how license rights to facilitate Yi Xin’s development and commercialization.
The
Company gave Yi Xin the exclusive rights for China, which is a market it has not otherwise entered, both for Yi Xin’s new generations
of FastPack-based products and for Yi Xin-manufactured versions of our existing FastPack product lines. Yi Xin also has the right to
sell its new generations of FastPack-based diagnostic test systems throughout the world (but not to or toward current customers of the
Company’s existing generations of FastPack products). After March 31, 2022, Yi Xin has the right to sell Yi Xin-manufactured versions
of existing FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-US
customers of those products), as well as the right to buy Qualigen-manufactured FastPack 1.0, IP and PRO products from us at distributor
prices for resale in and for the United States (but not to or toward current U.S. customers of those products). The Company did not license
Yi Xin to sell in the U.S. market any Yi Xin-manufactured versions of those legacy FastPack 1.0, IP and PRO product lines. In the Technology
Transfer Agreement the Company also confirmed that after March 31, 2022 it would not seek new FastPack customers outside the United States,
European Union, Canada and Mexico.
On July 20, 2023, the Company entered into a Purchase
Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc., a wholly-owned subsidiary of the Company. Pursuant
to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued and outstanding shares of common stock of Qualigen,
Inc. The Technology Transfer Agreement with Yi Xin described above transferred to Chembio upon the closing of this transaction. See Note
16 - Subsequent Events: Stock Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A. to our unaudited condensed consolidated
financial statements for additional details.
UCL
Business Limited
In
January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a
genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London,
including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for
University College London.) The program’s lead compound is now being developed at Qualigen under the name QN-302 as a candidate
for treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. The License Agreement
required a $150,000 upfront payment, reimbursement of past patent prosecution expenses (approximately $160,000), and (if and when applicable)
tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty
sublicensing consideration paid to Qualigen.
For
both the three months ended June 30, 2023 and 2022, there were license costs of $0, and for the six months ended June 30, 2023
and 2022, there were license costs of approximately $0 and $310,000, respectively, related to this agreement which are included in research
and development expenses in the condensed consolidated statements of operations and other comprehensive loss.
Prediction
Biosciences
In
November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS to develop and manufacture
diagnostic tests for use in the stroke Physician Office Laboratory (POL) market. The Company recognizes development revenue and product
sales over the performance period of the contract. Product sales related to this agreement for the three months ended June 30, 2023
and 2022 were $0 for both periods, and for the six months ended June 30, 2023 and 2022 were approximately $86,000 and $0, respectively,
and are recorded in net product sales in the condensed consolidated statements of operations and other comprehensive loss.
QN-302 Phase 1 Study
In
June 2023, the Company entered into a Master Clinical Research Services Agreement with Translational Drug Development, LLC
(“TD2”) where TD2 agreed to perform certain clinical research and development services for the Company including but not
limited to trial management, side identification and selection, site monitoring/management, medical monitoring, project management,
data collection, statistical programming or analysis, quality assurance auditing, scientific and medical communications, regulatory
affairs consulting and submissions, strategic consulting, and/or other related services. From time to time, the Company shall enter
into Statements of Work (“SOW”) with TD2 for the performance of specific services under this Master Clinical Research
Services Agreement (see Note 16 - Subsequent Events: QN-302 Phase 1 Study).
In
June 2023, the Company entered into a Master Laboratory Services Agreement with MLM Medical Labs, LLC (“MLM”) where MLM
agreed to perform certain clinical research and development services for the Company including but not limited to laboratory,
supply, testing, validation, data management, and storage services. From time to time, the Company shall enter into work orders with
MLM for the performance of specific services under this Master Laboratory Services Agreement (see Note 16 - Subsequent Events:
QN-302 Phase 1 Study).
In
June 2023, the Company entered into a Master Services Agreement with Clinigen Clinical Supplies Management, Inc.
(“Clinigen”) where Clinigen agreed to provide certain pharmaceutical products and/or services. From time to time, the
Company shall enter into Statements of Work (“SOW”) with Clinigen for the performance of specific services under this
Master Services Agreement (see Note 16 - Subsequent Events: QN-302 Phase 1 Study).
|
X |
- References
+ Details
Name: |
QLGN_DisclosureResearchAndLicenseAgreementsAbstract |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionResearch And License Agreements [Text Block]
+ References
+ Details
Name: |
QLGN_ResearchAndLicenseAgreementsTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
STOCKHOLDERS’ EQUITY
|
6 Months Ended |
Jun. 30, 2023 |
Equity [Abstract] |
|
STOCKHOLDERS’ EQUITY |
NOTE
14 — STOCKHOLDERS’ EQUITY
As
of June 30, 2023 and December 31, 2022, the Company had two classes of authorized capital stock: common stock and preferred
stock.
Common
Stock
Holders
of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject
to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive
dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, any
remaining assets will be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of any
preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive,
subscription or conversion rights and there are no redemption or sinking fund provisions.
On
December 22, 2022, the Company issued to Alpha Capital, an 8%
Senior Convertible Debenture in the aggregate principal amount of $3,300,000
for a purchase price of $3,000,000
pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is convertible, at any time, and
from time to time, at Alpha Capital’s option, into shares of common stock of the Company, at a price equal to $1.32
per share, and other terms and conditions described in the Debenture (see Note 10 - Convertible Debt - Related Party). As part of
this transaction, the Company issued to Alpha Capital a warrant to purchase 2,500,000
shares of the Company’s common stock (see Note 9 - Warrant Liabilities). Between January 9 and 12, 2023, Alpha Capital
voluntarily converted $1,111,078
of its outstanding the Debenture principal into 841,726
shares of common stock at a conversion price of $1.32
per share.
At
June 30, 2023, the Company has reserved 4,565,097 shares of authorized but unissued common stock for possible future issuance. At
June 30, 2023, shares were reserved in connection with the following:
SCHEDULE
OF RESERVED SHARES
| |
| | |
Exercise of issued and future grants of stock options | |
| 445,163 | |
Exercise of stock warrants | |
| 4,119,934 | |
Total | |
| 4,565,097 | |
Preferred
Stock
At
June 30, 2023 and December 31, 2022, there were no shares of preferred stock outstanding.
Stock
Options and Warrants
Stock
Options
The
Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting
period.
In
April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of incentive
or non-statutory common stock options and other types of awards to qualified employees, officers, directors, consultants and other service
providers. At June 30, 2023 and December 31, 2022, there were 445,163 and 608,012 outstanding stock options, respectively,
under the 2020 Plan and on such dates there were 310,539 and 147,690 shares reserved under the 2020 Plan, respectively, for future grant.
The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that are outstanding at June 30, 2023, and changes during the six-month period then ended:
SCHEDULE
OF STOCK OPTION ACTIVITY
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range of Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
608,012 |
|
$ |
35.02 |
|
|
$5.14
- $51.30 |
|
|
8.09 |
|
Granted |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Expired |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Forfeited |
|
|
(162,849 |
) |
|
36.01 |
|
|
5.14
- 51.30 |
|
|
— |
|
Total
outstanding – June 30, 2023 |
|
|
445,163 |
|
$ |
34.68 |
|
|
$5.14
— $51.30 |
|
|
7.59 |
|
Exercisable
(vested) |
|
|
323,355 |
|
$ |
44.79 |
|
|
$5.14
— $51.30 |
|
|
7.13 |
|
Non-Exercisable
(non-vested) |
|
|
121,808 |
|
$ |
7.83 |
|
|
$5.14
- $35.20 |
|
|
8.85 |
|
There
was approximately $0.9 and $2.7 million of compensation cost related to outstanding stock options for the six months ended June 30,
2023 and 2022, respectively. As of June 30, 2023, there was approximately $0.5 million of total unrecognized compensation cost related
to unvested stock-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.47 years.
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range of Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
484,186 |
|
$ |
60.70 |
|
$12.40 — $14,657.50 |
|
|
8.52 |
|
Granted |
|
|
2,500 |
|
|
10.50 |
|
|
10.50 |
|
|
9.54 |
|
Expired |
|
|
(9,386 |
) |
|
935.90 |
|
|
57.50
- 14,657.50 |
|
|
— |
|
Forfeited |
|
|
(517 |
) |
|
35.10 |
|
|
12.40
- 49.70 |
|
|
— |
|
Total
outstanding – June 30, 2022 |
|
|
476,783 |
|
$ |
43.30 |
|
|
$10.50
— $51.30 |
|
|
8.19 |
|
Exercisable
(vested) |
|
|
264,366 |
|
$ |
48.40 |
|
|
$12.40
— $50.13 |
|
|
8.00 |
|
Non-Exercisable
(non-vested) |
|
|
212,417 |
|
$ |
36.80 |
|
|
$10.50
— $51.30 |
|
|
8.48 |
|
The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant. The options awarded under the 2020 Plan
will vest as determined by the Board of Directors but will not exceed a ten-year period.
Fair
Value of Equity Awards
The
Company utilizes the Black-Scholes option pricing model to value awards under its equity plans. Key valuation assumptions include:
● | Expected
dividend yield. The expected dividend is assumed to be zero, as the Company has never
paid dividends and has no current plans to pay any dividends on the Company’s common
stock. |
● | Expected
stock-price volatility. The Company’s expected volatility is derived from the average
historical volatilities of publicly traded companies within the Company’s industry
that the Company considers to be comparable to the Company’s business over a period
approximately equal to the expected term. |
● | Risk-free
interest rate. The risk-free interest rate is based on the U.S. Treasury yield in effect
at the time of grant for zero coupon U.S. Treasury notes with maturities approximately equal
to the expected term. |
● | Expected
term. The expected term represents the period that the stock-based awards are expected
to be outstanding. The Company’s historical share option exercise experience does not
provide a reasonable basis upon which to estimate an expected term because of a lack of sufficient
data. Therefore, the Company estimates the expected term by using the simplified method provided
by the SEC. The simplified method calculates the expected term as the average of the time-to-vesting
and the contractual life of the options. |
The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:
SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
Expected dividend yield | |
| 0.00 | % | |
| 0.00 | % |
Expected stock-price volatility | |
| — | | |
| 102 | % |
Risk-free interest rate | |
| — | | |
1.58% — 1.67 | % |
Expected average term of options (in years) | |
| — | | |
| 6.00 | |
Stock price | |
$ | — | | |
$ | 1.05 | |
The
Company recorded share-based compensation expense and classified it in the unaudited condensed consolidated statements of operations
as follows:
SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE
| |
2023 | | |
2022 | |
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
General and administrative | |
$ | 807,980 | | |
$ | 2,329,418 | |
Research and development | |
| 98,165 | | |
| 361,029 | |
Total | |
$ | 906,145 | | |
$ | 2,690,447 | |
Equity
Classified Compensatory Warrants
In
connection with the $4.0 million equity capital raise as part of the May 2020 reverse recapitalization transaction, the Company issued
common stock warrants to an advisor and its designees for the purchase of 81,143 reverse split adjusted shares of the Company’s
common stock at a reverse split adjusted exercise price of $11.10 per share. The issuance cost of these warrants was charged to additional
paid-in capital, and did not result in expense in the Company’s condensed consolidated statements of operations and comprehensive
loss.
In
addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier for the purchase of 66,802
reverse split adjusted shares of Company common stock (originally exercisable to purchase Series C convertible preferred stock) at a
weighted average exercise price of $23.40
per share. These are to be differentiated from the Series C Warrants described in Note 9 - Warrant Liabilities.
During
the year ended December 31, 2021, the Company issued equity classified compensatory warrants to a service provider for the purchase of
60,000 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $13.20 per share. The fair
value issuance cost of approximately $0.3 million using the Black-Scholes options pricing model for these warrants was charged to general
and administrative expenses in the Company’s condensed consolidated statements of operations and comprehensive loss. On April 25,
2022, 60,000 warrants were repriced from $13.20 to a reverse split adjusted exercise price of $6.00 and extended from June 3, 2023 to September 14, 2023. The increase in fair value of $67,370 using a Monte Carlo pricing model for the modification of these warrants was
charged to general and administrative expenses in the Company’s condensed consolidated statements of operations and comprehensive
loss. On April 25, 2022 and May 26, 2022 an additional 67,619 reverse split adjusted warrants were repriced from a reverse split adjusted
exercise price of $11.10 to $5.136. The increase in fair value of $31,010 using a Monte Carlo pricing model for the modification of these
warrants was charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements
of operations and comprehensive loss. On December 22, 2022, 67,620 warrants were repriced from a reverse split adjusted exercise price
of $5.136 to $1.32. The increase in fair value of $8,548 using a Monte Carlo pricing model for the modification of these warrants was
charged to additional paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations
and comprehensive loss.
No
compensatory warrants were issued during the six months ended June 30, 2023.
The
following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June
30, 2023:
SCHEDULE
OF WARRANT ACTIVITY
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
1.73 |
|
Granted
to advisor and its designees |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2023 |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
1.24 |
|
Exercisable |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
|
1.24 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
The
following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June 30,
2022:
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
179,065 |
|
$ |
15.20 |
|
$11.10
— $25.40 |
|
2.64 |
|
Granted
to advisor and its designees |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2022 |
|
|
179,065 |
|
$ |
10.60 |
|
$5.14
— $25.40 |
|
2.23 |
|
Exercisable |
|
|
179,065 |
|
$ |
10.60 |
|
$5.14
— $25.40 |
|
|
2.23 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
There
were no compensation costs related to outstanding equity classified compensatory warrants for the six months ended June 30, 2023
and $67,370 for the six months ended June 30, 2022.
Noncompensatory
Equity Classified Warrants
In
May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to Alpha Capital (a related party) for the
purchase of 27,048 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise price of $11.10 per share
(of which warrants for 20,000 shares were subsequently exercised in December 2020). In July 2020, the Company issued noncompensatory
equity classified warrants to Alpha Capital for the purchase of 78,019 reverse split adjusted shares of Company common stock at a reverse
split adjusted exercise price of $0.01 per share (which were subsequently exercised in July 2020), and 192,068 reverse split adjusted
shares of Company common stock at a reverse split adjusted exercise price of $52.50 per share. In August 2020, the Company issued noncompensatory
equity classified warrants to Alpha Capital for the purchase of 128,783 reverse split adjusted shares of Company common stock at a reverse
split adjusted exercise price of $60.00 per share. In December 2020, the Company issued noncompensatory equity classified warrants to
Alpha Capital for the purchase of 100,000 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $0.10 per share (which were exercised in February 2021) and 219,101 reverse split adjusted shares of Company common stock at
a reverse split adjusted exercise price of $40.70 per share. In May 2022, the Company issued noncompensatory equity classified warrants
to Alpha Capital for the purchase of 331,464 reverse split adjusted shares of Company common stock at a reverse split adjusted exercise
price of $0.01 per share.
On
November 29, 2021, with the exception of the warrants to purchase reverse split adjusted shares of the Company’s common
stock at a reverse split adjusted exercise price of $11.10 per share, the exercise prices of all outstanding warrants to purchase a total
of 539,951 reverse split adjusted shares of the Company’s common stock were modified to a reverse split adjusted exercise price
of $20.00 per share and each of their remaining terms extended by six months. The fair value of the modification cost of these warrant
modifications of approximately $2.3 million was charged to additional paid-in capital and did not result in expense on the Company’s
condensed consolidated statements of operations and comprehensive loss. In May 2022, pre-funded warrants to purchase 331,464 reverse
split adjusted shares of the Company’s common stock at a reverse split adjusted exercise price of $0.01 per share with no expiration
date were issued. These warrants were subsequently exercised during the period ended September 30, 2022.
In
conjunction with the NanoSynex Acquisition, on April 25, 2022 the exercise price of 7,048 reverse split adjusted
outstanding warrants with an exercise price of $11.10 per share was modified to a reverse split adjusted exercise price of $6.00. The
increase in fair value of $2,533, using a Monte Carlo pricing model for the modification of these warrants, was charged to additional
paid-in capital and did not result in expense on the Company’s condensed consolidated statements of operations and comprehensive
loss. On May 26, 2022, the reverse split adjusted exercise price of these warrants was modified again to $5.136, and the increase in
fair value of $696, using a Monte Carlo pricing model for the modification of these warrants, was included in consideration transferred
in the NanoSynex Acquisition. On December 22, 2022, the exercise price of these warrants was modified again to $1.32. The increase in
fair value of $891, using a Monte Carlo pricing model for the modification of those warrants, was charged to additional paid-in capital
and did not result in expense on the Company’s condensed consolidated statements of operations and comprehensive loss.
No
noncompensatory equity classified warrants were issued during the six months ended June 30, 2023.
The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2023:
SCHEDULE
OF WARRANT ACTIVITY
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
547,003 |
|
$ |
19.76 |
|
$1.32
- $20.00 |
|
0.33 |
|
Legacy
Ritter warrants |
|
|
— |
|
|
— |
|
|
|
|
|
Granted |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
(455,685 |
) |
|
20.00 |
|
|
20.00 |
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2023 |
|
|
91,318 |
|
$ |
18.56 |
|
|
|
- |
|
Exercisable |
|
|
91,318 |
|
$ |
18.56 |
|
$1.32
— $20.00 |
|
|
0.58 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2022:
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
554,914 |
|
$ |
20.10 |
|
|
|
|
|
Legacy
Ritter warrants |
|
|
— |
|
|
— |
|
|
|
|
|
Granted |
|
|
331,464 |
|
|
0.01 |
|
|
0.01 |
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2022 |
|
|
886,378 |
|
$ |
12.60 |
|
|
|
|
|
Exercisable |
|
|
886,378 |
|
$ |
12.60 |
|
$0.01
— $37.70 |
|
|
0.82 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
|
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//505/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
+ Details
Name: |
us-gaap_StockholdersEquityNoteDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
RELATED PARTY TRANSACTIONS
|
6 Months Ended |
Jun. 30, 2023 |
Related Party Transactions [Abstract] |
|
RELATED PARTY TRANSACTIONS |
NOTE
15 — RELATED PARTY TRANSACTIONS
Convertible
Debt
On
December 22, 2022, the Company issued to Alpha Capital, an 8% Senior Convertible Debenture in the aggregate principal amount of $3,300,000
for a purchase price of $3,000,000 pursuant to the terms of a Securities Purchase Agreement, dated December 21, 2022. The Debenture is
convertible, at any time, and from time to time, at Alpha Capital’s option, into shares of common stock of the Company, at a price
equal to $1.32 per share, subject to adjustment as described in the Debenture and other terms and conditions described in the Debenture,
including the Company’s receipt of the necessary stockholder approvals (See Note 10 - Convertible Debt - Related Party). Between
January 9 and 12, 2023, Alpha Capital voluntarily converted $1,111,078 of the Debenture principal into 841,726 shares of common stock
at a conversion price of $1.32 per share.
Short-Term
Debt
NanoSynex
has four separate notes payable outstanding to Alpha Capital, issued between March 26, 2020 and September 2, 2021, aggregating to a total
principal outstanding balance of $905,000, and aggregate accrued interest of $60,155 for a total outstanding balance of $965,155 as of
June 30, 2023. The Notes all accrue interest at 2.62% per annum, accrued daily, and provide that the full amount of principal and interest
under each Note shall be due immediately prior to a Liquidation Event (the Maturity Date) unless due earlier in accordance with the terms
of the Notes. “Liquidation Event” means either (i) the merger or consolidation of NanoSynex into any other entity, other
than one in control or under control of NanoSynex or NanoSynex’s majority shareholder; (ii) a transaction or series of transactions
resulting in the transfer of all or substantially all of NanoSynex’s assets or issued and outstanding share capital (other than
to a company under the control of NanoSynex or NanoSynex’s majority shareholders; or (iii) an underwritten public offering by NanoSynex
of its ordinary shares. Notwithstanding the above, if NanoSynex receives subsequent debt, convertible debt, or equity funding with gross
proceeds of USD $3,000,000 or more, then the unused portion of these Notes shall be due and payable upon the actual receipt of such funding
(See Note 8 - Short-Term Debt - Related Party).
NanoSynex
Acquisition
The
Company acquired a 52.8% voting equity interest in NanoSynex on May 26, 2022 through: (1) the purchase of 2,232,861 shares Preferred
A-1 Stock of NanoSynex from Alpha Capital (a related party) for 350,000 reverse split adjusted shares of the Company’s common stock
and a prefunded warrant to purchase 331,464 reverse split adjusted shares of the Company’s common stock at a purchase price of
$0.001 per share (these warrants were subsequently exercised on September 13, 2022), and (2) the purchase of 381,786 shares of Series
B preferred stock of NanoSynex from NanoSynex in exchange for $600,000.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(e)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//850/tableOfContent
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-6
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 850 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
SUBSEQUENT EVENTS
|
6 Months Ended |
Jun. 30, 2023 |
Subsequent Events [Abstract] |
|
SUBSEQUENT EVENTS |
NOTE
16 — SUBSEQUENT EVENTS
QN-302
Phase 1 Study
Between
July 5-13, 2023, pursuant to the Master Clinical Research Services Agreement with TD2, Master Services Agreement with Clinigen, and
Master Laboratory Services Agreement with MLM (see Note 13 - Research and License Agreements), the Company entered into work orders
with these vendors to provide clinical trial services for the conduct of the QN-302 Phase 1 study. The estimated project timeline
was set to start in July 2023 and continue until July 2026. The total amount to be paid under these work orders is currently
expected to be approximately $7.6 million over the term of the QN-302 Phase 1 study.
Stock
Purchase Agreement with Chembio Diagnostics, Inc. and Biosynex, S.A.
On
July 20, 2023, the Company entered into the Purchase Agreement with Chembio, Biosynex, S.A. (“Biosynex”), and Qualigen, Inc.,
a wholly-owned subsidiary of the Company. Pursuant to the Purchase Agreement, the Company agreed to sell to Chembio all of the issued
and outstanding shares of common stock of Qualigen, Inc., which was the legal entity operating the Company’s FastPack™ diagnostics
business. The Transaction closed on July 20, 2023. Following the consummation of the Transaction, Qualigen, Inc. became a wholly-owned
subsidiary of Chembio.
The aggregate net purchase price paid to the Company for the Shares was $5.2 million in cash, based on a base purchase price of $5.8
million, subject to certain post-closing adjustments, upward or downward, as applicable, for: (i) cash held by Qualigen, Inc. as of the
closing of the Transaction; (ii) net working capital of Qualigen, Inc. as of the closing of the Transaction, (iii) certain indebtedness
of Qualigen, Inc. as of the closing of the Transaction, and (iv) certain Transaction expenses as of the closing of the Transaction. Of
the $5.2 million in cash, $450,000 is being held in escrow to satisfy certain Company indemnification obligations. Any amounts remaining
in the Indemnity Escrow that have not been offset or reserved for claims will be released to the Company within five business days following
the date that is 18 months after the closing.
Amendment and Settlement Agreement with NanoSynex Ltd.
On
July 20, 2023, the Company entered into the NanoSynex Amendment, which amended the NanoSynex Funding Agreement with NanoSynex, to, among
other things, provide for the further funding of NanoSynex, as contemplated by the NanoSynex Funding Agreement.
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
In
the event we fail to make any future advances, we have agreed to forfeit additional shares in a number that will be equal to a fraction,
the numerator of which is the amount of the default (i.e., the amount that we should have, but failed, to advance to NanoSynex
pursuant to the terms of the NanoSynex Amendment), and the denominator of which shall be the price per share that we originally paid
in consideration for our Preferred A-1 shares of NanoSynex to the previous holder thereof, being $1.5716 per share.
The NanoSynex Amendment
supersedes any payments contemplated by the Original NanoSynex Agreement, such that except as described in the NanoSynex Amendment, the
Company will have no further payment obligations to NanoSynex under the Original NanoSynex Agreement or otherwise (including by way of
equity investment, loan financing or credit lines), and NanoSynex will have no further payment obligations to the Company for advances
previously received under the Original NanoSynex Agreement.
Stockholder
Approval of Alpha Stock Issuance Proposal
On
July 13, 2023, the Company held its 2023 annual meeting of stockholders, at which the issuance to Alpha Capital of common stock pursuant
to the terms and conditions of (a) the Debenture and (b) the Alpha Warrant were approved in accordance with Nasdaq Listing Rule 5635(d),
which requires stockholder approval prior to the issuance of more than 20% of the Company’s issued and outstanding common stock.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContent
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)
|
6 Months Ended |
Jun. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
Organization |
Organization
Qualigen,
Inc., a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell
point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and
was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the “Company”) operates in one business segment. In
May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (“Ritter”) and
Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.’s capital stock were exchanged for Qualigen Therapeutics,
Inc.’s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital
Market under the ticker symbol “RTTR,” commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted
basis, under the trading symbol “QLGN” on May 26, 2020.
On
May 26, 2022, the Company acquired 2,232,861 shares
of Series A-1 Preferred Stock of NanoSynex, Ltd. (“NanoSynex”) from Alpha Capital Anstalt (“Alpha Capital”),
a related party, in exchange for 350,000 reverse
split adjusted shares of the Company’s common stock and a prefunded warrant to purchase 331,464 reverse
split adjusted shares of the Company’s common stock at an exercise price of $0.001 per
share. These warrants were
subsequently exercised on September 13, 2022.
Concurrently with this transaction, the Company also purchased 381,786 shares
of Series B preferred stock from NanoSynex for a total purchase price of $600,000.
The transactions resulted in the Company acquiring a 52.8%
interest in NanoSynex (the “NanoSynex Acquisition”). NanoSynex is a micro-biologics diagnostics company domiciled in
Israel. On July 20, 2023, the Company entered into an Amendment and Settlement Agreement with NanoSynex Ltd. (the
“NanoSynex Amendment”), which amended the Master Funding Agreement for the Operational and Technology Funding of
NanoSynex Ltd., dated May 26, 2022, by and between the Company and NanoSynex (the “NanoSynex Funding Agreement”), a
majority owned subsidiary of the Company, to, among other things, provide for the further funding of NanoSynex, as contemplated by
the NanoSynex Funding Agreement (see Note 16 - Subsequent Events: Amendment and Settlement Agreement with NanoSynex Ltd.
).
|
Basis of Presentation |
Basis
of Presentation
The
accompanying condensed consolidated financial statements of the Company have been prepared in conformity with accounting principles generally
accepted in the United States of America (“U.S. GAAP”), Regulation S-X and rules and regulations of the Securities and Exchange
Commission (“SEC”).
|
Principles of Consolidation |
Principles
of Consolidation
The
accompanying condensed consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All
intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is
meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. In general, the functional
currency of the Company and its subsidiaries is the U.S. dollar, however for NanoSynex, the functional currency is the local currency,
New Israeli Shekels (NIS). As such, assets and liabilities for NanoSynex are translated into U.S. dollars and the effects of foreign
currency translation adjustments are reflected as a component of accumulated other comprehensive income within the Company’s consolidated
statements of changes in stockholders’ equity.
|
Accounting Estimates |
Accounting
Estimates
Management
uses estimates and assumptions in preparing its condensed consolidated financial statements in accordance with U.S. GAAP. Those estimates
and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported
revenues and expenses. The most significant estimates relate to the estimated fair value of in-process research and development, goodwill,
warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and
returns, and warranty costs. Actual results could vary from the estimates that were used.
|
Reverse Stock Split |
Reverse
Stock Split
On
November 23, 2022, the Company effected a 1-for-10, as determined by the Company’s board of directors, reverse stock split of its
outstanding shares of common stock (the “Reverse Stock Split”). The Reverse Stock Split reduced the Company’s shares
of outstanding common stock, stock options, and warrants to purchase shares of our common stock. Fractional shares of common stock that
would have otherwise resulted from the Reverse Stock Split were rounded down to the nearest whole share and cash in lieu of fractional
shares was paid to stockholders. All share and per share data for all periods presented in the accompanying financial statements and
the related disclosures have been adjusted retrospectively to reflect the Reverse Stock Split. The number of authorized shares of common
stock and the par value per share remains unchanged.
|
Cash |
Cash
The
Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash
equivalents. Restricted cash includes cash that is restricted due to Israeli banking regulations.
The
Company maintains the majority of its cash in government money market mutual funds and in accounts at banking institutions in the U.S.
that are of high quality. Cash held in these accounts often exceed the FDIC insurance limits. If such banking institutions were to fail,
the Company could lose all or a portion of amounts held in excess of such insurance limitations. In March 2023, Silicon Valley Bank and
Signature Bank, and more recently in May 2023, First Republic Bank, were closed due to liquidity concerns and taken over by the Federal
Deposit Insurance Corporation (FDIC). While the Company did not have an account at any of these banks, in the event of failure of any
of the financial institutions where the Company maintains its cash and cash equivalents, there can be no assurance that the Company would
be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely
affect our business and financial position.
|
Inventory, Net |
Inventory,
Net
Inventory
is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews
the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified
as excess or obsolete.
|
Impairment of Long-Lived Assets |
Impairment
of Long-Lived Assets
The
Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate
that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows
is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between
the net book value of the assets and their estimated fair values. During the three and six months ended June 30, 2023 and 2022,
no such impairment losses have been recorded.
|
Segment Reporting |
Segment
Reporting
Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. To date, the Company
has viewed its operations and managed its business as one segment operating primarily within the United States and Israel.
|
Accounts Receivable, Net |
Accounts
Receivable, Net
The
Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers
and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with
an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance
of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without
recourse to the Company.
The
Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The
Company’s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable.
Accounts
receivable, net is comprised of the following at:
SCHEDULE
OF ACCOUNTS RECEIVABLE
| |
June 30, 2023 | | |
December 31, 2022 | |
Accounts Receivable | |
$ | 733,964 | | |
$ | 726,449 | |
Less Reserves and Allowances | |
| (54,584 | ) | |
| (187,862 | ) |
Accounts receivable,
net | |
$ | 679,380 | | |
$ | 538,587 | |
|
Research and Development |
Research
and Development
Except
for acquired in process research and development (IPR&D), the Company expenses research and development costs as incurred including
therapeutics license costs.
|
R&D Grants |
R&D
Grants
NanoSynex
has received R&D grants from Israel Innovation Authority (IIA) and from the European Commission. These grants may provide cash funding
to NanoSynex from time to time in advance of the applicable costs being incurred. When such cash funding is received from these grants
in advance, the proceeds are recorded as a current or non-current R&D grant liability based on the time from the condensed consolidated
balance sheets date to the expected future date of recognition as a reduction to research and development expenses.
|
Patent Costs |
Patent
Costs
The
Company expenses all costs as incurred in connection with patent applications (including direct application fees, and the legal and consulting
expenses related to making such applications) and such costs are included in general and administrative expenses in the condensed consolidated
statement of operations.
|
Shipping and Handling Costs |
Shipping
and Handling Costs
The
Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and
outbound freight are generally recorded in cost of sales which totaled approximately $78,000 and $72,000, respectively, for the three
months ended June 30, 2023 and 2022, and approximately $144,000 and $111,000, respectively, for the six months ended June 30,
2023 and 2022. Other shipping and handling costs included in general and administrative, research and development, and sales and marketing
expenses were $0 and $4,000 for the three months ended June 30, 2023 and 2022, respectively, and
approximately $4,000 and $8,000 for the six months ended June 30, 2023 and 2022, respectively.
|
Revenue from Contracts with Customers |
Revenue
from Contracts with Customers
The
Company applies the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine
revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services
are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction
price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and
(v) recognition of revenue when (or as) the Company satisfies each performance obligation.
Product
Sales
The
Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System.
Disposable products include reagent packs, which are diagnostic tests for prostate-specific antigen, testosterone, thyroid disorders,
pregnancy, and Vitamin D.
The
Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order
and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable
products using separate purchase orders after the equipment (“analyzer”) has been provided to the customer. The initial delivery
of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery
of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are
not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant
discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days.
The
performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The
disposable products are shipped Free on Board (“FOB”) shipping point. For disposable products that are shipped FOB shipping
point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave
the Company’s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time.
The
Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to
fulfill the promise to transfer the disposable products and not as a separate performance obligation.
The
Company’s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected
the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to
obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company’s
contracts.
Contract
Asset and Liability Balances
The
timing of the Company’s revenue recognition may differ from the timing of payment by the Company’s customers. The Company
records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when
payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are
satisfied.
Multiple
performance obligations include contracts that combine both the Company’s analyzer and a customer’s future reagent purchases
under a single contract. In some sales contracts, the Company provides analyzers at no charge to customers. Title to the analyzer is
maintained by the Company and the analyzer is returned by the customer to the Company at the end of the purchase agreement.
During
the three months ended June 30, 2023 and 2022, product sales are stated net of an allowance for estimated returns of approximately $28,000
and $10,000, respectively. During the six months ended June 30, 2023 and 2022, product sales are stated net of an allowance for estimated
returns of approximately $33,000 and $53,000, respectively.
|
Deferred Revenue |
Deferred
Revenue
Payments
received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales,
multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the
time from the condensed consolidated balance sheets date to the future date of revenue recognition.
|
Operating Leases |
Operating
Leases
Effective
April 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2018-11, Leases (Topic 842) Targeted Improvements
(“Topic 842”). In accordance with the guidance in Topic 842, the Company recognizes lease liabilities and corresponding
right-of-use-assets for all leases with terms of greater than 12 months. Leases with a term of 12 months or less will be accounted for
in a manner similar to the guidance for operating leases prior to the adoption of Topic 842. (See Note
12 - Commitments and Contingencies for more information).
|
Property and Equipment, Net |
Property
and Equipment, Net
Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:
SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT
Machinery and equipment | |
| 5 years | |
Computer equipment | |
| 3 years | |
Molds and tooling | |
| 5 years | |
Furniture and fixtures | |
| 5 years | |
Leasehold
improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally
designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable
to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until
the relevant assets are completed and placed in service.
The
Company’s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when
conditions are present that indicate impairment.
|
Business Combinations |
Business
Combinations
The
Company accounts for business combinations using the acquisition method pursuant to FASB ASC Topic 805. This method requires, among other
things, that results of operations of acquired companies are included in Qualigen’s financial results beginning on the respective acquisition
date, and that assets acquired and liabilities assumed are recognized at fair value as of the acquisition date. Intangible assets acquired
in a business combination are recorded at fair value using a discounted cash flow model. The discounted cash flow model requires assumptions
about the timing and amount of future net cash flows, the cost of capital and terminal values from the perspective of a market participant.
Each of these factors can significantly affect the value of the intangible asset. Any excess of the fair value of consideration transferred
(the “purchase price”) over the fair values of the net assets acquired is recognized as goodwill. The fair value of assets
acquired and liabilities assumed in certain cases may be subject to revision based on the final determination of fair value during a
period of time not to exceed 12 months from the acquisition date. Legal costs, due diligence costs, business valuation costs and all
other acquisition-related costs are expensed when incurred.
|
Goodwill |
Goodwill
Goodwill
represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets
acquired, when accounted for using the purchase method of accounting. Goodwill has an indefinite useful life and is not amortized
but is reviewed for impairment annually and whenever events or changes in circumstances indicate that the carrying value of the
goodwill may not be recoverable. In testing for impairment, the fair value of the reporting unit is compared to the carrying value.
If the net assets assigned to the reporting unit exceed the fair value of the reporting unit, an impairment loss equal to the
difference is recorded. As a result of the annual goodwill impairment analysis, the Company recognized a $4,239,000
non-cash goodwill and fixed asset impairment charge in the valuation of its business acquisition of NanoSynex for the fiscal year
ended December 31, 2022. There were no
impairment losses during the three and six months ended June 30, 2023 and 2022.
|
Intangible Assets |
Intangible
Assets
In
Process R&D
Acquired
in process R&D (IPR&D) represents the fair value assigned to the research and development assets that have not reached technological
feasibility. The value assigned to IPR&D is determined by estimating the costs to develop the acquired technology into commercially
viable products, estimating the resulting revenue from the projects, and discounting the net cash flow to present value. The revenue
and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of success of developing the
new product. Additionally, projections consider relevant market sizes and growth factors, expected trends in technology and the nature
and expected timing of new product introductions. The rates utilized to discount the net cash flow to its present value are commensurate
with the stage of development of the project and uncertainties in the economic estimates used in the projections. Upon the acquisition
of acquired IPR&D, an assessment is completed as to whether the acquisition constitutes an acquisition of a single asset or a group
of assets. Multiple factors are considered in this assessment, including the nature of the technology acquired, the presence or absence
of separate cash flows, the development process and stage of completion, quantitative significance, and the Company’s rationale for entering
into the transaction.
If
a business is acquired, as defined under the applicable accounting standards, then the acquired IPR&D is capitalized as an intangible
asset. If an asset or group of assets is acquired that do not meet the definition under the applicable accounting standards, then the
acquired IPR&D is expensed on its acquisition date. Future costs to develop these assets are recorded to research and development
expense in the Company’s condensed consolidated statements of operations and other comprehensive income (loss) as they are incurred.
IPR&D
is evaluated for impairment annually using the same methodology as described above for calculating fair value. If the carrying value
of the acquired IPR&D exceeds the fair value, then the intangible asset is written down to its fair value, with the resulting adjustment
recorded as a charge to operations. Changes in estimates and assumptions used in determining the fair value of acquired IPR&D could
result in an impairment.
Other
Intangible Assets, Net
Other
intangible assets consist of patent-related costs and costs for license agreements. Management reviews the carrying value of other intangible
assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate
that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating
results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be
recovered.
If
the Company determines that the carrying value of other intangible assets will not be recovered from the undiscounted future cash flows
expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible
assets as impaired and reduces them by a charge to operations in the amount of the impairment.
Costs
related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally 5 to 17
years, using the straight-line method. Amortization of patents and licenses commences once final approval of the patent or license has
been obtained. Patent and license costs are charged to operations if it is determined that the patent or license will not be obtained.
|
Derivative Financial Instruments and Warrant Liabilities |
Derivative
Financial Instruments and Warrant Liabilities
The
Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates
all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain
features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported
in the condensed consolidated statements of operations and other comprehensive income (loss). Depending on the features of the derivative
financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative
instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments
should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 9- Warrant Liabilities).
Fair
Value Measurements
The
Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established
by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of
its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy
gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements).
The guidance establishes three levels of the fair value hierarchy as follows:
| ● | Level
1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or
liabilities that the Company has the ability to access at the measurement date; |
| ● | Level
2 - Inputs other than quoted prices that are observable for the assets or liability either
directly or indirectly, including inputs in markets that are not considered to be active;
and |
| ● | Level
3 - Inputs that are unobservable. |
|
Fair Value of Financial Instruments |
Fair
Value of Financial Instruments
Cash,
accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates
fair value due to the short-term nature of these instruments.
|
Comprehensive Loss |
Comprehensive
Loss
Comprehensive
loss consists of net income and foreign currency translation adjustments. Comprehensive gains (losses) have been reflected in the statements
of operations and comprehensive loss and as a separate component in the statements of stockholders’ equity for all periods presented.
|
Stock-Based Compensation |
Stock-Based
Compensation
Stock-based
compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair
value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over
the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more
reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s
stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in
an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.
|
Income Taxes |
Income
Taxes
Deferred
income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting
that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods
and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses,
and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences.
Deferred
tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all
of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws
and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income
in future years.
|
Sales and Excise Taxes |
Sales
and Excise Taxes
Sales
and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with
corresponding tax payable. These balances are removed from the condensed consolidated balance sheet as cash is collected from customers
and remitted to the tax authority.
|
Warranty Costs |
Warranty
Costs
The
Company’s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications
for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in
the period in which the revenue is recognized based on historical data and the Company’s best estimates of analyzer failure rates
and costs to repair.
Accrued
warranty liabilities were approximately $140,000 and $138,000, respectively, as of June 30, 2023 and December 31, 2022 and
are included in accrued expenses and other current liabilities on the accompanying condensed consolidated balance sheets. Warranty costs
were approximately $63,000 and $22,000 for the three months ended June 30, 2023 and 2022, respectively, and approximately $104,000
and $41,000 for the six months ended June 30, 2023 and 2022, respectively, and are included in cost of product sales in the condensed
consolidated statements of operations and other comprehensive loss.
|
Foreign Currency Translation |
Foreign
Currency Translation
The
functional currency for the Company is the U.S. dollar. The functional currency for NanoSynex, the Company’s newly acquired majority
owned subsidiary, is the New Israeli Shekel (NIS). The financial statements of NanoSynex are translated into U.S. dollars using exchange
rates in effect at each period end for assets and liabilities; using exchange rates in effect during the period for results of operations;
and using historical exchange rates for certain equity accounts. The adjustment resulting from translating the financial statements of
NanoSynex is reflected as a separate component of other comprehensive income (loss).
Other
comprehensive loss related to the effects of foreign currency translation adjustments attributable to NanoSynex was ($56,747) and $65,540 for the three months ending June 30, 2023 and 2022, respectively, and $119,473 and $65,540 for the six months ending June 30, 2023 and 2022, respectively.
|
War in Ukraine |
War
in Ukraine
In
February 2022, Russia invaded Ukraine. While the Company has no direct exposure in Russia and Ukraine, the Company continues to monitor
any broader impact to the global economy, including with respect to inflation, supply chains and fuel prices. The full impact of the
conflict on the Company’s business and financial results remains uncertain and will depend on the severity and duration of the
conflict and its impact on regional and global economic conditions.
|
Inflation and Global Economic Conditions |
Inflation
and Global Economic Conditions
During
the year ended 2022 and continuing into the current fiscal year, global commodity and labor markets experienced significant inflationary
pressures attributable to ongoing economic recovery and supply chain issues. The Company is subject to inflationary pressures with respect
to raw materials, labor and transportation. Accordingly, the Company continues to take actions with its customers and suppliers to mitigate
the impact of these inflationary pressures in the future. Actions to mitigate inflationary pressures with suppliers include aggregation
of purchase requirements to achieve optimal volume benefits, negotiation of cost-reductions and identification of more cost competitive
suppliers. While these actions are designed to offset the impact of inflationary pressures, the Company cannot provide assurance that
it will be successful in fully offsetting increased costs resulting from inflationary pressure. In
addition, the global economy suffers from slowing growth and rising interest rates, and some economists believe that there may be a global
recession in the near future. If the global economy slows, our business would be adversely affected.
|
Impact of COVID-19 Pandemic |
Impact
of COVID-19 Pandemic
The
COVID-19 pandemic has had a dramatic impact on businesses globally and on the Company’s business as well. During the height of
the pandemic sales of diagnostic products decreased significantly and the Company’s net loss increased significantly, as deferral
of patients’ non-emergency visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests.
For 2023 we continue to experience recovery in demand.
Other
accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s
condensed consolidated financial statements.
|
X |
- DefinitionDeferred Revenue Policy [TextBlock]
+ References
+ Details
Name: |
QLGN_DeferredRevenuePolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDerivative Financial Instruments And Warrant Liabilities [Policy TextBlock]
+ References
+ Details
Name: |
QLGN_DerivativeFinancialInstrumentsAndWarrantLiabilitiesPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionImpact Of Covid 19 Pandemic [Policy Text Block]
+ References
+ Details
Name: |
QLGN_ImpactOfCovid19PandemicPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionInflation And Global Economic Conditions [Policy Text Block]
+ References
+ Details
Name: |
QLGN_InflationAndGlobalEconomicConditionsPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionOrganization [PolicyText Block]
+ References
+ Details
Name: |
QLGN_OrganizationPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPatent Costs Policy [TextBlock]
+ References
+ Details
Name: |
QLGN_PatentCostsPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionResearch And Development Grants Policy [TextBlock]
+ References
+ Details
Name: |
QLGN_ResearchAndDevelopmentGrantsPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionReverse Stock Split [Policy Text Block]
+ References
+ Details
Name: |
QLGN_ReverseStockSplitPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSales And Excise Taxes [Policy Text Block]
+ References
+ Details
Name: |
QLGN_SalesAndExciseTaxesPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShipping And Handling Costs Policy [TextBlock]
+ References
+ Details
Name: |
QLGN_ShippingAndHandlingCostsPolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWar In Ukraine [Policy Text Block]
+ References
+ Details
Name: |
QLGN_WarInUkrainePolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWarranty Reserve [Policy Text Block]
+ References
+ Details
Name: |
QLGN_WarrantyReservePolicyTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BasisOfAccountingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 05 -Paragraph 4 -Subparagraph (a)-(d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479515/805-10-05-4
+ Details
Name: |
us-gaap_BusinessCombinationsPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1
+ Details
Name: |
us-gaap_CashAndCashEquivalentsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (b),(f(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_CompensationRelatedCostsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for comprehensive income.
+ References
+ Details
Name: |
us-gaap_ComprehensiveIncomePolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 810 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1
+ Details
Name: |
us-gaap_ConsolidationPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for determining the fair value of financial instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 60 -Paragraph 1 -SubTopic 10 -Topic 820 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 825 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1
+ Details
Name: |
us-gaap_FairValueOfFinancialInstrumentsPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//830/tableOfContent
+ Details
Name: |
us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.CC) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 05 -Paragraph 4 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4
+ Details
Name: |
us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(h)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20
+ Details
Name: |
us-gaap_IncomeTaxPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 920 -SubTopic 350 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483256/920-350-50-4
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_IntangibleAssetsFiniteLivedPolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 330 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482105/912-330-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//330/tableOfContent
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 330 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483080/330-10-50-4
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 6 -Subparagraph (a) -SubTopic 10 -Topic 270 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482989/270-10-45-6
+ Details
Name: |
us-gaap_InventoryPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for leasing arrangement entered into by lessee.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1
+ Details
Name: |
us-gaap_LesseeLeasesPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpensePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4
+ Details
Name: |
us-gaap_RevenueRecognitionPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for segment reporting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 47 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482785/280-10-55-47
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 29 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-29
+ Details
Name: |
us-gaap_SegmentReportingPolicyPolicyTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for accounts receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1
Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1
Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6
Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15
+ Details
Name: |
us-gaap_TradeAndOtherAccountsReceivablePolicy |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8
+ Details
Name: |
us-gaap_UseOfEstimates |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
SCHEDULE OF ACCOUNTS RECEIVABLE |
Accounts
receivable, net is comprised of the following at:
SCHEDULE
OF ACCOUNTS RECEIVABLE
| |
June 30, 2023 | | |
December 31, 2022 | |
Accounts Receivable | |
$ | 733,964 | | |
$ | 726,449 | |
Less Reserves and Allowances | |
| (54,584 | ) | |
| (187,862 | ) |
Accounts receivable,
net | |
$ | 679,380 | | |
$ | 538,587 | |
|
SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT |
Property
and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis
over the estimated useful lives of the related assets as follows:
SCHEDULE
OF USEFUL LIVES OF PROPERTY AND EQUIPMENT
Machinery and equipment | |
| 5 years | |
Computer equipment | |
| 3 years | |
Molds and tooling | |
| 5 years | |
Furniture and fixtures | |
| 5 years | |
|
X |
- DefinitionSchedule Of Useful Lives Of Property And Equipment [Table TextBlock]
+ References
+ Details
Name: |
QLGN_ScheduleOfUsefulLivesOfPropertyAndEquipmentTableTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
INVENTORY, NET (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Inventory Disclosure [Abstract] |
|
SCHEDULE OF INVENTORY |
Inventory,
net consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF INVENTORY
| |
June 30, 2023 | | |
December 31, 2022 | |
Raw materials | |
$ | 1,027,455 | | |
$ | 949,796 | |
Work in process | |
| 177,591 | | |
| 200,318 | |
Finished goods | |
| 358,353 | | |
| 436,183 | |
Total
inventory | |
$ | 1,563,399 | | |
$ | 1,586,297 | |
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483489/210-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfInventoryCurrentTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS |
Prepaid
expenses and other current assets consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS
| |
June 30, 2023 | | |
December 31, 2022 | |
Prepaid insurance | |
$ | 938,106 | | |
$ | 1,377,323 | |
Prepaid manufacturing expenses | |
| 51,710 | | |
| 43,820 | |
Other prepaid expenses | |
| 65,288 | | |
| 227,451 | |
Prepaid research and development expenses | |
| 211,337 | | |
| — | |
Other current assets | |
| 11,636 | | |
| 12,626 | |
Prepaid expenses and
other current assets | |
$ | 1,278,077 | | |
$ | 1,661,220 | |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.
+ References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
PROPERTY AND EQUIPMENT, NET (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Property, Plant and Equipment [Abstract] |
|
SCHEDULE OF PROPERTY AND EQUIPMENT |
Property
and equipment, net consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF PROPERTY AND EQUIPMENT
| |
June 30, 2023 | | |
December 31, 2022 | |
Machinery and equipment | |
$ | 2,735,507 | | |
$ | 2,510,148 | |
Computer equipment | |
| 369,589 | | |
| 395,836 | |
Leasehold improvements | |
| 336,916 | | |
| 333,271 | |
Molds and tooling | |
| 260,002 | | |
| 260,002 | |
Furniture and fixtures | |
| 144,832 | | |
| 144,832 | |
Equipment held for lease | |
| 1,405,384 | | |
| 1,399,444 | |
Property and equipment, gross | |
| 5,252,230 | | |
| 5,043,533 | |
Accumulated depreciation | |
| (4,678,583 | ) | |
| (4,623,446 | ) |
Fixed asset impairment | |
| (75,000 | ) | |
| (75,000 | ) |
Property and equipment,
net | |
$ | 498,647 | | |
$ | 345,087 | |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
GOODWILL, IPR&D AND OTHER INTANGIBLES (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Goodwill and Intangible Assets Disclosure [Abstract] |
|
SCHEDULE OF GOODWILL AND OTHER INTANGIBLES |
SCHEDULE
OF GOODWILL AND OTHER INTANGIBLES
| |
| |
June 30, | | |
December 31, | |
| |
| |
2023 | | |
2022 | |
| |
Estimated Useful Lives | |
Gross carrying amounts | | |
Gross carrying amounts | |
| |
| |
| | |
| |
Goodwill | |
| |
$ | 625,602 | | |
$ | 625,602 | |
| |
| |
| | | |
| | |
Finite-lived intangible assets: | |
| |
| | | |
| | |
Developed-product-technology rights | |
8 - 17 years | |
$ | 479,103 | | |
$ | 479,103 | |
Licensing rights | |
10 years | |
| 418,836 | | |
| 418,836 | |
Less: Accumulated amortization | |
| |
| (764,869 | ) | |
| (752,237 | ) |
Total finite-lived intangible assets, net | |
| |
| 133,070 | | |
| 145,702 | |
Indefinite-lived intangible assets: | |
| |
| | | |
| | |
In-process research and development | |
| |
| 5,700,000 | | |
| 5,700,000 | |
Total other intangible assets, net | |
| |
$ | 5,833,070 | | |
$ | 5,845,702 | |
|
X |
- References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
+ Details
Name: |
us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Payables and Accruals [Abstract] |
|
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES |
Accrued
expenses and other current liabilities consisted of the following at June 30, 2023 and December 31, 2022:
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES
| |
June 30, 2023 | | |
December 31, 2022 | |
Board compensation | |
$ | 84,000 | | |
| 70,000 | |
Equipment held for lease | |
| — | | |
| 154,433 | |
Franchise, sales and use taxes | |
| 30,407 | | |
| 27,531 | |
Income taxes | |
| 6,921 | | |
| 4,663 | |
Interest (Convertible debt - related party) | |
| 50,101 | | |
| 2,829 | |
License fees | |
| 100,026 | | |
| 150,130 | |
Payroll | |
| 484,048 | | |
| 209,303 | |
Professional fees | |
| 368,032 | | |
| 238,211 | |
Research and development | |
| 523,490 | | |
| 322,987 | |
Royalties | |
| 16,383 | | |
| 13,158 | |
Warranty liability | |
| 140,370 | | |
| 137,568 | |
Other | |
| 176,777 | | |
| 181,043 | |
Accrued expenses and other current liabilities | |
$ | 1,980,555 | | |
$ | 1,511,856 | |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.
+ References
+ Details
Name: |
us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
WARRANT LIABILITIES (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Warrant Liabilities |
|
SCHEDULE OF WARRANTS ACTIVITY |
The
following table summarizes the activity in liability classified warrants for the six months ended June 30, 2023:
SCHEDULE OF WARRANTS ACTIVITY
| |
Common Stock Warrants | |
| |
Shares | | |
Weighted– Average Exercise Price | | |
Range of Exercise Price | | |
Weighted– Average Remaining Life (Years) | |
Total outstanding – December 31, 2022 | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.9 | |
Exercised | |
| — | | |
| — | | |
| — | | |
| — | |
Forfeited | |
| — | | |
| — | | |
| — | | |
| — | |
Expired | |
| — | | |
| — | | |
| — | | |
| — | |
Granted | |
| — | | |
| — | | |
| — | | |
| — | |
Total outstanding – June 30, 2023 | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.41 | |
Exercisable | |
| 3,849,571 | | |
$ | 1.53 | | |
| $1.32 - $1.65 | | |
| 3.41 | |
The
following table summarizes the activity in liability classified warrants for the six months ended June 30, 2022:
| |
Common
Stock Warrants | |
| |
Shares | | |
Weighted–
Average Exercise Price | | |
Range
of Exercise Price | | |
Weighted–
Average Remaining Life (Years) | |
Total outstanding
–December 31, 2021 | |
| 248,161 | | |
$ | 7.20 | | |
| | | |
| 2.00 | |
Exercised | |
| (536 | ) | |
| 7.20 | | |
| | | |
| | |
Forfeited | |
| (247,625 | ) | |
| 7.20 | | |
| | | |
| | |
Expired | |
| — | | |
| — | | |
| | | |
| | |
Granted | |
| 346,896 | | |
| 5.10 | | |
| | | |
| | |
Total outstanding –
June 30, 2022 | |
| 346,896 | | |
$ | 5.10 | | |
| | | |
| | |
Exercisable | |
| 346,896 | | |
$ | 5.10 | | |
$ | 5.10 | | |
| 1.51 | |
|
SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES |
The
following table presents the Company’s fair value hierarchy for its liabilities measured at fair value on a recurring basis as
of June 30, 2023:
SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES
| |
Quoted | | |
| | |
| | |
| |
| |
Market | | |
Significant | | |
| | |
| |
| |
Prices for | | |
Other | | |
Significant | | |
| |
| |
Identical | | |
Observable | | |
Unobservable | | |
| |
| |
Assets | | |
Inputs | | |
Inputs | | |
| |
Common Stock Warrant liabilities | |
(Level 1) | | |
(Level 2) | | |
(Level 3) | | |
Total | |
Balance as of December 31, 2022 | |
$ | — | | |
$ | — | | |
$ | 3,622,647 | | |
$ | 3,622,647 | |
Exercises | |
| — | | |
| — | | |
| — | | |
| — | |
Gain on change in fair value of warrant liabilities | |
| — | | |
| — | | |
| (1,478,967 | ) | |
| (1,478,967 | ) |
Balance as of June 30, 2023 | |
$ | — | | |
$ | — | | |
$ | 2,143,680 | | |
$ | 2,143,680 | |
|
SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES |
The
following are the weighted average and the range of assumptions used in estimating the fair value of warrant liabilities (weighted average
calculated based on the number of outstanding warrants on each issuance) as of June 30, 2023 and 2022:
SCHEDULE
OF ASSUMPTIONS OF WARRANT LIABILITIES
|
|
June
30, 2023 |
|
June
30, 2022 |
|
|
|
Range |
|
Weighted
Average |
|
Range |
|
Weighted
Average |
|
Risk-free
interest rate |
|
4.05%
— 5.31% |
|
|
4.49 |
% |
2.80%
— 2.87% |
|
|
2.82 |
% |
Expected
volatility (peer group) |
|
66.3%
— 134% |
|
|
110.55 |
% |
74%
— 96% |
|
|
78.6 |
% |
Term
of warrants (in years) |
|
.39
— 4.98 |
|
3.41 |
|
1.39
— 1.99 |
|
1.51 |
|
Expected
dividend yield |
|
|
0.00 |
% |
|
0.00 |
% |
|
0.00 |
% |
|
0.00 |
% |
|
X |
- References
+ Details
Name: |
QLGN_DisclosureWarrantLiabilitiesAbstract |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSchedule Of Assumptions Of Warrant Liabilities [Table Text Block]
+ References
+ Details
Name: |
QLGN_ScheduleOfAssumptionsOfWarrantLiabilitiesTableTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSchedule Of Fair Value Hierarchy For Warrant Liabilities [Table Text Block]
+ References
+ Details
Name: |
QLGN_ScheduleOfFairValueHierarchyForWarrantLiabilitiesTableTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
CONVERTIBLE DEBT- RELATED PARTY (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Debt Disclosure [Abstract] |
|
SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT |
Convertible
debt-related party is comprised of the following as of June 30, 2023 and December 31, 2022:
SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT
| |
June 30, 2023 | | |
December 31, 2022 | |
Senior secured convertible debenture | |
$ | 2,078,922 | | |
$ | 3,300,000 | |
Discount on convertible debenture | |
| (1,266,503 | ) | |
| (3,239,803 | ) |
Total convertible debt-related party | |
$ | 812,419 | | |
$ | 60,197 | |
|
X |
- DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount.
+ References
+ Details
Name: |
us-gaap_ConvertibleDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
EARNINGS (LOSS) PER SHARE (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Earnings Per Share [Abstract] |
|
SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE |
The following potentially dilutive securities have been excluded from diluted net loss per share
as of June 30, 2023 and 2022 because their effect would be anti-dilutive:
SCHEDULE
OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE
| |
As of June 30, | |
| |
2023 | | |
2022 | |
Shares of common stock subject to outstanding options | |
| 445,163 | | |
| 476,783 | |
Shares of common stock subject to outstanding warrants | |
| 4,119,934 | | |
| 1,412,338 | |
Total common stock equivalents | |
| 4,565,097 | | |
| 1,889,121 | |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
COMMITMENTS AND CONTINGENCIES (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Commitments and Contingencies Disclosure [Abstract] |
|
SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES |
The
tables below show the operating lease right-of-use assets and operating lease liabilities as of June 30, 2023, including the changes
during the periods:
SCHEDULE
OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES
| |
Operating lease right-of-use assets | |
Net right-of-use assets at December 31, 2022 | |
$ | 1,422,538 | |
Less amortization of operating lease right-of-use assets | |
| (116,568 | ) |
Operating lease right-of-use assets at June 30, 2023 | |
$ | 1,305,970 | |
| |
Operating lease liabilities | |
Lease liabilities at December 31, 2022 | |
$ | 1,542,564 | |
Less principal payments on operating lease liabilities | |
| (116,756 | ) |
Lease liabilities at June 30, 2023 | |
| 1,425,808 | |
Less non-current portion | |
| (1,168,653 | ) |
Current portion at June 30, 2023 | |
$ | 257,155 | |
|
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES |
As
of June 30, 2023, future minimum payments during the next five fiscal years and thereafter are as follows:
SCHEDULE
OF MATURITIES OF OPERATING LEASE LIABILITIES
Year Ending December 31, | |
Amount | |
2023 (six months) | |
| 184,171 | |
2024 | |
| 379,392 | |
2025 | |
| 390,773 | |
2026 | |
| 402,497 | |
2027 | |
| 379,164 | |
Total | |
| 1,735,997 | |
Less present value discount | |
| (310,189 | ) |
Operating lease liabilities | |
$ | 1,425,808 | |
|
X |
- DefinitionSchedule Of Operating Lease Right Of Use Assets And Liabilities [Table Text Block]
+ References
+ Details
Name: |
QLGN_ScheduleOfOperatingLeaseRightOfUseAssetsAndLiabilitiesTableTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
STOCKHOLDERS’ EQUITY (Tables)
|
6 Months Ended |
Jun. 30, 2023 |
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
SCHEDULE OF RESERVED SHARES |
SCHEDULE
OF RESERVED SHARES
| |
| | |
Exercise of issued and future grants of stock options | |
| 445,163 | |
Exercise of stock warrants | |
| 4,119,934 | |
Total | |
| 4,565,097 | |
|
SCHEDULE OF STOCK OPTION ACTIVITY |
The
following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers
that are outstanding at June 30, 2023, and changes during the six-month period then ended:
SCHEDULE
OF STOCK OPTION ACTIVITY
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range of Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
608,012 |
|
$ |
35.02 |
|
|
$5.14
- $51.30 |
|
|
8.09 |
|
Granted |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Expired |
|
|
— |
|
|
— |
|
|
— |
|
|
— |
|
Forfeited |
|
|
(162,849 |
) |
|
36.01 |
|
|
5.14
- 51.30 |
|
|
— |
|
Total
outstanding – June 30, 2023 |
|
|
445,163 |
|
$ |
34.68 |
|
|
$5.14
— $51.30 |
|
|
7.59 |
|
Exercisable
(vested) |
|
|
323,355 |
|
$ |
44.79 |
|
|
$5.14
— $51.30 |
|
|
7.13 |
|
Non-Exercisable
(non-vested) |
|
|
121,808 |
|
$ |
7.83 |
|
|
$5.14
- $35.20 |
|
|
8.85 |
|
There
was approximately $0.9 and $2.7 million of compensation cost related to outstanding stock options for the six months ended June 30,
2023 and 2022, respectively. As of June 30, 2023, there was approximately $0.5 million of total unrecognized compensation cost related
to unvested stock-based compensation arrangements. This cost is expected to be recognized over a weighted average period of 1.47 years.
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range of Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
484,186 |
|
$ |
60.70 |
|
$12.40 — $14,657.50 |
|
|
8.52 |
|
Granted |
|
|
2,500 |
|
|
10.50 |
|
|
10.50 |
|
|
9.54 |
|
Expired |
|
|
(9,386 |
) |
|
935.90 |
|
|
57.50
- 14,657.50 |
|
|
— |
|
Forfeited |
|
|
(517 |
) |
|
35.10 |
|
|
12.40
- 49.70 |
|
|
— |
|
Total
outstanding – June 30, 2022 |
|
|
476,783 |
|
$ |
43.30 |
|
|
$10.50
— $51.30 |
|
|
8.19 |
|
Exercisable
(vested) |
|
|
264,366 |
|
$ |
48.40 |
|
|
$12.40
— $50.13 |
|
|
8.00 |
|
Non-Exercisable
(non-vested) |
|
|
212,417 |
|
$ |
36.80 |
|
|
$10.50
— $51.30 |
|
|
8.48 |
|
|
SCHEDULE OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD |
The
material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented
were as follows:
SCHEDULE
OF ASSUMPTION USED IN BLACK-SCHOLES OPTION-PRICING METHOD
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
Expected dividend yield | |
| 0.00 | % | |
| 0.00 | % |
Expected stock-price volatility | |
| — | | |
| 102 | % |
Risk-free interest rate | |
| — | | |
1.58% — 1.67 | % |
Expected average term of options (in years) | |
| — | | |
| 6.00 | |
Stock price | |
$ | — | | |
$ | 1.05 | |
|
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE |
The
Company recorded share-based compensation expense and classified it in the unaudited condensed consolidated statements of operations
as follows:
SCHEDULE
OF SHARE-BASED COMPENSATION EXPENSE
| |
2023 | | |
2022 | |
| |
For the Six Months Ended June 30, | |
| |
2023 | | |
2022 | |
General and administrative | |
$ | 807,980 | | |
$ | 2,329,418 | |
Research and development | |
| 98,165 | | |
| 361,029 | |
Total | |
$ | 906,145 | | |
$ | 2,690,447 | |
|
Compensatory Warrant Activity [Member] |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
SCHEDULE OF WARRANT ACTIVITY |
The
following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June
30, 2023:
SCHEDULE
OF WARRANT ACTIVITY
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
1.73 |
|
Granted
to advisor and its designees |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2023 |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
1.24 |
|
Exercisable |
|
|
179,046 |
|
$ |
9.12 |
|
$1.32
— $25.40 |
|
|
1.24 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
The
following table summarizes the activity in the common stock equity classified compensatory warrants for the six months ended June 30,
2022:
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
179,065 |
|
$ |
15.20 |
|
$11.10
— $25.40 |
|
2.64 |
|
Granted
to advisor and its designees |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2022 |
|
|
179,065 |
|
$ |
10.60 |
|
$5.14
— $25.40 |
|
2.23 |
|
Exercisable |
|
|
179,065 |
|
$ |
10.60 |
|
$5.14
— $25.40 |
|
|
2.23 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
|
Non Compensatory Warrant Activity [Member] |
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
SCHEDULE OF WARRANT ACTIVITY |
The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2023:
SCHEDULE
OF WARRANT ACTIVITY
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2022 |
|
|
547,003 |
|
$ |
19.76 |
|
$1.32
- $20.00 |
|
0.33 |
|
Legacy
Ritter warrants |
|
|
— |
|
|
— |
|
|
|
|
|
Granted |
|
|
— |
|
|
— |
|
|
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
(455,685 |
) |
|
20.00 |
|
|
20.00 |
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2023 |
|
|
91,318 |
|
$ |
18.56 |
|
|
|
- |
|
Exercisable |
|
|
91,318 |
|
$ |
18.56 |
|
$1.32
— $20.00 |
|
|
0.58 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
The
following table summarizes the noncompensatory equity classified warrant activity for the six months ended June 30, 2022:
|
|
Common
Stock |
|
|
|
Shares |
|
Weighted–
Average
Exercise
Price |
|
Range
of
Exercise Price |
|
Weighted–
Average
Remaining
Life (Years) |
|
Total
outstanding – December 31, 2021 |
|
|
554,914 |
|
$ |
20.10 |
|
|
|
|
|
Legacy
Ritter warrants |
|
|
— |
|
|
— |
|
|
|
|
|
Granted |
|
|
331,464 |
|
|
0.01 |
|
|
0.01 |
|
|
|
Exercised |
|
|
— |
|
|
— |
|
|
|
|
|
Expired |
|
|
— |
|
|
— |
|
|
|
|
|
Forfeited |
|
|
— |
|
|
— |
|
|
|
|
|
Total
outstanding – June 30, 2022 |
|
|
886,378 |
|
$ |
12.60 |
|
|
|
|
|
Exercisable |
|
|
886,378 |
|
$ |
12.60 |
|
$0.01
— $37.70 |
|
|
0.82 |
|
Non-Exercisable |
|
|
— |
|
$ |
— |
|
$ |
— |
|
|
— |
|
|
X |
- DefinitionSchedule Of Reserved Shares [Table Text Block]
+ References
+ Details
Name: |
QLGN_ScheduleOfReservedSharesTableTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSummary Of Warrant Activity [Table Text Block]
+ References
+ Details
Name: |
QLGN_SummaryOfWarrantActivityTableTextBlock |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=QLGN_NonCompensatoryWarrantActivityMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF ACCOUNTS RECEIVABLE (Details) - USD ($)
|
Dec. 31, 2023 |
Jun. 30, 2023 |
Dec. 31, 2022 |
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
|
|
Accounts Receivable |
$ 726,449
|
$ 733,964
|
|
Less Reserves and Allowances |
(187,862)
|
(54,584)
|
|
Accounts receivable, net |
$ 538,587
|
$ 679,380
|
$ 538,587
|
X |
- DefinitionAmount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(3)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableGrossCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of allowance for credit loss on accounts receivable, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4
+ Details
Name: |
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative) - USD ($)
|
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
|
|
May 26, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Jul. 20, 2023 |
Dec. 22, 2022 |
Apr. 25, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Warrants to purchase common stock |
|
|
|
|
|
|
|
|
|
|
219,101
|
Warrants exercise price |
|
|
|
|
|
|
|
|
|
$ 13.20
|
$ 40.70
|
Reverse stock split |
These warrants were
subsequently exercised on September 13, 2022
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period, value, acquisitions |
|
|
$ 1,844,500
|
|
|
|
|
|
|
|
|
Impairment losses on construction-in-progress |
|
$ 0
|
0
|
$ 0
|
$ 0
|
|
|
|
|
|
|
Allowance for estimated returns |
|
28,000
|
10,000
|
33,000
|
53,000
|
|
|
|
|
|
|
Goodwill impairment charges |
|
|
|
|
|
$ 4,239,000
|
|
|
|
|
|
Goodwill and intangible asset impairment |
|
|
|
0
|
0
|
|
|
|
|
|
|
Estimated useful lives |
|
|
|
|
|
|
5 years
|
|
|
|
|
Accrued warranty liabilities |
|
140,370
|
|
140,370
|
|
137,568
|
|
|
|
|
|
Warranty costs |
|
63,000
|
22,000
|
104,000
|
41,000
|
|
|
|
|
|
|
Adjustment net of tax |
|
$ (56,747)
|
65,540
|
$ 119,473
|
65,540
|
|
|
|
|
|
|
Minimum [Member] | Patents and Licenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
Estimated useful lives |
|
5 years
|
|
5 years
|
|
|
|
|
|
|
|
Maximum [Member] | Patents and Licenses [Member] |
|
|
|
|
|
|
|
|
|
|
|
Estimated useful lives |
|
17 years
|
|
17 years
|
|
|
|
|
|
|
|
Selling and Marketing Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
Other shipping and handling costs |
|
$ 0
|
4,000
|
$ 4,000
|
8,000
|
|
|
|
|
|
|
Shipping and Handling [Member] |
|
|
|
|
|
|
|
|
|
|
|
Other shipping and handling costs |
|
78,000
|
$ 72,000
|
144,000
|
$ 111,000
|
|
|
|
|
|
|
Pre-funded Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase common stock |
331,464
|
|
|
|
|
|
|
|
|
|
|
Warrants exercise price |
$ 0.001
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
Warrants to purchase common stock |
67,619
|
|
|
|
|
|
|
67,620
|
67,619
|
|
|
Warrants exercise price |
|
|
|
|
|
|
|
|
$ 6.00
|
|
|
Accrued warranty liabilities |
|
$ 140,000
|
|
$ 140,000
|
|
138,000
|
|
|
|
|
|
Warrant [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Warrants exercise price |
$ 11.10
|
|
|
|
|
|
|
$ 5.136
|
11.10
|
|
|
Warrant [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
Warrants exercise price |
$ 5.136
|
|
|
|
|
|
|
$ 1.32
|
$ 5.136
|
|
|
Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period shares acquisitions |
381,786
|
|
|
|
|
|
|
|
|
|
|
NanoSynex Ltd [Member] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period shares acquisitions |
350,000
|
|
|
|
|
|
|
|
|
|
|
Voting interests acquired |
52.80%
|
|
|
|
|
|
|
|
|
|
|
Adjustment net of tax |
|
|
|
|
|
$ 65,540
|
|
|
|
|
|
NanoSynex Ltd [Member] | Series A-1 Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period shares acquisitions |
2,232,861
|
|
|
|
|
|
|
|
|
|
|
NanoSynex Ltd [Member] | Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period shares acquisitions |
381,786
|
|
|
|
|
|
|
|
|
|
|
Stock issued during period, value, acquisitions |
$ 600,000
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionAllowances for sales return.
+ References
+ Details
Name: |
QLGN_AllowancesForSalesReturn |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4
+ Details
Name: |
us-gaap_AssetImpairmentCharges |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_CostOfGoodsAndServicesSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill.
+ References
+ Details
Name: |
us-gaap_GoodwillAndIntangibleAssetImpairment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2
+ Details
Name: |
us-gaap_GoodwillImpairmentLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A
+ Details
Name: |
us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ProductWarrantyAccrual |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8
+ Details
Name: |
us-gaap_ProductWarrantyExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued pursuant to acquisitions during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 4 -Subparagraph (SAB Topic 4.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-4
+ Details
Name: |
us-gaap_StockholdersEquityReverseStockSplit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_PatentsAndLicensesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_SellingAndMarketingExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
LIQUIDITY (Details Narrative) - USD ($)
|
|
1 Months Ended |
6 Months Ended |
12 Months Ended |
13 Months Ended |
|
|
|
Jul. 20, 2023 |
Dec. 31, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2023 |
Mar. 31, 2024 |
Nov. 30, 2023 |
Jan. 12, 2023 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
Cash |
$ 5,200,000
|
$ 7,034,434
|
$ 1,341,659
|
|
$ 7,034,434
|
|
|
|
|
Accumulated deficit |
|
103,385,172
|
110,695,598
|
|
103,385,172
|
|
|
|
|
Net cash used in operating activities |
|
|
5,562,416
|
$ 7,827,798
|
$ 13,200,000
|
|
|
|
|
Share based compensation |
$ 5,800,000
|
|
906,145
|
$ 2,690,447
|
|
|
|
|
|
Escrow deposit |
|
|
$ 450,000
|
|
|
|
|
|
|
Proceeds from issuance of common stock |
|
$ 8,800,000
|
|
|
|
|
|
|
|
Proceeds from issuance of debt |
|
|
|
|
|
$ 3.0
|
|
|
|
Aggregrate amount |
|
|
|
|
|
|
|
|
$ 1,111,078
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
Sale of stock price per share |
$ 1.5716
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Amendment and Settlement Agreement [Member] |
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
Aggregrate amount |
$ 380,000
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Amendment and Settlement Agreement [Member] | NanoSynex Ltd [Member] |
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
Aggregrate amount |
$ 1,610,000
|
|
|
|
|
|
$ 670,000
|
$ 560,000
|
|
NanoSynex Ltd [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
|
|
|
|
Business acquisition, description of acquired entity |
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
|
|
|
|
|
|
|
|
|
X |
- DefinitionWith respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_EscrowDeposit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the additional capital contribution to the entity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOfCommonStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of accumulated undistributed earnings (deficit).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=QLGN_AmendmentAndSettlementAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=QLGN_NanoSynexLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF INVENTORY (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Inventory Disclosure [Abstract] |
|
|
Raw materials |
$ 1,027,455
|
$ 949,796
|
Work in process |
177,591
|
200,318
|
Finished goods |
358,353
|
436,183
|
Total inventory |
$ 1,563,399
|
$ 1,586,297
|
X |
- References
+ Details
Name: |
us-gaap_InventoryDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryFinishedGoods |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryRawMaterials |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InventoryWorkInProcess |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.2
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
Prepaid insurance |
$ 938,106
|
$ 1,377,323
|
Prepaid manufacturing expenses |
51,710
|
43,820
|
Other prepaid expenses |
65,288
|
227,451
|
Prepaid research and development expenses |
211,337
|
|
Other current assets |
11,636
|
12,626
|
Prepaid expenses and other current assets |
$ 1,278,077
|
$ 1,661,220
|
X |
- DefinitionPreapaid research and development expenses.
+ References
+ Details
Name: |
QLGN_PreapaidResearchAndDevelopmentExpenses |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionPrepaid manufacturing expenses.
+ References
+ Details
Name: |
QLGN_PrepaidManufacturingExpenses |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of current assets classified as other.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1
+ Details
Name: |
us-gaap_OtherPrepaidExpenseCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5
+ Details
Name: |
us-gaap_PrepaidInsurance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.23.2
SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
$ 5,252,230
|
$ 5,043,533
|
Accumulated depreciation |
(4,678,583)
|
(4,623,446)
|
Fixed asset impairment |
(75,000)
|
(75,000)
|
Property and equipment, net |
498,647
|
345,087
|
Machinery and Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
2,735,507
|
2,510,148
|
Computer Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
369,589
|
395,836
|
Leasehold Improvements [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
336,916
|
333,271
|
Molds and Tooling [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
260,002
|
260,002
|
Furniture and Fixtures [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
144,832
|
144,832
|
Equipment [Member] |
|
|
Property, Plant and Equipment [Line Items] |
|
|
Property and equipment, gross |
$ 1,405,384
|
$ 1,399,444
|
X |
- Definition
+ References
+ Details
Name: |
QLGN_FixedAssetImpairments |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)
|
|
3 Months Ended |
6 Months Ended |
Mar. 31, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
Depreciation expense |
|
$ 19,000
|
$ 24,000
|
$ 37,000
|
$ 48,000
|
Payments to acquire assets |
|
|
|
$ 246,418
|
$ 63,483
|
Sekisui Distribution Agreement [Member] |
|
|
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
|
|
Payments to acquire assets |
$ 154,000
|
|
|
|
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1
+ Details
Name: |
us-gaap_Depreciation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=QLGN_SekisuiDistributionAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF GOODWILL AND OTHER INTANGIBLES (Details) - USD ($)
|
Jul. 20, 2023 |
Jun. 30, 2023 |
Dec. 31, 2022 |
Finite-Lived Intangible Assets [Line Items] |
|
|
|
Goodwill |
|
$ 625,602
|
$ 625,602
|
Finite lived intangible asset useful life |
5 years
|
|
|
Less: Accumulated amortization |
|
(764,869)
|
(752,237)
|
Total finite-lived intangible assets, net |
|
133,070
|
145,702
|
Total other intangible assets, net |
|
5,833,070
|
5,845,702
|
In Process Research and Development [Member] |
|
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
|
Total other intangible assets, net |
|
5,700,000
|
5,700,000
|
Developed-Product-Technology Rights [Member] |
|
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
|
Licensing rights |
|
$ 479,103
|
479,103
|
Developed-Product-Technology Rights [Member] | Minimum [Member] |
|
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
|
Finite lived intangible asset useful life |
|
8 years
|
|
Developed-Product-Technology Rights [Member] | Maximum [Member] |
|
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
|
Finite lived intangible asset useful life |
|
17 years
|
|
Licensing Rights [Member] |
|
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
|
Licensing rights |
|
$ 418,836
|
$ 418,836
|
Finite lived intangible asset useful life |
|
10 years
|
|
X |
- DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1
Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_Goodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph ((a)(1),(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1
+ Details
Name: |
us-gaap_IntangibleAssetsNetExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_DevelopedProductTechnologyRightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=QLGN_LicensingRightsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
GOODWILL, IPR&D AND OTHER INTANGIBLES (Details Narrative) - USD ($)
|
3 Months Ended |
6 Months Ended |
12 Months Ended |
|
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Jul. 20, 2023 |
Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
Goodwill, impairment loss |
|
|
|
|
$ 4,239,000
|
|
Impairment of intangible assets |
$ 0
|
$ 0
|
$ 0
|
$ 0
|
|
|
Accumulated amortization |
764,869
|
|
764,869
|
|
752,237
|
|
Estimated useful life |
|
|
|
|
|
5 years
|
Patents [Member] |
|
|
|
|
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
Finite lived intangible assets gross |
131,000
|
|
131,000
|
|
140,000
|
|
Accumulated amortization |
348,000
|
|
348,000
|
|
339,000
|
|
Amortization of intangible assets |
9,000
|
5,000
|
9,000
|
9,000
|
|
|
License [Member] |
|
|
|
|
|
|
Finite-Lived Intangible Assets [Line Items] |
|
|
|
|
|
|
Finite lived intangible assets gross |
2,000
|
|
2,000
|
|
5,000
|
|
Accumulated amortization |
417,000
|
|
417,000
|
|
$ 414,000
|
|
Amortization of intangible assets |
$ 3,000
|
$ 3,000
|
$ 3,000
|
$ 3,000
|
|
|
X |
- DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_AmortizationOfIntangibleAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetUsefulLife |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 928 -SubTopic 340 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5
+ Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482598/350-20-45-2
+ Details
Name: |
us-gaap_GoodwillImpairmentLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -SubTopic 30 -Topic 350 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Payables and Accruals [Abstract] |
|
|
Board compensation |
$ 84,000
|
$ 70,000
|
Equipment held for lease |
|
154,433
|
Franchise, sales and use taxes |
30,407
|
27,531
|
Income taxes |
6,921
|
4,663
|
Interest (Convertible debt - related party) |
50,101
|
2,829
|
License fees |
100,026
|
150,130
|
Payroll |
484,048
|
209,303
|
Professional fees |
368,032
|
238,211
|
Research and development |
523,490
|
322,987
|
Royalties |
16,383
|
13,158
|
Warranty liability |
140,370
|
137,568
|
Other |
176,777
|
181,043
|
Accrued expenses and other current liabilities |
$ 1,980,555
|
$ 1,511,856
|
X |
- DefinitionAccrued equipment held for lease.
+ References
+ Details
Name: |
QLGN_AccruedEquipmentHeldForLease |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAccrued franchise sales and use taxes.
+ References
+ Details
Name: |
QLGN_AccruedFranchiseSalesAndUseTaxes |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionResearch and development.
+ References
+ Details
Name: |
QLGN_AccruedResearchAndDevelopmentCurrent |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedPayrollTaxesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedProfessionalFeesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_AccruedRoyaltiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_OtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for estimated claims under standard and extended warranty protection rights granted to customers.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (c)(5) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ProductWarrantyAccrual |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
SHORT TERM DEBT-RELATED PARTY (Details Narrative) - USD ($)
|
17 Months Ended |
|
|
|
|
Sep. 02, 2021 |
Jun. 30, 2023 |
Jan. 12, 2023 |
Dec. 31, 2022 |
Dec. 22, 2022 |
Short-Term Debt [Line Items] |
|
|
|
|
|
Short term debt principal outstanding |
|
|
$ 1,111,078
|
|
|
Accrued interest |
|
$ 50,101
|
|
$ 2,829
|
|
Short term debt outstanding balance |
|
965,155
|
|
$ 950,722
|
|
Accrued interest rate |
|
|
|
|
8.00%
|
Notes Payable [Member] | Nano Synex Ltd [Member] |
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
Short term debt principal outstanding |
$ 905,000
|
|
|
|
|
Accrued interest |
|
60,155
|
|
|
|
Short term debt outstanding balance |
|
$ 965,155
|
|
|
|
Accrued interest rate |
2.62%
|
|
|
|
|
Proceeds from related party debt |
$ 3,000,000
|
|
|
|
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ShortTermBorrowings |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=QLGN_NotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF WARRANTS ACTIVITY (Details) - Series C Warrants [Member] - Common Stock Warrants [Member] - $ / shares
|
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Number of Shares, Warrants Outstanding Beginning |
3,849,571
|
248,161
|
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning |
$ 1.53
|
$ 7.20
|
Weighted Average Remaining Contractual Term |
3 years 10 months 24 days
|
|
Number of Shares, Warrants Exercised |
|
(536)
|
Weighted Average Exercise Price Per Share Warrants Exercised |
|
$ 7.20
|
Number of Shares, Warrants Forfeited |
|
(247,625)
|
Weighted Average Exercise Price Per Share Warrants Forfeited |
|
$ 7.20
|
Number of Shares, Warrants Expired |
|
|
Weighted Average Exercise Price Per Share Warrants Expired |
|
|
Number of Shares, Warrants Granted |
|
346,896
|
Weighted Average Exercise Price Per Share Warrants Granted |
|
$ 5.10
|
Number of Shares, Warrants Outstanding Ending |
3,849,571
|
346,896
|
Weighted Average Exercise Price Per Share Warrants Outstanding Ending |
$ 1.53
|
$ 5.10
|
Weighted Average Remaining Contractual Term |
3 years 4 months 28 days
|
2 years
|
Number of Shares, Warrants Exercisable |
3,849,571
|
346,896
|
Weighted Average Exercise Price Per Share Exercisable |
$ 1.53
|
$ 5.10
|
Range of Exercise Price, Exercisable |
|
$ 5.10
|
Exercisable Weighted Averag Remaining Contractual Term |
3 years 4 months 28 days
|
1 year 6 months 3 days
|
Minimum [Member] |
|
|
Range of Exercise Beginning |
$ 1.32
|
|
Range of Exercise Ending |
1.32
|
|
Range of Exercise Price, Exercisable |
1.32
|
|
Maximum [Member] |
|
|
Range of Exercise Beginning |
1.65
|
|
Range of Exercise Ending |
1.65
|
|
Range of Exercise Price, Exercisable |
$ 1.65
|
|
X |
- DefinitionRange of exercise price, exercisable (vested).
+ References
+ Details
Name: |
QLGN_RangeOfExercisePriceExercisableVested |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average exercise price per share exercisable (vested).
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average exercise price per share warrants exercised.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average exercise price per share warrants forfeited.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments outstanding exercisable weighted average remaining contractual term 2.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm2 |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of non-option equity outstanding and currently nonvested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNonExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of non-option equity instruments exercised by participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares under non-option equity instrument agreements for which rights to exercise lapsed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(4) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of non-option equity instruments granted to participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=QLGN_CommonStockWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details) - USD ($)
|
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Platform Operator, Crypto-Asset [Line Items] |
|
|
Fair value for warrant liabilities, beginning balance |
$ 3,622,647
|
|
Common Stock Warrant liabilities, Exercises |
|
$ (858)
|
Change in fair value of warrant liabilities |
(1,478,967)
|
|
Fair value for warrant liabilities, ending balance |
2,143,680
|
|
Fair Value, Inputs, Level 1 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Fair value for warrant liabilities, beginning balance |
|
|
Common Stock Warrant liabilities, Exercises |
|
|
Change in fair value of warrant liabilities |
|
|
Fair value for warrant liabilities, ending balance |
|
|
Fair Value, Inputs, Level 2 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Fair value for warrant liabilities, beginning balance |
|
|
Common Stock Warrant liabilities, Exercises |
|
|
Change in fair value of warrant liabilities |
|
|
Fair value for warrant liabilities, ending balance |
|
|
Fair Value, Inputs, Level 3 [Member] |
|
|
Platform Operator, Crypto-Asset [Line Items] |
|
|
Fair value for warrant liabilities, beginning balance |
3,622,647
|
|
Common Stock Warrant liabilities, Exercises |
|
|
Change in fair value of warrant liabilities |
(1,478,967)
|
|
Fair value for warrant liabilities, ending balance |
$ 2,143,680
|
|
X |
- DefinitionChange in fair value of warrant liabilities.
+ References
+ Details
Name: |
QLGN_ChangeInFairValueOfWarrantLiabilities |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ References
+ Details
Name: |
QLGN_FairValueAdjustmentOfWarrant |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFair value of warrant liabilities on date of exercise.
+ References
+ Details
Name: |
QLGN_FairValueOfWarrantLiabilitiesOnDateOfExercise |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.23.2
SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)
|
Jun. 30, 2023 |
Jun. 30, 2022 |
Measurement Input, Expected Dividend Rate [Member] |
|
|
Fair value assumptions, measurement input, percentages |
0.00
|
0.00
|
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
|
Fair value assumptions, measurement input, percentages |
4.05
|
2.80
|
Minimum [Member] | Measurement Input, Price Volatility [Member] |
|
|
Fair value assumptions, measurement input, percentages |
66.3
|
74
|
Minimum [Member] | Measurement Input, Expected Term [Member] |
|
|
Fair value assumptions, measurement input, term |
4 months 20 days
|
1 year 4 months 20 days
|
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
|
Fair value assumptions, measurement input, percentages |
5.31
|
2.87
|
Maximum [Member] | Measurement Input, Price Volatility [Member] |
|
|
Fair value assumptions, measurement input, percentages |
134
|
96
|
Maximum [Member] | Measurement Input, Expected Term [Member] |
|
|
Fair value assumptions, measurement input, term |
4 years 11 months 23 days
|
1 year 11 months 26 days
|
Weighted Average [Member] | Measurement Input, Risk Free Interest Rate [Member] |
|
|
Fair value assumptions, measurement input, percentages |
4.49
|
2.82
|
Weighted Average [Member] | Measurement Input, Price Volatility [Member] |
|
|
Fair value assumptions, measurement input, percentages |
110.55
|
78.6
|
Weighted Average [Member] | Measurement Input, Expected Term [Member] |
|
|
Fair value assumptions, measurement input, term |
3 years 4 months 28 days
|
1 year 6 months 3 days
|
Weighted Average [Member] | Measurement Input, Expected Dividend Rate [Member] |
|
|
Fair value assumptions, measurement input, percentages |
0.00
|
0.00
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_WeightedAverageMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
WARRANT LIABILITIES (Details Narrative) - $ / shares
|
Dec. 22, 2022 |
May 26, 2022 |
Apr. 25, 2022 |
Jun. 30, 2023 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Exercise price of warrant |
|
|
|
|
$ 13.20
|
$ 40.70
|
Warrant to purchase shares |
|
|
|
|
60,000
|
|
Minimum [Member] | Series C Warrants [Member] |
|
|
|
|
|
|
Exercise price of warrant |
$ 1.32
|
$ 5.136
|
$ 6.00
|
|
|
|
Warrants and rights outstanding term |
|
|
|
4 months 24 days
|
|
|
Maximum [Member] | Series C Warrants [Member] |
|
|
|
|
|
|
Exercise price of warrant |
$ 5.136
|
$ 6.00
|
$ 7.195
|
|
|
|
Warrants and rights outstanding term |
|
|
|
11 months 26 days
|
|
|
Series C Warrants [Member] |
|
|
|
|
|
|
Exercise price of warrant |
|
|
|
$ 7.195
|
|
|
Warrants issued |
1,002,717
|
49,952
|
49,318
|
|
|
|
Warrants forfeited |
|
247,625
|
|
|
|
|
Warrants reissued |
|
346,896
|
|
|
|
|
Series C Warrants [Member] | Alpha Capital [Member] |
|
|
|
|
|
|
Exercise price of warrant |
$ 1.65
|
|
|
|
|
|
Warrant to purchase shares |
2,500,000
|
|
|
|
|
|
Conversion price percentage |
125.00%
|
|
|
|
|
|
X |
- DefinitionConversion price percentage.
+ References
+ Details
Name: |
QLGN_ConversionPricePercentage |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of non-vested options forfeited.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPeriod between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2
+ Details
Name: |
us-gaap_WarrantsAndRightsOutstandingTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=QLGN_SeriesCWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF SENIOR SECURED CONVERTIBLE DEBT (Details) - USD ($)
|
Jun. 30, 2023 |
Dec. 31, 2022 |
Short-Term Debt [Line Items] |
|
|
Total convertible debt-related party |
$ 812,419
|
$ 60,197
|
Senior Secured Convertible Debt [Member] |
|
|
Short-Term Debt [Line Items] |
|
|
Senior secured convertible debenture |
2,078,922
|
3,300,000
|
Discount on convertible debenture |
(1,266,503)
|
(3,239,803)
|
Total convertible debt-related party |
$ 812,419
|
$ 60,197
|
X |
- DefinitionIncluding the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_ConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount, after accumulated amortization, of debt discount.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_SecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=QLGN_SeniorSecuredConvertibleDebtMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
CONVERTIBLE DEBT- RELATED PARTY (Details Narrative) - USD ($)
|
|
|
3 Months Ended |
6 Months Ended |
|
|
|
|
Jan. 12, 2023 |
Dec. 22, 2022 |
Jun. 30, 2023 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 30, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Conversion price |
$ 1.32
|
|
|
|
|
|
|
|
|
Warrant to purchase shares |
|
|
|
|
|
|
|
60,000
|
|
Exercise price of warrant |
|
|
|
|
|
|
|
$ 13.20
|
$ 40.70
|
Debenture accrues interest rate |
|
8.00%
|
|
|
|
|
|
|
|
Shares of Common stock, issued |
|
|
5,052,463
|
5,052,463
|
|
4,210,737
|
|
|
|
Debt discount amortization |
|
|
$ 364,000
|
$ 898,000
|
|
|
|
|
|
Fair value of warrants |
|
|
|
(1,478,967)
|
$ (698,042)
|
|
|
|
|
Shares of common stock |
841,726
|
|
|
|
|
|
|
|
|
Debenture voluntarily converted |
$ 1,111,078
|
|
|
|
|
|
|
|
|
Debt conversion of convertible debt |
$ 1,100,000
|
|
|
|
|
|
|
|
|
Accrued interest |
|
|
383,000
|
945,000
|
|
|
|
|
|
Fair value of warrants |
|
|
2,000,000.0
|
2,000,000.0
|
|
|
|
|
|
Derivative fair value of warrants |
|
|
$ 0
|
$ 0
|
|
|
|
|
|
Alpha Capital [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Beneficial ownership percentage |
|
9.99%
|
|
|
|
|
|
|
|
Shares of Common stock, issued |
|
|
|
|
|
|
5,157,087
|
|
|
Series C Warrants [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Exercise price of warrant |
|
|
$ 7.195
|
$ 7.195
|
|
|
|
|
|
Senior Convertible Debenture [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Principal amount percentage |
|
105.00%
|
|
|
|
|
|
|
|
Alpha Capital [Member] | Series C Warrants [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Warrant to purchase shares |
|
2,500,000
|
|
|
|
|
|
|
|
Exercise price of warrant |
|
$ 1.65
|
|
|
|
|
|
|
|
Conversion price percentage |
|
125.00%
|
|
|
|
|
|
|
|
Alpha Capital [Member] | Senior Convertible Debenture [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Senior convertible debenture rate |
|
8.00%
|
|
|
|
|
|
|
|
Principal amount |
|
$ 3,300,000
|
|
|
|
|
|
|
|
Purchase Price |
|
$ 3,000,000
|
|
|
|
|
|
|
|
Conversion price |
|
$ 1.32
|
|
|
|
|
|
|
|
Alpha Capital Other Third Parties [Member] |
|
|
|
|
|
|
|
|
|
Short-Term Debt [Line Items] |
|
|
|
|
|
|
|
|
|
Debt discount amortization |
|
|
|
$ 300,000
|
|
|
|
|
|
Fair value of warrants |
|
|
|
2,800,000
|
|
|
|
|
|
Fair value of embedded derivative features |
|
|
$ 0
|
0
|
|
|
|
|
|
Fees and costs paid |
|
|
|
$ 100,000
|
|
|
|
|
|
X |
- DefinitionConversion price percentage.
+ References
+ Details
Name: |
QLGN_ConversionPricePercentage |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFair value adjustments of warrant.
+ References
+ Details
Name: |
QLGN_FairValueAdjustmentsOfWarrant |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionPrincipal amount percentage.
+ References
+ Details
Name: |
QLGN_PrincipalAmountPercentage |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock issued as dividends during the period. Excludes stock splits.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_CommonStockDividendsShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFair value of the assets less the liabilities of a derivative or group of derivatives.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10
+ Details
Name: |
us-gaap_DerivativeFairValueOfDerivativeNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionNet fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as assets, net of those classified as liabilities.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 5 -SubTopic 10 -Topic 815 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480463/815-10-45-5
+ Details
Name: |
us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_SecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPercentage increase in the stated interest rate on a short-term debt instrument.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtInterestRateIncrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=QLGN_AlphaCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=QLGN_AlphaCapitalOtherThirdPartiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares
|
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total common stock equivalents |
4,565,097
|
1,889,121
|
Shares of Common Stock Subject to Outstanding Options [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total common stock equivalents |
445,163
|
476,783
|
Shares of Common Stock Subject to Outstanding Warrants [Member] |
|
|
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
Total common stock equivalents |
4,119,934
|
1,412,338
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=QLGN_SharesOfCommonStockSubjectToOutstandingOptionsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=QLGN_SharesOfCommonStockSubjectToOutstandingWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details) - USD ($)
|
6 Months Ended |
|
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
Operating lease right-of-use assets |
$ 1,422,538
|
|
|
Less amortization of operating lease right-of-use assets |
(116,567)
|
$ (109,803)
|
|
Operating lease right-of-use assets |
1,305,970
|
|
|
Lease liabilities at December 31, 2022 |
1,425,808
|
|
|
Less non-current portion |
(1,168,653)
|
|
$ (1,301,919)
|
Current portion at Decebmer 31, 2022 |
257,155
|
|
$ 240,645
|
Long term Operating Lease Agreement [Member] |
|
|
|
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |
|
|
|
Operating lease right-of-use assets |
1,422,538
|
|
|
Less amortization of operating lease right-of-use assets |
(116,568)
|
|
|
Operating lease right-of-use assets |
1,305,970
|
|
|
Lease liabilities at December 31, 2021 |
1,542,564
|
|
|
Less principal payments on operating lease liabilities |
(116,756)
|
|
|
Lease liabilities at December 31, 2022 |
1,425,808
|
|
|
Less non-current portion |
(1,168,653)
|
|
|
Current portion at Decebmer 31, 2022 |
$ 257,155
|
|
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1
+ Details
Name: |
us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiabilityNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeasePayments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of lessee's right to use underlying asset under operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAsset |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=QLGN_LongtermOperatingLeaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)
|
Jun. 30, 2023
USD ($)
|
Commitments and Contingencies Disclosure [Abstract] |
|
2023 (six months) |
$ 184,171
|
2024 |
379,392
|
2025 |
390,773
|
2026 |
402,497
|
2027 |
379,164
|
Total |
1,735,997
|
Less present value discount |
(310,189)
|
Operating lease liabilities |
$ 1,425,808
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6
+ Details
Name: |
us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1
+ Details
Name: |
us-gaap_OperatingLeaseLiability |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
v3.23.2
COMMITMENTS AND CONTINGENCIES (Details Narrative)
|
|
|
|
3 Months Ended |
6 Months Ended |
|
|
|
Jul. 20, 2023
USD ($)
$ / shares
|
Apr. 05, 2022
USD ($)
|
Dec. 15, 2021
USD ($)
ft²
|
Jun. 30, 2023
USD ($)
|
Jun. 30, 2022
USD ($)
|
Jun. 30, 2023
USD ($)
|
Jun. 30, 2022
USD ($)
|
Mar. 31, 2024
USD ($)
|
Nov. 30, 2023
USD ($)
|
Jan. 12, 2023
USD ($)
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
Area of land | ft² |
|
|
22,624
|
|
|
|
|
|
|
|
Operating lease term |
|
|
61 months
|
|
|
|
|
|
|
|
Operating lease term description |
|
|
November 1, 2022 to November 30, 2027
|
|
|
|
|
|
|
|
Payments for Rent |
|
|
$ 1,950,710
|
|
|
|
|
|
|
|
Tenant improvement allowance |
|
|
339,360
|
|
|
|
|
|
|
|
Weighted-average remaining lease term |
|
|
|
4 years 3 months 18 days
|
|
4 years 3 months 18 days
|
|
|
|
|
Weighted-average discount rate |
|
|
|
8.90%
|
|
8.90%
|
|
|
|
|
Operating lease expense |
|
|
|
$ 114,000
|
$ 119,000
|
$ 230,000
|
$ 233,000
|
|
|
|
Aggregrate amount |
|
|
|
|
|
|
|
|
|
$ 1,111,078
|
Litigation Settlement, Amount Awarded to Other Party |
|
$ 96,558
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
Sale of Stock, Price Per Share | $ / shares |
$ 1.5716
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Amendment and Settlement Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
Aggregrate amount |
$ 380,000
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Amendment and Settlement Agreement [Member] | NanoSynex Ltd [Member] |
|
|
|
|
|
|
|
|
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
Aggregrate amount |
$ 1,610,000
|
|
|
|
|
|
|
$ 670,000
|
$ 560,000
|
|
NanoSynex Ltd [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business acquisition, description of acquired entity |
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
|
|
|
|
|
|
|
|
|
|
First 12 Months [Member] |
|
|
|
|
|
|
|
|
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] |
|
|
|
|
|
|
|
|
|
|
Payments for Rent |
|
|
$ 335,966
|
|
|
|
|
|
|
|
X |
- DefinitionTenant improvement allowance.
+ References
+ Details
Name: |
QLGN_TenantImprovementAllowance |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionWith respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionDescription of lessee's operating lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3
+ Details
Name: |
us-gaap_LesseeOperatingLeaseDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3
+ Details
Name: |
us-gaap_LesseeOperatingLeaseTermOfContract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount awarded to other party in judgment or settlement of litigation.
+ References
+ Details
Name: |
us-gaap_LitigationSettlementAmountAwardedToOtherParty |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of operating lease expense. Excludes sublease income.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4
+ Details
Name: |
us-gaap_OperatingLeaseExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionWeighted average discount rate for operating lease calculated at point in time.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4
+ Details
Name: |
us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionCash payments to lessor's for use of assets under operating leases.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25
+ Details
Name: |
us-gaap_PaymentsForRent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=QLGN_AmendmentAndSettlementAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=QLGN_NanoSynexLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=QLGN_FirstTwelveMonthsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)
|
1 Months Ended |
3 Months Ended |
6 Months Ended |
13 Months Ended |
47 Months Ended |
|
Mar. 31, 2022 |
Jan. 31, 2022 |
Feb. 28, 2021 |
Nov. 30, 2020 |
Jul. 31, 2020 |
Jun. 30, 2020 |
Mar. 31, 2019 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2023 |
Apr. 30, 2022 |
Dec. 31, 2021 |
Proceeds from convertible debt |
|
|
|
|
|
|
|
|
|
|
|
$ 3.0
|
|
|
Research and development expense |
|
|
|
|
|
|
|
$ 1,326,544
|
$ 1,506,227
|
$ 3,448,095
|
$ 3,370,972
|
|
|
|
Revenue from contract with customer excluding assessed tax |
|
|
|
|
|
|
|
1,627,031
|
1,430,534
|
3,234,201
|
2,152,563
|
|
|
|
Yi Xin Zhen Duan Jishu Ltd [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred revenue |
|
|
|
|
|
|
|
0
|
0
|
0
|
0
|
|
|
$ 670,000
|
Prediction Biosciences SAS [Member] | Product [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue from contract with customer excluding assessed tax |
|
|
|
|
|
|
|
0
|
|
86,000
|
0
|
|
|
|
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from convertible debt |
|
|
|
|
|
|
|
|
|
|
|
|
$ 50,000
|
|
Reimbursement of research expenses |
|
|
|
|
|
|
|
|
|
|
|
|
805,000
|
|
Patent costs |
|
|
|
|
|
|
|
|
|
|
|
|
$ 200,000
|
|
Agreement term payment description |
|
|
|
|
|
|
|
|
|
|
|
|
In addition, the Company agreed to pay ULRF
(i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of
4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last
to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the
first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement,
and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs
associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments
ranging from $100,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.
|
|
Marketing approval expenses |
|
|
|
|
|
|
|
|
|
|
|
|
$ 500,000
|
|
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative sales |
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
5,000,000
|
|
Regulatory marketing approval, expenses |
|
|
|
|
|
|
|
|
|
|
|
|
500,000
|
|
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
50,000
|
|
|
|
|
|
|
|
100,000
|
|
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
100,000
|
|
|
|
|
|
|
|
200,000
|
|
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
150,000
|
|
|
|
|
|
|
|
350,000
|
|
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
50,000
|
|
|
|
|
|
|
|
100,000
|
|
Shortfall payments |
|
|
|
|
|
|
|
|
|
|
|
|
10,000
|
|
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
$ 5,000,000
|
|
|
|
|
|
|
|
5,000,000
|
|
Shortfall payments |
|
|
|
|
|
|
|
|
|
|
|
|
50,000
|
|
Sponsored Research and License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expense |
|
|
|
|
|
|
|
0
|
77,000
|
0
|
164,000
|
|
|
|
License cost |
|
|
|
|
|
|
|
1,000
|
14,000
|
29,000
|
18,000
|
|
|
|
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reimbursement of research expenses |
$ 2,700,000
|
|
$ 2,700,000
|
|
|
|
$ 693,000
|
|
|
|
|
|
|
|
Agreement term payment description |
|
|
|
|
In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor
drug candidates. Under the agreement, the Company took over development, regulatory approval and commercialization of the candidates
from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000
for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on
patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales
above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed
Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF
license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted
in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to July 2020,
|
|
|
|
|
|
|
|
|
|
Marketing approval expenses |
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
|
|
|
Revenue |
|
|
|
|
500,000,000
|
|
|
|
|
|
|
|
$ 500,000,000
|
|
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Upfront license fee |
|
|
|
|
20,000
|
|
|
|
|
|
|
|
|
|
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Upfront license fee |
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
Sponsored Research Agreements And License [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development expense |
|
|
|
|
|
|
|
333,000
|
220,000
|
556,000
|
405,000
|
|
|
|
License cost |
|
|
|
|
|
|
|
15,000
|
16,000
|
22,000
|
69,000
|
|
|
|
License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
License cost |
|
|
|
|
|
|
|
$ 0
|
$ 0
|
$ 0
|
$ 310,000
|
|
|
|
Reimbursement of patent |
|
$ 160,000
|
|
|
|
|
|
|
|
|
|
|
|
|
License Agreement [Member] | Upfront Payment [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reimbursement of patent |
|
$ 150,000
|
|
|
|
|
|
|
|
|
|
|
|
|
License Agreement [Member] | University of Louisville Research Foundation [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Agreement term payment description |
|
|
|
|
|
the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated
with the commercialization of QN-165 as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net
sales above a cumulative $250,000,000), until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by
Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years
of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses
granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation,
filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000
upon the achievement of certain regulatory and commercial milestones.
|
|
|
|
|
|
|
|
|
Marketing approval expenses |
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
|
|
Revenue |
|
|
|
|
|
500,000,000
|
|
|
|
|
|
|
|
|
Upfront license fee |
|
|
|
|
|
24,000
|
|
|
|
|
|
|
|
|
License Agreement [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative sales |
|
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
License Agreement [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
License Agreement [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
|
100,000
|
|
|
|
|
|
|
|
|
License Agreement [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
|
150,000
|
|
|
|
|
|
|
|
|
License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
Research and development expense |
|
|
|
$ 430,000
|
|
250,000
|
|
|
|
|
|
|
|
|
Upfront license fee |
|
|
|
|
|
5,000
|
|
|
|
|
|
|
|
|
License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Milestone payment |
|
|
|
|
|
5,000,000
|
|
|
|
|
|
|
|
|
Upfront license fee |
|
|
|
|
|
$ 50,000
|
|
|
|
|
|
|
|
|
X |
- DefinitionAgreement term payment, description.
+ References
+ Details
Name: |
QLGN_AgreementTermPaymentDescription |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRegulatory marketing approval, expenses.
+ References
+ Details
Name: |
QLGN_RegulatoryMarketingApprovalExpenses |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRegulatory marketing approval expenses one.
+ References
+ Details
Name: |
QLGN_RegulatoryMarketingApprovalExpensesOne |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
QLGN_ReimbursementOfPatent |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionReimbursement of research expenses.
+ References
+ Details
Name: |
QLGN_ReimbursementOfResearchExpenses |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
+ Details
Name: |
us-gaap_ProceedsFromConvertibleDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4
+ Details
Name: |
us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
dei_LegalEntityAxis=QLGN_YiXinZhenDuanJishuLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=QLGN_PredictionBiosciencesSASMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=us-gaap_ProductMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=QLGN_UniversityOfLouisvilleResearchFoundationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_ProductOrServiceAxis=QLGN_LicensedProductSalesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=QLGN_PhaseOneClinicalTrialMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=QLGN_PhaseTwoClinicalTrialMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=QLGN_PhaseThreeClinicalTrialMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=QLGN_LicenseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=QLGN_UpfrontPaymentMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
X |
- DefinitionAggregate number of common shares reserved for future issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockCapitalSharesReservedForFutureIssuance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_StockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares
|
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending |
1 year 5 months 19 days
|
|
Employees and Non-employee Service Provider [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Number of shares, options outstanding, beginning |
608,012
|
484,186
|
Range of Exercise price, Options Outstanding |
$ 35.02
|
$ 60.70
|
Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning |
8 years 1 month 2 days
|
8 years 6 months 7 days
|
Number of shares, options granted |
|
2,500
|
Weighted average exercise price, options granted |
|
$ 10.50
|
Number of shares, options expired |
|
(9,386)
|
Weighted average exercise price, options expired |
|
$ 935.90
|
Number of shares, options forfeited |
(162,849)
|
(517)
|
Weighted average exercise price, options forfeited |
$ 36.01
|
$ 35.10
|
Number of Shares, Options Outstanding at Ending |
445,163
|
476,783
|
Range of Exercise price, Options Outstanding |
$ 34.68
|
$ 43.30
|
Weighted- Average Remaining Contractual Life (in Years), Outstanding at Ending |
7 years 7 months 2 days
|
8 years 2 months 8 days
|
Number of shares, options exercisable (vested) |
323,355
|
264,366
|
Range of exercise price, options exercisable (vested) |
$ 44.79
|
$ 48.40
|
Weighted- Average Remaining Contractual Life (in Years), Options Exercisable (vested) |
7 years 1 month 17 days
|
8 years
|
Number of shares, options non-exercisable (non-vested) |
121,808
|
212,417
|
Weighted average exercise price, options non-exercisable (non-vested) |
$ 7.83
|
$ 36.80
|
Weighted- Average Remaining Contractual Life (in Years), Options Non-exercisable (non-vested) |
8 years 10 months 6 days
|
8 years 5 months 23 days
|
Range of Exercise price, Options Outstanding |
|
$ 10.50
|
Weighted- Average Remaining Contractual Life (in Years), Options Granted |
|
9 years 6 months 14 days
|
Employees and Non-employee Service Provider [Member] | Minimum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Range of Exercise price, Options Outstanding |
$ 5.14
|
$ 12.40
|
Range of Exercise price, Options Forfeited |
5.14
|
12.40
|
Range of Exercise price, Options Outstanding |
5.14
|
10.50
|
Range of exercise price, options exercisable (vested) |
5.14
|
12.40
|
Range of exercise price, options non-exercisable (non-vested) |
5.14
|
10.50
|
Range of Exercise price, Options Outstanding |
|
57.50
|
Employees and Non-employee Service Provider [Member] | Maximum [Member] |
|
|
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] |
|
|
Range of Exercise price, Options Outstanding |
51.30
|
14,657.50
|
Range of Exercise price, Options Forfeited |
51.30
|
49.70
|
Range of Exercise price, Options Outstanding |
51.30
|
51.30
|
Range of exercise price, options exercisable (vested) |
51.30
|
50.13
|
Range of exercise price, options non-exercisable (non-vested) |
$ 35.20
|
51.30
|
Range of Exercise price, Options Outstanding |
|
$ 14,657.50
|
X |
- DefinitionShare based compensation arrangement by share based payment award option expired weighted average exercise price.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpiredWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award option granted weighted average exercise price.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionGrantedWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average exercise price, options non-exercisable (non-vested).
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToNonVestExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted- Average Remaining Contractual Life (in Years), Options Granted.
+ References
+ Details
Name: |
QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.
+ References
+ Details
Name: |
QLGN_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted- average remaining contractual life (in years), options non-exercisable (non-vested).
+ References
+ Details
Name: |
QLGN_WeightedAverageRemainingContractualLifeInYearsOptionsNonexercisableNonvested |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
+ Details
Name: |
us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price of options that were either forfeited or expired.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of share options (or share units) granted during the period.
+ ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-vested options outstanding.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average grant-date fair value of non-vested options outstanding.
+ References
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=QLGN_EmployeesAndNonemployeeServiceProviderMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
X |
- References
+ Details
Name: |
us-gaap_EquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe maximum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe minimum risk-free interest rate assumption that is used in valuing an option on its own shares.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExpected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.23.2
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)
|
6 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Total |
$ 906,145
|
$ 2,690,447
|
General and Administrative Expense [Member] |
|
|
Total |
807,980
|
2,329,418
|
Research and Development Expense [Member] |
|
|
Total |
$ 98,165
|
$ 361,029
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SCHEDULE OF WARRANT ACTIVITY (Details) - $ / shares
|
6 Months Ended |
12 Months Ended |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Non Compensatory Warrant Activity [Member] |
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
Number of Shares, Warrants Outstanding Beginning |
547,003
|
554,914
|
554,914
|
|
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning |
$ 19.76
|
$ 20.10
|
$ 20.10
|
|
Weighted average remaining life (Years) exercisable |
|
|
3 months 29 days
|
|
Number of shares, warrants granted |
|
331,464
|
|
|
Weighted average exercise price per share warrants granted |
|
$ 0.01
|
|
|
Number of Shares, Warrants Exercised |
|
|
|
|
Weighted average exercise price per share warrants exercised |
|
|
|
|
Number of Shares, Warrants Expired |
(455,685)
|
|
|
|
Weighted average exercise price per share warrants expired |
$ 20.00
|
|
|
|
Number of Shares, Warrants Forfeited |
|
|
|
|
Weighted average exercise price per share warrants forfeited |
|
|
|
|
Number of Shares, Warrants Outstanding Ending |
91,318
|
886,378
|
547,003
|
554,914
|
Weighted Average Exercise Price Per Share Warrants Outstanding Ending |
$ 18.56
|
$ 12.60
|
$ 19.76
|
$ 20.10
|
Number of Shares, Warrants Exercisable |
91,318
|
886,378
|
|
|
Weighted Average Exercise Price Per Share Exercisable |
$ 18.56
|
$ 12.60
|
|
|
Weighted average remaining life (Years) exercisable |
6 months 29 days
|
9 months 25 days
|
|
|
Number of shares legal ritter warrants |
|
|
|
|
Weighted average exercise price per share warrants expired |
$ 20.00
|
|
|
|
Number of Shares, Warrants Exercisable |
|
|
|
|
Weighted Average Exercise Price Per Share Exercisable |
|
|
|
|
Range of exercise price, granted |
|
0.01
|
|
|
Minimum [Member] | Non Compensatory Warrant Activity [Member] |
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
Range of exercise price |
1.32
|
|
|
|
Range of exercise price - ending |
|
|
1.32
|
|
Range of exercise price - Exercisable |
1.32
|
0.01
|
|
|
Maximum [Member] | Non Compensatory Warrant Activity [Member] |
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
Range of exercise price |
20.00
|
|
|
|
Range of exercise price - ending |
|
|
$ 20.00
|
|
Range of exercise price - Exercisable |
$ 20.00
|
$ 37.70
|
|
|
Compensatory Warrant Activity [Member] |
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
Number of Shares, Warrants Outstanding Beginning |
179,046
|
179,065
|
179,065
|
|
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning |
$ 9.12
|
$ 15.20
|
$ 15.20
|
|
Weighted average remaining life (Years) exercisable |
1 year 2 months 26 days
|
2 years 2 months 23 days
|
1 year 8 months 23 days
|
2 years 7 months 20 days
|
Number of shares, warrants granted |
|
|
|
|
Weighted average exercise price per share warrants granted |
|
|
|
|
Number of Shares, Warrants Exercised |
|
|
|
|
Weighted average exercise price per share warrants exercised |
|
|
|
|
Number of Shares, Warrants Expired |
|
|
|
|
Weighted average exercise price per share warrants expired |
|
|
|
|
Number of Shares, Warrants Forfeited |
|
|
|
|
Weighted average exercise price per share warrants forfeited |
|
|
|
|
Number of Shares, Warrants Outstanding Ending |
179,046
|
179,065
|
179,046
|
179,065
|
Weighted Average Exercise Price Per Share Warrants Outstanding Ending |
$ 9.12
|
$ 10.60
|
$ 9.12
|
$ 15.20
|
Number of Shares, Warrants Exercisable |
179,046
|
179,065
|
|
|
Weighted Average Exercise Price Per Share Exercisable |
$ 9.12
|
$ 10.60
|
|
|
Weighted average remaining life (Years) exercisable |
1 year 2 months 26 days
|
2 years 2 months 23 days
|
|
|
Number of shares, warrants non-exercisable |
|
|
|
|
Weighted Average Exercise Price Per Share Non-Exercisable |
|
|
|
|
Range of Exercise Price, Non-Exercisable |
|
|
|
|
Compensatory Warrant Activity [Member] | Minimum [Member] |
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
Range of exercise price |
1.32
|
11.10
|
11.10
|
|
Range of exercise price - ending |
1.32
|
5.14
|
1.32
|
11.10
|
Range of exercise price - Exercisable |
1.32
|
5.14
|
|
|
Compensatory Warrant Activity [Member] | Maximum [Member] |
|
|
|
|
Accumulated Other Comprehensive Income (Loss) [Line Items] |
|
|
|
|
Range of exercise price |
25.40
|
25.40
|
25.40
|
|
Range of exercise price - ending |
25.40
|
25.40
|
$ 25.40
|
$ 25.40
|
Range of exercise price - Exercisable |
$ 25.40
|
$ 25.40
|
|
|
X |
- DefinitionRange of exercise price exercisable granted.
+ References
+ Details
Name: |
QLGN_RangeOfExercisePriceExercisableGranted |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionRange of exercise price, exercisable (vested).
+ References
+ Details
Name: |
QLGN_RangeOfExercisePriceExercisableVested |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionRange of exercise price, non-exercisable (non-vested).
+ References
+ Details
Name: |
QLGN_RangeOfExercisePriceNonexercisableNonvested |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionRange Of Exercise Price Outstanding.
+ References
+ Details
Name: |
QLGN_RangeOfExercisePriceOutstanding |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares, warrants non-exercisable (non-vested).
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNonVestedNumber |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares into which fully or partially vestednon-option equity outstanding as of the balance sheet date can be currently converted under the non-option equity plan.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average exercise price per share non-exercisable (non-vested).
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageNonVestedExercise |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average exercise price per share exercisable (vested).
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments exercisable weighted average vested non exercise price
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageVestedNonExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average exercise price per share warrants exercised.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments expired in period weighted average exercise price.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments expired in range of exercise price.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredInRangeOfExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average exercise price per share warrants forfeited.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments exercised in period weighted average common stock warrants reverse recapitalization.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments legal ritter warrants.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsLegalRitterWarrants |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments non exercisable number
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsNonExercisableNumber |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for vested portions of non-option equity outstanding and currently vested exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingExercisableWeightedAveragRemainingContractualTerm1 |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionShare based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price one.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAveragRemainingContractualTerm1 |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock non-option equity plan.
+ References
+ Details
Name: |
QLGN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20
+ Details
Name: |
us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of non-option equity instruments exercised by participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(2) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares under non-option equity instrument agreements for which rights to exercise lapsed.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(4) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(3) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNet number of non-option equity instruments granted to participants.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(1) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of equity instruments other than options outstanding, including both vested and non-vested instruments.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=QLGN_NonCompensatoryWarrantActivityMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
|
|
|
|
|
|
1 Months Ended |
6 Months Ended |
12 Months Ended |
|
|
|
|
|
|
|
Jul. 20, 2023 |
Jan. 12, 2023 |
Dec. 22, 2022 |
May 26, 2022 |
Apr. 25, 2022 |
Dec. 31, 2020 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Dec. 31, 2021 |
Dec. 31, 2022 |
May 31, 2022 |
Nov. 29, 2021 |
Aug. 31, 2020 |
Jul. 31, 2020 |
May 31, 2020 |
Dec. 31, 2017 |
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price |
|
$ 1.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
|
|
|
|
60,000
|
|
|
|
|
|
|
|
Debenture voluntarily converted |
|
$ 1,111,078
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares of common stock |
|
841,726
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan shares available |
|
|
|
|
|
|
4,565,097
|
|
|
|
|
|
|
|
|
|
Compensation cost |
$ 5,800,000
|
|
|
|
|
|
$ 906,145
|
$ 2,690,447
|
|
|
|
|
|
|
|
|
Unrecognized compensation cost |
|
|
|
|
|
|
$ 500,000
|
|
|
|
|
|
|
|
|
|
Cost is expected to be recognized over a weighted average period |
|
|
|
|
|
|
1 year 5 months 19 days
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
|
219,101
|
|
|
|
|
|
|
|
|
|
|
Class of warrant or right, exercise |
|
|
|
|
|
$ 40.70
|
|
|
$ 13.20
|
|
|
|
|
|
|
|
Fair value of issuance cost |
|
|
|
|
|
|
|
|
$ 300,000
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
$ (1,478,967)
|
(698,042)
|
|
|
|
|
|
|
|
|
Compensation cost |
|
|
|
|
|
|
906,145
|
2,690,447
|
|
|
|
|
|
|
|
|
Nano Synex Ltd [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
7,048
|
|
|
|
|
|
|
|
|
|
|
|
Class of warrant or right, exercise |
|
|
$ 1.32
|
$ 5.136
|
$ 11.10
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
$ 891
|
$ 696
|
$ 2,533
|
|
|
|
|
|
|
|
|
|
|
|
Modified to exercise price |
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation cost |
|
|
|
|
|
|
807,980
|
2,329,418
|
|
|
|
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
60,000
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
67,620
|
67,619
|
67,619
|
|
|
|
|
|
|
|
|
|
|
|
Class of warrant or right, exercise |
|
|
|
|
$ 6.00
|
|
|
|
|
|
|
|
|
|
|
|
Reverse stock split, price per share |
|
|
|
|
$ 13.20
|
|
|
|
|
|
|
|
|
|
|
|
Warrants extended date description |
|
|
|
|
June 3, 2023 to September 14, 2023
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
$ 8,548
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of warrant or right, exercise |
|
|
$ 5.136
|
$ 11.10
|
$ 11.10
|
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of warrant or right, exercise |
|
|
$ 1.32
|
$ 5.136
|
$ 5.136
|
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] | General and Administrative Expense [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
|
$ 67,370
|
|
|
|
|
|
|
|
|
|
|
|
Additional Paid-in Capital [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair value adjustment of warrants |
|
|
|
$ 31,010
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensatory Warrant Activity [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation cost |
|
|
|
|
|
|
$ 0
|
67,370
|
|
|
|
|
|
|
|
|
Equity Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan shares available |
|
|
|
|
|
|
445,163
|
|
|
|
|
|
|
|
|
|
Equity Option [Member] | 2020 Stock Incentive Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plan shares available |
|
|
|
|
|
|
310,539
|
|
|
147,690
|
|
|
|
|
|
|
Options outstanding |
|
|
|
|
|
|
445,163
|
|
|
608,012
|
|
|
|
|
|
|
Share-Based Compensation Arrangement by Share-Based Payment Award, Description |
|
|
|
|
|
|
The
exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive
stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair
market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share
on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the
date of grant
|
|
|
|
|
|
|
|
|
|
Share-Based Payment Arrangement, Option [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Compensation cost |
|
|
|
|
|
|
$ 900,000
|
$ 2,700,000
|
|
|
|
|
|
|
|
|
Compensatory Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Issuance or sale of equity |
|
|
|
|
|
|
$ 4,000,000.0
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
|
|
81,143
|
|
|
|
|
|
|
|
|
66,802
|
Class of warrant or right, exercise |
|
|
|
|
|
|
$ 11.10
|
|
|
|
|
|
|
|
|
$ 23.40
|
Noncompensatory Equity Classified Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
|
|
|
|
|
|
331,464
|
27,048
|
|
192,068
|
27,048
|
|
Class of warrant or right, exercise |
|
|
|
|
|
|
|
|
|
|
$ 0.01
|
$ 20.00
|
|
$ 52.50
|
$ 11.10
|
|
Fair value adjustment of warrants |
|
|
|
|
|
|
$ 2,300,000
|
|
|
|
|
|
|
|
|
|
Warrants exercised |
|
|
|
|
|
20,000
|
|
|
|
|
|
|
|
|
|
|
Number of outstanding warrants to purchase, shares |
|
|
|
|
|
|
|
|
|
|
|
539,951
|
|
|
|
|
Noncompensatory Equity Classified Warrants [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of warrant or right, exercise |
|
|
|
|
|
|
|
|
|
|
|
$ 11.10
|
|
|
|
|
Series C Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of warrant or right, exercise |
|
|
|
|
|
|
$ 7.195
|
|
|
|
|
|
|
|
|
|
Alpha Capital [Member] | Noncompensatory Equity Classified Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
|
100,000
|
|
|
|
|
|
|
|
78,019
|
|
|
Class of warrant or right, exercise |
|
|
|
|
|
$ 0.10
|
|
|
|
|
|
|
|
$ 0.01
|
|
|
Alpha Capital [Member] | Noncompensatory Equity Classified Warrants [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
|
|
|
|
|
|
|
|
|
|
128,783
|
|
|
|
Class of warrant or right, exercise |
|
|
|
|
|
|
|
|
|
|
|
|
$ 60.00
|
|
|
|
Alpha Capital [Member] | Series C Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase of warrants |
|
|
2,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of warrant or right, exercise |
|
|
$ 1.65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alpha Capital [Member] | Senior Convertible Debenture [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Class of Stock [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Senior convertible debenture rate |
|
|
8.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
$ 3,300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Purchase Price |
|
|
$ 3,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price |
|
|
$ 1.32
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionFair value of Issuance cost.
+ References
+ Details
Name: |
QLGN_FairValueOfIssuanceCost |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionModified to exercise price.
+ References
+ Details
Name: |
QLGN_ModifiedToExercisePrice |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionStockholders equity reverse stock split price per share.
+ References
+ Details
Name: |
QLGN_StockholdersEquityReverseStockSplitPricePerShare |
Namespace Prefix: |
QLGN_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWarrants extended date, description.
+ References
+ Details
Name: |
QLGN_WarrantsExtendedDateDescription |
Namespace Prefix: |
QLGN_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_AllocatedShareBasedCompensationExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 272 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1
Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13
Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14
Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18
Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(27)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ClassOfStockLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of warrants or rights outstanding.
+ References
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate number of common shares reserved for future issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_CommonStockCapitalSharesReservedForFutureIssuance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock issued as dividends during the period. Excludes stock splits.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_CommonStockDividendsShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of expense (income) related to adjustment to fair value of warrant liability.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 13 -SubTopic 10 -Topic 480 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481766/480-10-25-13
+ Details
Name: |
us-gaap_FairValueAdjustmentOfWarrants |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3
+ Details
Name: |
us-gaap_ProceedsFromIssuanceOrSaleOfEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_SecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of noncash expense for share-based payment arrangement.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDescription of terms of share-based payment arrangement. Includes, but is not limited to, type of award or grantee and reason for issuance.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of options outstanding, including both vested and non-vested options.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionWeighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage increase in the stated interest rate on a short-term debt instrument.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtInterestRateIncrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_RangeAxis=srt_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=QLGN_CompensatoryWarrantActivityMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_StockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=QLGN_TwoThousandTwentyStockIncentivePlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=QLGN_CompensatoryWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AwardTypeAxis=QLGN_NoncompensatoryEquityClassifiedWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=QLGN_SeriesCWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
|
|
|
|
3 Months Ended |
17 Months Ended |
|
|
|
|
Jan. 12, 2023 |
Dec. 22, 2022 |
May 26, 2022 |
Jun. 30, 2022 |
Sep. 02, 2021 |
Jun. 30, 2023 |
Dec. 31, 2022 |
Dec. 31, 2021 |
Dec. 31, 2020 |
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
Conversion price |
$ 1.32
|
|
|
|
|
|
|
|
|
Short term debt principal outstanding |
$ 1,111,078
|
|
|
|
|
|
|
|
|
Shares of common stock |
841,726
|
|
|
|
|
|
|
|
|
Short term debt outstanding balance |
|
|
|
|
|
$ 965,155
|
$ 950,722
|
|
|
Accrued interest rate |
|
8.00%
|
|
|
|
|
|
|
|
Warrants to purchase shares |
|
|
|
|
|
|
|
60,000
|
|
Warrants exercise price |
|
|
|
|
|
|
|
$ 13.20
|
$ 40.70
|
Stock issued during period value acquisitions |
|
|
|
$ 1,844,500
|
|
|
|
|
|
Pre-funded Warrant [Member] |
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
Warrants to purchase shares |
|
|
331,464
|
|
|
|
|
|
|
Warrants exercise price |
|
|
$ 0.001
|
|
|
|
|
|
|
Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
Stock issued during period shares acquisitions |
|
|
381,786
|
|
|
|
|
|
|
NanoSynex Ltd [Member] |
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
Business acquisition, voting equity rate |
|
|
52.80%
|
|
|
|
|
|
|
Stock issued during period shares acquisitions |
|
|
350,000
|
|
|
|
|
|
|
NanoSynex Ltd [Member] | Series A-1 Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
Stock issued during period shares acquisitions |
|
|
2,232,861
|
|
|
|
|
|
|
NanoSynex Ltd [Member] | Series B Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
Stock issued during period shares acquisitions |
|
|
381,786
|
|
|
|
|
|
|
Stock issued during period value acquisitions |
|
|
$ 600,000
|
|
|
|
|
|
|
Notes Payable [Member] | Nano Synex Ltd [Member] |
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
Short term debt principal outstanding |
|
|
|
|
$ 905,000
|
|
|
|
|
Short term debt outstanding balance |
|
|
|
|
|
$ 965,155
|
|
|
|
Accrued interest rate |
|
|
|
|
2.62%
|
|
|
|
|
Proceeds from related party debt |
|
|
|
|
$ 3,000,000
|
|
|
|
|
Alpha Capital [Member] | Senior Convertible Debenture [Member] |
|
|
|
|
|
|
|
|
|
Related Party Transaction [Line Items] |
|
|
|
|
|
|
|
|
|
Senior convertible debenture rate |
|
8.00%
|
|
|
|
|
|
|
|
Principal amount |
|
$ 3,300,000
|
|
|
|
|
|
|
|
Purchase Price |
|
$ 3,000,000
|
|
|
|
|
|
|
|
Conversion price |
|
$ 1.32
|
|
|
|
|
|
|
|
X |
- DefinitionPercentage of voting equity interests acquired at the acquisition date in the business combination.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock issued as dividends during the period. Excludes stock splits.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
+ Details
Name: |
us-gaap_CommonStockDividendsShares |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date, including the current and noncurrent portions, of collateralized debt obligations (with maturities initially due after one year or beyond the operating cycle, if longer). Such obligations include mortgage loans, chattel loans, and any other borrowings secured by assets of the borrower.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_SecuredDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_ShortTermBorrowings |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionPercentage increase in the stated interest rate on a short-term debt instrument.
+ References
+ Details
Name: |
us-gaap_ShortTermDebtInterestRateIncrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares of stock issued during the period pursuant to acquisitions.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued pursuant to acquisitions during the period.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueAcquisitions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=QLGN_PrefundedWarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=QLGN_SeriesAOnePreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ShortTermDebtTypeAxis=QLGN_NotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
srt_TitleOfIndividualAxis=QLGN_AlphaCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=QLGN_SeniorConvertibleDebentureMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.23.2
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
|
|
|
3 Months Ended |
6 Months Ended |
|
|
|
|
Jul. 20, 2023 |
Jul. 13, 2023 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Jun. 30, 2023 |
Jun. 30, 2022 |
Mar. 31, 2024 |
Nov. 30, 2023 |
Jan. 12, 2023 |
Dec. 31, 2022 |
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Research and Development Expense |
|
|
$ 1,326,544
|
$ 1,506,227
|
$ 3,448,095
|
$ 3,370,972
|
|
|
|
|
Cash |
$ 5,200,000
|
|
1,341,659
|
|
1,341,659
|
|
|
|
|
$ 7,034,434
|
Escrow |
|
|
$ 450,000
|
|
$ 450,000
|
|
|
|
|
|
Aggregrate amount |
|
|
|
|
|
|
|
|
$ 1,111,078
|
|
Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Sale of stock price per share |
$ 1.5716
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | NanoSynex Ltd [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Business acquisition, description of acquired entity |
Pursuant to the terms of the NanoSynex Amendment, the Company agreed to advance to NanoSynex an aggregate amount of $1,610,000 as follows: (i) $380,000 within five business days of the execution of the NanoSynex Amendment, (ii) $560,000 on or before November 30, 2023, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding, and (iii) $670,000 on or before March 31, 2024, against which NanoSynex will issue a promissory note to the Company with a face value in the amount of such funding. The NanoSynex Amendment further provides that the initial payment of $380,000 will be satisfied by the Company’s surrender of the 281,000 Preferred B Shares of NanoSynex currently held by the Company, resulting in the Company’s ownership in NanoSynex being reduced from approximately 52.8% to approximately 49.97% of the issued and outstanding voting equity of NanoSynex.
|
|
|
|
|
|
|
|
|
|
Master Laboratory Services Agreement [Member] | Subsequent Event [Member] | MLM Medical Labs [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Research and Development Expense |
|
$ 7,600,000
|
|
|
|
|
|
|
|
|
Stock Purchase Agreement [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Cash |
$ 5,200,000
|
|
|
|
|
|
|
|
|
|
Purchase Price |
5,800,000
|
|
|
|
|
|
|
|
|
|
Escrow |
450,000
|
|
|
|
|
|
|
|
|
|
Amendment and Settlement Agreement [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Aggregrate amount |
380,000
|
|
|
|
|
|
|
|
|
|
Amendment and Settlement Agreement [Member] | Subsequent Event [Member] | NanoSynex Ltd [Member] |
|
|
|
|
|
|
|
|
|
|
Subsequent Event [Line Items] |
|
|
|
|
|
|
|
|
|
|
Aggregrate amount |
$ 1,610,000
|
|
|
|
|
|
$ 670,000
|
$ 560,000
|
|
|
X |
- DefinitionWith respect to a business combination completed during the period, this element provides a description of the business, other than the name, which may include the industry, size, products and other important information.
+ ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2
+ Details
Name: |
us-gaap_BusinessAcquisitionDescriptionOfAcquiredEntity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10
Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12
Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1
Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1
Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section 45 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-21
Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1
Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 210 -Topic 946 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480555/946-210-45-20
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B
Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B
Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C
Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2
Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1
Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.10) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1
+ Details
Name: |
us-gaap_EscrowDeposit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1
Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1
Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1
+ Details
Name: |
us-gaap_ResearchAndDevelopmentExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPer share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.
+ References
+ Details
Name: |
us-gaap_SaleOfStockPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
dtr-types:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2
Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2
+ Details
Name: |
us-gaap_SubsequentEventLineItems |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BusinessAcquisitionAxis=QLGN_NanoSynexLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=QLGN_MasterLaboratoryServicesAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=QLGN_MLMMedicalLabsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=QLGN_StockPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=QLGN_AmendmentAndSettlementAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=QLGN_NanoSynexLtdMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Qualigen Therapeutics (NASDAQ:QLGN)
過去 株価チャート
から 8 2024 まで 9 2024
Qualigen Therapeutics (NASDAQ:QLGN)
過去 株価チャート
から 9 2023 まで 9 2024